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ABSTRACT 
Despite the high frequency of oncogenic KRas mutations in cancer, the precise 
mechanistic consequences of these mutations are unclear. In pancreatic cancer 
KRas mutation is thought to initiate tumourigenesis. In colorectal cancer KRas 
mutation causes tumour progression following an initiating mutation of 
Adenomatous Polyposis Coli (Apc). 
In this thesis, in these two distinct scenarios, I examined the functional 
importance of, two downstream transcription targets of KRas signalling: Dual 
specificity phosphatase 6 (Dusp6) and Fos related antigen 1 (Fra1). Dusp6 is a 
phosphatase specific for Erk 1/2 and therefore is predicted to be a tumour 
suppressor. On the other hand, Fra1 is part of the AP-1 complex and is predicted 
to drive invasion and metastasis. 
The aim of this work was to: 
• Determine the implication of the MAPK pathway in colorectal cancer 
• Determine the functional significance of Dusp6 and Fra1 deletion in two in 
vivo models 
• Understand the mechanism of action of Dusp6 and Fra1 deletion 
In colorectal cancer, KRas activation did not appear to robustly activate MAPK 
pathway and moreover pharmacological inhibition of this pathway had no impact 
upon cells carrying mutations in both Apc and KRas. Mechanistically this was 
associated with increased levels of Dusp6 and Dusp6 deletion increased 
proliferation and tumourigenesis in a MAPK dependent manner. 
In pancreatic cancer, KRas mutation stimulated MAPK pathway and Dusp6 
deletion accelerated tumourigenesis. This again was partly dependant on the 
MAPK signalling pathway. 
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Surprisingly, Fra1 deletion did not have expected consequences in the intestine. 
Here Fra1 deletion did not modify invasion and instead accelerated 
tumourigenesis. Within the pancreas, Fra1 deletion strongly suppressed 
tumourigenesis though not metastasis. Further mechanistic studies are required 
to elucidate the mechanism to explain these phenomena. 
 
Overall, the deregulation of these two genes appears to be important events in 
cancer progression following KRas mutation. Importantly I have identified that 
Dusp6 can act as a potential tumour suppressor protein downstream of KRas 
mutation, whilst Fra1 can act as a context specific tumour suppressor or 
oncogene.
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INTRODUCTION 
1 Introduction to colon cancer 
1.1 Colorectal cancer 
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers in UK. It 
is the second most commonly diagnosed cancer for women and the third for men 
according to Cancer Research UK statistics for 2009 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/). It is the third 
cause of cancer death for both women and men and represents 10% of the total 
mortality by cancer in UK. However, comparing the statistics from 1999-2001 
with the 2008-2010 statistics there is a 14% reduction in the number of deaths 
from CRC. 
There are two types of CRC: sporadic and hereditary. Most cases of CRC are 
sporadic and multiple factors such as diet or alcohol consumption can contribute 
towards this, while familial CRC can be divided in 2 groups: Familial 
Adenomatous Polyposis (FAP) and Hereditary Non-Polyposis Colorectal Cancer 
(HNPCC). HNPCC patients have germline mutations in mismatch repair genes 
which lead to microsatellite instability. These germline mutations give an 80% 
chance of developing CRC, 60% for endometrial cancers and less than 20% for 
gastric, ovarian and bladder cancer (Lynch and de la Chapelle 2003). FAP is an 
autosomal dominant disease and is due to a germline mutation in the 
chromosome 5q where the gene Adenomatous polyposis Coli (Apc) is found 
(Bodmer, Bailey et al. 1987; Lynch and de la Chapelle 2003). This renders this 
hereditary disease the closest to sporadic CRC as mutations in the Apc tumour 
suppressor have been found in over 80% of sporadic CRC cases. 
The progression of CRC from benign adenoma to invasive carcinoma has been 
extensively studied and at the molecular level several genetic mutations have 
been shown to contribute in this process (Figure 1). The most frequent 
Introduction 
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mutations are in the genes Apc, KRas, p53 and smad4 (Vogelstein, Fearon et al. 
1988; Vogelstein, Fearon et al. 1989; Fodde, Smits et al. 2001). The first visible 
lesion in the colonic epithelium is the aberrant crypt focus (ACF). This consists 
of early microscopic lesions where dysplastic cells are found surrounded by 
normal non-dysplastic cells. These lesions progress into a polyp or adenoma. An 
adenoma is a benign tumour composed of dysplastic cells and starts to protrude 
into the lumen of the gut. These adenomas will then evolve progressively to 
adenocarcinoma, consisting of a malignant lesion made of a disorganised 
epithelium containing cells which have lost nuclear polarity, are poorly 
differentiated and can secrete mucus. These malignant lesions finally lead to 
metastases formation mostly in the liver. Given the frequency of the Apc 
mutation in human tumours and the fact that in murine models loss of Apc leads 
directly to ACF and adenoma formation (Sansom, Reed et al. 2004) it is often 
considered that this mutation may be the initiating event of CRC. Furthermore, 
a sequential model of the evolution of CRC has been proposed (Vogelstein, 
Fearon et al. 1988; Vogelstein, Fearon et al. 1989). However, there is no real 
proof of a defined mutational sequence even if for example the p53 mutation is 
believed to be a late event as it correlates with more advanced stages (Baker, 
Preisinger et al. 1990).  
 
 
Figure 1: Overview of the evolution of CRC 
Initiating mutations allow formation of aberrant crypt foci (ACF) evolving into benign early 
adenomas. Then accumulation of mutations allows the progression of adenomas to aggressive 
and invasive carcinomas. 
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1.2 Biology of the Intestinal epithelium 
In order to understand the carcinogenesis process within the intestinal 
epithelium, it is important to have an overview of the normal homeostasis (for 
review: (de Santa Barbara, van den Brink et al. 2003; Sancho, Batlle et al. 2004; 
Pinto and Clevers 2005)).  
1.2.1 Organisation of the intestinal epithelium 
The intestinal tract is composed of three layers: an inner mucosa absorbing the 
nutrients protected by a stroma layer surrounded by an external smooth muscle 
layer responsible for peristalsis. The gut epithelium is composed of luminal villi 
and crypts of Lierberkühn which are invaginations into the submucosa. These 
crypt-villus units are conserved through the entire small intestine whereas the 
colon contains only crypts with a flat surface epithelium. These units are 
composed of epithelial cells which are organised as monolayer which covers the 
surface of the gut (Figures 2 and 3). 
 
Figure 2: Gut epithelium organisation 
Stem cells produce transient amplifying cells which then actively generate other cell types which 
are progressively moving up the crypt-villus axis to be shed off in the gut lumen. 
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Figure 3: Mouse gut epithelium 
H&E of intestine (left panel) and colon (right panel) of a wild type mouse. In the intestine the 
cells are organised in a single cell layer from the bottom of the crypt in contact with the muscle 
layers to the top of the villus reaching the gut lumen. The colonic epithelium consists in long 
crypts organised in a similar way to the crypt-villus axis of the intestine. 
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The epithelial cells are highly specialised and are continuously produced and 
discarded throughout the life of the organism. The turnover of intestinal cells is 
estimated to three days in mice and five days in humans. Epithelial stem cells 
(four to six stem cells per crypts are estimated) are located at the bottom of the 
crypt and, undergoing asymmetric division, continuously produce 
undifferentiated progenitors named transient amplifying cells (TAC) leading to 
the four intestinal cell types: enterocytes, Goblet cells, Paneth cells and entero-
endocrine cells. Recently the Clevers laboratory generated a very elegant new 
mouse model that allows lineage tracing from individual Lgr5 positive epithelial 
stem cells, namely the Cre-reporter allele R26R-Confetti (Snippert, van der Flier 
et al. 2010). To do so, they integrated into the Rosa26 locus a CAG promoter 
followed by a LoxP-flanked Neo cassette (serving as a STOP cassette) and the 
Brainbow 2.1 construct (Livet, Weissman et al. 2007). The R26R-Confetti allele 
functions as a stochastic multicolour Cre recombinase reporter of multiple 
fluorescent proteins from a single genomic locus. These R26R-Confetti mice 
allow a way to label and distinguish individual cells with nuclear localized, 
membrane-targeted, or cytoplasmic fluorescent proteins in recombined cells. 
Cre-mediated recombination will remove the STOP cassette and a fluorescent 
marker will be expressed in the newly produced cells allowing us to distinguish 
between the stem cells and their progeny. This work allowed the Clevers 
laboratory to show that although there are many intestinal stem cells per crypts, 
crypts purify through a stochastic process so all cells will be the daughters of a 
single Lgr5 positive intestinal stem cell.  
Within the intestinal epithelium many of the cell types have a specific position 
through the crypt-villus axis as well as a defined number and their 
mislocalisation and/or change in number indicate a disturbed homeostasis which 
may be linked to cancer. 
In the small intestine, up to 80% of epithelial cells are enterocytes. They are 
columnar cells with apical microvilli helping the absorption of nutrients going 
through the intestinal tract. The Goblet cells are responsible for mucus 
production. They can represent up to 5% of the cells and they are spread from 
the crypt to the top of the villi. They are characterised by mucous granules in 
Introduction 
 
21
their cytoplasm. The entero-endocrine cells are responsible for the secretion of 
hormones important in the censoring of the luminal content such as 
cholecystokinin, glucagon-like peptide-1 and oxyntomodulin. Their number is 
very low and they are located predominantly in the villus. Paneth cells express 
the marker cluster of differentiation 24 (CD24), are located at the bottom of the 
crypts and their original function was proposed to be associated with the 
antimicrobial barrier because of enzyme production such as defensins and 
lysozyme, however, they are now also thought to be an important component of 
the stem cell niche (Sato, van Es et al. 2011). Moreover, they are not found in 
the villus and seem restricted to the crypt compartment despite the cell 
migration from the crypt to the top of the villus. 
In the colon, the differentiated cells are mainly enterocytes and Goblet cells. 
However a CD24 positive cell population located between stem cells is believed 
to play the role of Paneth cells (Sato, van Es et al. 2011). The Goblet cells are 
found in a higher proportion compared to the intestine and are located in the 
mid-crypt area. Some endocrine cells can be found at the base of the crypt 
nearby the stem cells. 
The epithelium renewal is achieved by cell migration from the crypt to the villus 
while proliferation and differentiation is constantly maintained (Potten and 
Loeffler 1990). The TACs undergo up to seven divisions before they terminally 
differentiate into their progeny which will be move higher on the crypt-villus 
axis. This constant cell renewal leads to the elimination of the old cells placed 
at the top of the villi into the lumen. Any modification of this tightly regulated 
process is a sign of a potentially malignant lesion. 
1.2.2 Intestinal stem cells 
Intestinal stem cells are self-renewing undifferentiated cells able to give rise to 
all cell types within a tissue and which function as a reservoir of new cells in 
normal tissue homeostasis and injury. They are usually long lived and can either 
be quiescent or actively cycling. They are located within a stem cell niche 
thought to be constituted by Paneth cells (Sato, van Es et al. 2011). They are 
also thought to undergo asymmetric division to generate the fast cycling 
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transient amplifying cells (TAC) which are responsible for the maintenance of 
the villus by dividing and differentiating when at the crypt villus junction. 
However, identifying stem cells remains difficult and controversial, and in the 
intestine at least two distinct populations of cells have been classified as stem 
cells. 
Crypt base columnar, Lgr5+ stem cells 
In 1974 Cheng and Leblond first described the crypt base columnar (CBC) cells as 
occupying the nine lowest positions of the crypt interspersed among the Paneth 
cells (Cheng and Leblond 1974; Bjerknes and Cheng 2005). These cells were 
marked by a one hour radioactive 3H-Thymidine labelling targeting cells 
undergoing DNA replication. Furthermore, a continuous labelling with 
3H-Thymidine showed that these cells were actively dividing and able to 
generate all the epithelial cells (Cheng and Leblond 1974). Recently Leucine-rich 
repeat containing G-protein coupled receptor 5 (Lgr5) has been described as a 
robust marker of these stem cells (Barker and Clevers 2007; Barker, van Es et al. 
2007). Lgr5 expression has been confirmed in transgenic Lgr5-EGFP+ mice where 
GFP fluorescence was observed at the bottom of intestinal crypts. Furthermore, 
elegant experiments have shown that Lgr5 is a bona fide stem cell marker via 
lineage tracing. Here, Lgr5-EGFP+-CreER mice were intercrossed with the Cre 
activable lox-STOP-lox ROSA26 (R26R)-LacZ reporter which facilitated the 
visualisation of Lgr5 positive cells progeny (Soriano 1999; Barker, van Es et al. 
2007). Tamoxifen injection activated the Lac-Z reporter specifically in Lgr5 
positive CBC cells allowing the tracking of daughter cells (Barker and Clevers 
2007). This proved the ability of CBC cells to generate all intestinal epithelium 
cells. 
Lgr5 is a target and a component of the Wnt pathway. Wnt signalling is essential 
for intestinal homeostasis, with the highest levels specifying both the Paneth 
and stem cell fate. Transgenic mice expressing, under the control of the villin 
promoter, Dickkopf (Dkk), a secreted inhibitor of the Wnt pathway, have a 
strong reduction of crypt formation and shortened villus structures in adult mice 
intestine (Pinto, Gregorieff et al. 2003). In Lgr5-GFP transgenic mice the 
expression of Dkk by adenovirus induced a drastic loss of Lgr5 expression (Yan, 
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Chia et al. 2012). Furthermore, a conditional deletion of β-Catenin within the 
adult intestine rapidly leads to crypt death by increased apoptosis and 
mislocalisation of Paneth cells (Ireland, Kemp et al. 2004). Following crypt 
death, a rapid repopulation of the epithelium by unrecombined cells was 
observed. Lgr5 function, by binding the Wnt agonist R-Spondin, allows maximal 
activation of the Wnt signalling pathway (de Lau, Barker et al. 2011; Glinka, 
Dolde et al. 2011). Thus this may explain why intestinal stem cells have the 
highest levels of Wnt signalling in the adult intestine. Deletion of Lgr5 has little 
phenotype alone in the adult intestine, presumably due to compensation by the 
other Lgr6 (de Lau, Barker et al. 2011). Deletion of both Lgr5 and Lgr4 rapidly 
leads to crypt death suggesting that Lgr5 is not only a marker of intestinal stem 
cells but also an important specifier of intestinal stem cell fate (de Lau, Barker 
et al. 2011).  
As well as a stem cell marker, it appears that Lgr5 positive cells may be the cell 
of origin for intestinal adenomas (Barker, Ridgway et al. 2009). Using Lgr5-EGFP-
IRES-creER knock-in mice (where Lgr5 positive cells are specifically targeted), 
Apc deletion was targeted to the stem cells and led rapidly to large highly 
proliferative adenomas. In contrast targeting Apc deletion outside of the stem 
cell region led to small lesions that very rarely formed adenomas and if so these 
took much longer. 
Given the lack of antibodies to Lgr5, the Lgr5-EGFP mouse has been very useful 
to isolate stem cells from the murine intestine and further define this intestinal 
stem cell population. This has led to a number of other markers that are highly 
enriched in the crypt columnar cells such as Achaete scute-like 2 (Ascl2) and 
Olfactomedin 4 (Olfm4). These markers are not only enriched in stem cells but 
also in colorectal cancer. In human CRC both Lgr5 and Ascl2, another Wnt target 
gene (Sansom, Reed et al. 2004), are highly expressed (over 70%) and correlated 
(Ziskin, Dunlap et al. 2012). Ascl2 co-localises with Lrg5 positive cells and is 
located at the base of the crypts as shown by in situ hybridisation. Furthermore 
Ascl2 deletion leads to intestinal stem cell loss (van der Flier, van Gijn et al. 
2009). Therefore Ascl2 is considered as another CBC stem cell population 
marker. Olfm4 is expressed in Lgr5 positive cells of the bottom of the crypt (van 
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der Flier, Haegebarth et al. 2009; van der Flier, van Gijn et al. 2009) yet its 
expression is interestingly Wnt independent. Prominin 1 (Prom1, also named 
CD133) is expressed in cells with the same characteristics as the CBC cell and co-
expresses with Lgr5 at the bottom of the crypt. Moreover, CD133 positive cells 
were able to generate all intestinal cell types (Zhu, Gibson et al. 2009). It is 
important to note that Ascl2, Olfm4 and CD133 overlap CBC Lgr5 positive cells 
but also mark cells further up in the crypt and therefore are thought to be 
conserved in daughters arising from CBC cells. The Batlle group had shown in 
human CRC, the Lgr5 high population overlaps with the Ephrin B2 (EphB2) 
Receptor high population, which there are antibodies to, that allows FACs 
sorting and isolation of the Lgr5 high cells from human CRC (Batlle, Henderson et 
al. 2002; Merlos-Suarez, Barriga et al. 2011). Isolation of this population showed 
it enriched for tumour initiating capacity. Moreover tumours with high 
expression of these markers showed increased chances of relapse. This finding is 
somewhat controversial as the Medema group has shown that although colon 
cancer stem cells are defined by high Wnt activity, the tumours that carry the 
worse prognosis instead have the intestinal stem cell markers hypermethylated 
(de Sousa, Colak et al. 2011). It is perhaps unsurprising that in a complex 
situation of colorectal cancer where tumours carry many mutations that simple 
correlation between the intestinal stem cells and cancer has not been found. It 
is interesting to note that recently it has been suggested that a BRaf-like 
signature carries a poor prognosis in CRC and this is associated with lower levels 
of Wnt signalling and hence might be expected to have low levels of the stem 
cells markers (Popovici, Budinska et al. 2012). 
Label-Retaining Stem cells 
In parallel with the Cheng and Leblond studies another intestinal stem cell 
population was described by Potten et al (Potten, Kovacs et al. 1974). They 
labelled cells undergoing DNA replication by using3H-Thymidine and showed that 
among the proliferative cells 15 to 20% were slowly dividing (hence their name: 
label-retaining cells (LRC)). These cells were described as located at the position 
+4 of the crypt just above the Paneth cells. B lymphoma Mo-MLV insertion region 
1 homolog (Bmi1) is essential for the self-renewal of hematopoietic cells and its 
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role in other adult stem cell populations has been studied in a mouse model 
expressing a tamoxifen-inducible Cre from the Bmi1 locus (Sangiorgi and 
Capecchi 2008). In a similar set of experiments to the ones I described above 
with Lgr5-CreER these mice were then crossed to the Rosa 26 Lac-Z reporter and 
lineage tracing was observed. One slight caveat to these experiments is that 
both the Clevers laboratory and the recent work by the de Sauvage group have 
shown Bmi1 expressed throughout the crypt (Sangiorgi and Capecchi 2008; 
Itzkovitz, Lyubimova et al. 2012; Munoz, Stange et al. 2012). This would 
therefore suggest that although the Bmi1 positive cells would contain the label 
retaining cells, not every Bmi1 positive cell would be a LRC. The existence of a 
‘back-up’ population of cells which can replace the Lgr5 positive is however not 
in doubt. Recent experiments have shown that targeting the Lgr5 stem cells with 
diphtheria toxin does not kill the intestine and a non-Lgr5 positive stem cell 
population repopulates the intestine (Tian, Biehs et al. 2011). This does not 
necessarily have to be a LRC as cells may fall back into the niche and then 
repopulate the intestine. Recent experiments by the Clevers and Fodde 
laboratories have suggested that there may be secretory/differentiated 
progenitor cells that repopulate the crypt post injury (van Es, Sato et al. 2012; 
Wang, Sacchetti et al. 2012). Given these cells have differentiated they could be 
thought also as LRC cells as differentiated cells would retain a BrdU or histone 
2B-GFP (H2B-GFP) label. However this is rather a different concept to a 
specialized back up population of slowly dividing stem cells. 
Other markers have been reported for the +4 stem cell population. Telomerase 
is a ribonucleoprotein complex that helps maintain the integrity of chromosome 
ends through numerous cell divisions. Telomerase reverse transcriptase (Tert) 
expression has been shown in the intestine. Moreover, a transgenic mouse model 
expressing Tert together with the GFP reporter demonstrated the presence of 
long label retaining single cells (Breault, Min et al. 2008) which are mostly in G0 
since they do not express the cell cycle marker Ki67 (Montgomery, Carlone et al. 
2011). In addition, the Tert positive cells are distinct from the Lgr5 positive 
cells, are also located at the +4 position of the crypt, are radioresistant and 
exert multipotency. Furthermore, Tert expression is also in a gradient 
decreasing from the bottom of the crypt towards the top of the crypt. Another 
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marker for the slow cycling stem cells has also been suggested: Leucine-rich 
repeats and immunoglobulin-like domains 1 (Lrig1). Lrig1 is an inhibitor of the 
growth factor erythroblastic leukemia viral oncogene homolog 2 (ErbB) 
signalling. A lineage tracing experiment in transgenic mice expressing the Lac-Z 
reporter under the control of Tamoxifen injection in the Lrig positive cells (Lrig-
CreER-R26R/LacZ mice) showed that a single injection of the inducer labels 
single cells located at the bottom of the intestinal crypts and that the labelling 
is spreading to the entire crypt villus structure within fourteen days (Powell, 
Wang et al. 2012). Also, Lrig cells are actively repopulating irradiation damaged 
crypts. Consistently with a slow cycling stem cell population, only 25% of the 
Lrig positive cells exhibit Ki67 whereas the rate of Lgr5 positive cells is 75%. In 
addition Lrig and Lgr5 rarely colocalise in cells. Interestingly Apc deletion in Lrig 
positive cells as well as Lrig deletion in adult intestinal cell resulted in large 
adenoma formation. 
 
In conclusion, there are at least 2 distinct stem cell populations within the 
intestine which have been described to have different roles in intestinal 
epithelium maintenance. First, the rapid cycling population in charge of the 
constant turnover of cells during normal maintenance and secondly, quiescent, 
slow cycling or differentiated population which may act as a reservoir for the 
fast cycling population after specific injuries. Whether this back up population 
needs to have a specific identity is still unclear or whether this reflect cells that 
fall back into the niche upon killing of the Lgr5 positive cells and then adopt a 
stem cell fate. These questions will no doubt be unravelled over the next few 
years in this rapidly evolving field. However for the purpose of my thesis there is 
little doubt that the Lgr5 positive cells mark a population of intestinal stem cells 
that express a specific signature of genes. 
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1.2.3  Identifying different epithelial lineages within the intestinal 
epithelium  
The intestinal epithelium is a highly organised structure. The visualisation of the 
different cell types, the migration of the cells and the area of proliferation is a 
powerful tool to distinguish the normal tissue from a diseased one. For each cell 
type, a specific histochemical or immunohistochemical stain has been developed 
in order to characterise them. 
The Goblet cells produce acidic mucus. Therefore, it is possible to stain them 
using a basic dye, the alcian blue, targeting the acidic polysaccharides of the 
mucus colouring it in blue. Entero-endocrine cells are argyrophil which means 
that they can be impregnated with silver. A staining (grimelius staining) 
combining silver and a reducing agent turning it into visible metalic silver is used 
to visualise them. As previously mentioned, Paneth cells are secreting enzymes 
such as defensins and lysozyme therefore they can be visualised by lysozyme 
immunohistochemistry (IHC). 
Bromodeoxyuridine (BrdU) is a synthetic analogue of thymidine and is 
incorporated during S-Phase of the cell cycle. In mouse tissues, an IHC for BrdU 
allows the visualisation of proliferative cells at a specific time. Cell migration 
can also be visualised using BrdU labelling. The BrdU is incorporated for 
approximately two hours after injection as it is bioavailable only for this amount 
of time. In the mouse normal epithelium, two hours after injection, the BrdU 
positive cells are located in the crypt compartment. At 48 hours after injection, 
the BrdU positive cells are now located only in the villi and not in the crypt, 
indicating the cell migration up the axis (Figure 4). When the intestinal 
epithelium is transformed such as in the case of a homozygous Apc mutation, an 
increase in proliferation is observed as highlighted by the higher BrdU 
incorporation. 
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Figure 4: Cell migration in mouse intestinal epithelium 
BrdU was injected in wild type mice. After two hours, the BrdU was incorporated in the cells in 
S-phase. Mice were sacrificed 2 hours (left panel) and 48 hours (right panel) after BrdU injection. 
An IHC for BrdU was performed. The BrdU positive cells appear in brown. At 2 hours after BrdU 
injection, the BrdU positive cells are located in the intestinal crypts. At 48 hours after injection, 
the positive cells are located in the villi illustrating the cell movement in the epithelium.  
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1.3 The WNT signalling cascade 
There are three pathways associated with Wnt ligands: the Wnt/Ca2+ pathway, 
the non-canonical planar cell polarity pathway and the canonical pathway 
(Clevers 2006). In this thesis I will focus only on the canonical pathway. This 
pathway is active during embryogenesis and regulates the self-renewal of several 
tissues in adult. Consequently, a deregulation of this pathway is often seen in 
cancer and especially in CRC. 
1.3.1 The canonical WNT pathway 
The Wnt signalling pathway is widely conserved and consists in an activation 
cascade of several proteins starting by the binding of the Wnt ligand to its 
receptors. Wnt was first discovered in Drosophila where the wingless (wg) gene 
was showed to control segment polarity during development of the larva 
(Nusslein-Volhard and Wieschaus 1980). Not long after this discovery, the gene 
Int1 was identified in mice as an oncogene in virus-induced mammary tumours 
(Nusse and Varmus 1982). Then, wg was showed to be the homologue of the 
murine Int1 gene (Rijsewijk, Schuermann et al. 1987), the contraction of the two 
names giving its final designation Wnt. There are 19 Wnt genes conserved in 
mammals (http://www.stanford.edu/group/nusselab/cgi-bin/Wnt/). The first 
Wnt protein purified and biochemically characterized was the murine Wnt3a 
(Willert, Brown et al. 2003). Wnts are cysteine rich proteins of approximately 
350-400 amino acids that contain an N-terminal signal peptide for secretion. 
The Wnt cascade (Figure 5 A) starts with the binding of a Wnt ligand to a 
transmembrane frizzled receptor (Fz) associated with a transmembrane receptor 
low-density lipoprotein receptor-related protein 5/6 (LRP5/6). This results in the 
scaffold protein Axin to translocate to the membrane and bind the intracellular 
tail of the LRP5/6 receptor. The outcome of this interaction is the dissociation 
of the β-Catenin destruction complex consisting of Axin, Glycogen synthase 
kinase 3β (GSK3β), casein kinase 1 (CK1) and Apc (Reya and Clevers 2005; 
Clevers 2006). Simultaneously, the binding of Wnt ligand to its receptor results 
in the phosphorylation of dishevelled (Dsh) proteins which then inhibit the 
activity of GSK3β. Therefore GSK3β is unable to phosphorylate β-Catenin which 
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then will not be recognised by the E3 ubiquitin ligase containing the F-box 
β-transducin repeats-containing protein (β-TRCP) protein (Yanagawa, van 
Leeuwen et al. 1995; Mao, Wang et al. 2001; Cadigan and Liu 2006). The 
unphosporylated β-catenin can accumulate in the cytoplasm of the cell and is 
free to translocate to the nucleus. As β-catenin does not have a NLS its 
mechanism of the nuclear translocation is still not fully described and has 
generated conflicting reports. It was first thought that the protein binds directly 
to the nuclear membrane and translocates through the nucleopore by a 
mechanism relying on GTPase activity (Fagotto, Gluck et al. 1998). However, a 
more recent paper showed that β-catenin does not need interaction with the 
nucleoporins to enter the nucleus suggesting another mechanism (Suh and 
Gumbiner 2003). This study also showed that β-catenin encompasses two regions 
which could target it to the nucleus. Finally, β-catenin could also translocate by 
binding other proteins containing a NLS as suggested by its binding to the protein 
Kank (Wang, Kakinuma et al. 2006). Once in the nucleus, it binds to the 
Lymphoid enhancer factor/T-Cell factor (LEF/TCF) transcription factors to 
activate the transcription of Wnt target genes such as cMyc and cd44 (He, Sparks 
et al. 1998; Wielenga, Smits et al. 1999). 
When there is no Wnt signalling, CK1 and GSK3β are able to phosphorylate 
β-Catenin allowing it to be recognised and ubiquitinylated by the β-TRCP 
protein. Therefore, β-Catenin will be degraded by the proteasome and will not 
activate the Wnt target genes transcription (Aberle, Bauer et al. 1997; Polakis 
2000; Clevers 2006) (Figure 5 B). 
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Figure 5: The Wnt pathway 
A: Active Wnt pathway. B: Inactive Wnt pathway. 
Adapted from Fodde et al., Nature Review, 2001 
 
 
1.3.2 Adenomatous Polyposis Coli (APC) 
The human Apc gene encodes for a 312 KDa scaffold protein (Groden, Thliveris 
et al. 1991) which is a binding partner of β-Catenin (Rubinfeld, Souza et al. 
1993; Su, Vogelstein et al. 1993) and is essential for the formation of the 
β-catenin destruction complex (Figure 6). The N-Terminal (N-Ter) part of the 
Apc protein has a coiled-coil domain predicting a possible oligomerisation (Day 
and Alber 2000). It also contains an armadillo repeats domain which allows Apc 
to interact with the regulatory unit of protein phosphatases 2A (PP2A) (Seeling, 
Miller et al. 1999) or the Apc-stimulated guanine nucleotide exchange factor for 
Rho family proteins (Asef) (Kawasaki, Senda et al. 2000). How these interactions 
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are regulated is not known. The centre of the protein contains two specific 
repeated amino acid sequences which are the β-Catenin binding sites (Rubinfeld, 
Souza et al. 1993; Su, Vogelstein et al. 1993; Rubinfeld, Albert et al. 1996). 
While the first 15-amino-acid repeat sequence is constitutively binding 
β-Catenin, the other one (20-amino-acid repeat sequence) is phosphorylation 
dependant. Within the second sequence, a Ser-Ala-Met-Pro (SAMP motif) amino 
acid sequence responsible for Axin binding is found (Hart, de los Santos et al. 
1998; Fagotto, Jho et al. 1999). Several interaction motifs are found in the 
C-Terminal region of Apc notably one which allows binding to EB1, a microtubule 
binding protein (Askham, Moncur et al. 2000), which predicts also roles outside 
the Wnt cascade. Whereas the N-Terminal and the C-Terminal domains of Apc 
may vary between species, the centre of the protein is well conserved and is the 
site of most of the mutations leading to cancer (Nathke 2004). 
 
 
Figure 6: Structure of the Apc protein 
Adapted from Fodde et al., Nature Review, 2001 
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Mutations in Apc are found in 80% of sporadic CRCs and disturb its ability to form 
the β-Catenin destruction complex. To initiate tumourigenesis by disturbing this 
particular protein, the mutation of both Apc alleles is necessary. This is the 
reason why a loss of heterozygosity (LOH) in the chromosome 5q where Apc is 
located is important to initiate the tumour formation (Vogelstein, Fearon et al. 
1988; Vogelstein, Fearon et al. 1989). These characteristics of CRC are 
reproduced in our studies in vivo by the inducible mutation of Apc within the 
intestine of adult mice. In the work presented in this thesis I have investigated 
Apc loss in two ways. First, a mouse model where one copy of Apc is deleted 
from the adult intestine, the tumour formation depends on the sporadic loss of 
the other copy. These studies can last up to 400 days. Second, where the 
phenotype of Apc loss can be explored by acutely deleting both copies of Apc 
inducing the formation of a Crypt Progenitor-Like (CPL) phenotype which 
consists in altered crypt–villus architecture, a defect in migration of the cells 
along the crypt-villus axis and a nuclear localisation of β-Catenin in the gut 
epithelial cells (Sansom, Reed et al. 2004) (Figure 7). 
 
Figure 7: The CPL phenotype 
H&E of wild type intestine (left panel) and VilCre+ Apcfl/fl (right panel) taken at day 4 after Cre 
recombinase induction. The epithelium of the mouse which has lost the two copies of Apc is 
disorganised. The cells are no longer in a mono layer and the proliferative zone, indicated by the 
black dashed line, is drastically extended. 
WT Apcfl/fl
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2 Introduction to pancreatic cancer 
2.1 Pancreatic cancer 
Pancreatic cancer (PC) represents less than 3% of diagnosed cancers in the UK 
(http://www.cancerresearchuk.org/cancer-info/cancerstats/). However, it is 
the fifth cause of death by cancer for both men and women (respectively 4.7% 
and 5.4% of cancer death) with an average survival of only 6 months. Over the 
years, the mortality due to this cancer has not decreased. Patients are often 
diagnosed late with aggressive and metastatic cancer making it particularly 
difficult to treat. For this reason, surgical resection is possible for only 20% of PC 
patients.  
2.1.1 Biology of the pancreas 
The pancreas is a mixed gland which can be divided into two components: the 
endocrine and the exocrine pancreas (Figure 8). The endocrine pancreas consists 
of the islets of Langerhans and some extra-islet endocrine cells. It has an 
essential role in the glycaemia control as the islets comprise the 
glucagon-producing α-cells and the insulin-producing β-cells. The exocrine 
pancreas is composed of the acini and the ducts and is important for digestion. 
The acinar cells secrete digestive enzymes which are channelled in the duct 
system to the gut. The ductal epithelium is composed of cuboidal cells placed in 
a single layer surrounding the lumen of the duct. Any modification of this 
structure can be an early sign of PC. 
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Figure 8: The mouse pancreas organisation 
H&E of the pancreas of a wild type mouse. The three different structures can be observed: the 
acini, a duct and an islet of Langerhans. 
 
2.1.2 Pancreatic cancer (PC) 
There are several malignant PC forms, however, the most common and the most 
studied one is the Pancreatic Ductal Adenocarcinoma (PDAC). Most of the PDACs 
are sporadic but around 5% of cases occur in patients with increased risk factors 
such as breast cancer type 2 (brca2) or liver kinase B1 (lkb1) germline mutations 
(Jaffee, Hruban et al. 2002).  
The early pancreatic lesions are called pancreatic intraepithelial neoplasia 
(PanIN). There are three stages defined by the degree of architectural and 
nuclear atypia (see http://pathology.jhu.edu/pancreas_panin/) (Hruban, 
Goggins et al. 2000; Hruban, Adsay et al. 2001; Kern, Hruban et al. 2001). At the 
PanIN1A stage, cells undergo a basal delocalisation of the nucleus and exhibit 
abundant mucin. The PanIN1B lesions are similar to the PanIN1A but have a 
papillary, micropapillary or basally pseudostratified architecture. At the PanIN2, 
the lesions show nuclear abnormalities such as loss of polarity, hyperchromatism 
and/or enlarged nucleus. Finally the PanIN3 lesions show a disorganisation of the 
Acini
Duct
Islet
Blood 
vessel
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duct with cells placed in the lumen of the duct. There is abundant mucin 
production by dystrophic Goblet cells, increased and potentially abnormal 
mitoses and a loss of cell polarity. The PDAC presents severe dysplasia and is 
rapidly evolving to a metastatic stage (Figure 9). 
 
 
Figure 9: Overview of the evolution of PDAC 
Initiating mutations allow formation of PanIN 1 gradually evolving to further stages of PanINs. 
Then accumulation of mutations allows the progression of adenomas to aggressive and invasive 
adenocarcinomas. 
 
A genetic progression model has been proposed for PC (Hruban, Wilentz et al. 
2000). KRas is mutated in over 90% of cases and genes such as p16INK4A and p53 
are mutated in over 50% of cases. KRas mutation in mouse models of pancreatic 
cancer is capable of reproducing the entire PDAC evolution (Hingorani, Petricoin 
et al. 2003). The high MAPK pathway activation in these lesions induces 
senescence. Using mouse models, it has been shown that this senescence can be 
overcome by mutations in either p16INK4A or p53, which are common in PDAC 
(Morton, Timpson et al. 2010). Therefore selection to overcome KRas induced 
senescence may drive progression and further mutation in PC. 
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Epithelium PanIN 1 PanIN 2 PanIN 3 Adenocarcinoma
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2.2 The oncogene Ras 
Ras genes encode for small GTP-binding proteins which are major elements of 
several signalling pathways. Ras has two states: off when it is bound to the 
nucleotide guanosine diphosphate (GDP) and on when it is bound to guanosine 
triphosphate (GTP). The switch between the two states is achieved by guanine 
nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs). 
However, Ras has an intrinsic GAP activity. Oncogenic forms of Ras have reduced 
Ras-GAP activity and therefore are constitutively active inducing a strong 
deregulation of signalling pathways affecting transformation, invasion and 
angiogenesis (Ellis and Clark 2000). The three forms of Ras namely Harvey Ras 
(HRas), Neuroblastoma Ras (NRas) and Kirsten Ras (KRas) are found to be 
mutated in various cancers. Oncogenic KRas is often found in CRC and PC while 
oncogenic NRas is found in melanoma. 
2.2.1 KRas in CRC 
The Apc mutation is considered to initiate CRC formation. However, in order for 
the cancer to progress, other mutations are necessary and the constitutive 
activation of KRas is another common mutation with 25% to 40% of CRCs having 
this mutation. Indeed it has been shown that a minimum of 25% of the CRC 
patients had an oncogenic KRas (Benhattar, Losi et al. 1993; Kressner, Bjorheim 
et al. 1998; Conlin, Smith et al. 2005; Winder, Mundlein et al. 2009). The 
hotspots for mutation in KRas are codons 12, 13 and 61. In a study of 342 
patients diagnosed with colorectal cancer (Winder, Mundlein et al. 2009), most 
KRas mutations (21.7%) were found in codon 12. These reports highlight that the 
most frequent substitutions in codon 12 were glycine to aspartate (G12D) or 
valine (G12V). The prevalence of the mutations in codon 12 has been confirmed 
by other studies (Kressner, Bjorheim et al. 1998; Conlin, Smith et al. 2005; 
Winder, Mundlein et al. 2009). Therefore the mouse models I have used in this 
study carry the G12D (Jackson, Willis et al. 2001; Johnson, Mercer et al. 2001) or 
G12V mutations (Guerra, Mijimolle et al. 2003; Guerra, Schuhmacher et al. 
2007). It is interesting to note that in humans the G12V mutation resulted in 
worse prognosis compared to the other mutations (Benhattar, Losi et al. 1993). 
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The effects of oncogenic KRas in the gut have been modelled in vivo. In mouse 
models, oncogenic KRas alone modifies the homeostasis of the colonic 
epithelium leading to hyperplasia and formation of aberrant crypt foci (ACF) 
(Calcagno, Li et al. 2008; Haigis, Kendall et al. 2008). However, the activation of 
KRas alone is not sufficient for tumour progression and the concomitant deletion 
of Apc is necessary for malignant tumourigenesis.  
2.2.2 KRas in PC 
KRas mutations have been found in over 90% of PC (Almoguera, Shibata et al. 
1988; Smit, Boot et al. 1988; Hruban, van Mansfeld et al. 1993; van Es, Polak et 
al. 1995). This renders the mutation of KRas essential and presumably an 
initiating event in PCs. As in CRCs, the majority of the mutations occur in codon 
12 and a small subset occurs in codons 13 and 61. Consequently, the effects of 
oncogenic KRas in PCs are studied in vivo using the G12D and G12V mutations as 
for the CRCs. 
In vivo, the presence of oncogenic KRas targeted to the pancreas is sufficient to 
initiate PC. However there is a very long latency to develop PDAC suggesting 
other mutational events are required to drive tumour progression. Nevertheless, 
this model does recapitulate human pancreatic carcinogenesis with a 
reproduction of all stages of PC from the early PanIN lesions to the late PDAC 
(Hingorani, Petricoin et al. 2003). The mutation of p53 cooperates with the 
oncogenic KRas and helps drive metastatic spread (Hingorani, Wang et al. 2005; 
Morton, Klimstra et al. 2008). 
2.3 The MAPK pathway 
The Mitogen-Activated Protein Kinase (MAPK) pathway results, after activation 
by growth factors or cytokines, in the serial activation of the following proteins: 
Ras, Raf, Mek and Erk (Figure 10).  
After receptor activation by a ligand, a Src homology 2 domain-containing 
protein (Shc) interacts with the growth factor receptor and then recruits the 
GTP-exchange complex composed of growth factor receptor bound 2 (Grb2) and 
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Son of sevenless (Sos). Grb2/Sos complex recruits Ras-GTP which then recruits 
Raf from the membrane. Ras can also be activated by the Src Family Kinases 
(SFK) (Kim, Song et al. 2009; Matozaki, Murata et al. 2009). Raf activated by a 
tyrosine kinase, likely from the Src family, can then phosphorylate and therefore 
activate the mitogen-associated extracellular regulated kinase (Mek). Activated 
Mek phosphorylates specific threonine and tyrosine residues of extracellular 
regulated kinase (Erk) to activate it. Phosphorylated Erk has activating kinase 
functions in the cytoplasm and the nucleus where it can activate transcription 
factors such as ETS-like transcription factor 1 (Elk1) and Fos. 
 
 
Figure 10: Overview of the MAPK pathway 
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The MAPK pathway activation is triggered by several mutations. At the 
membrane level, the receptor tyrosine kinases (RTKs) can be overexpressed 
and/or constitutively active by mutations (Grandis and Sok 2004). As already 
mentioned Ras is often mutated particularly in pancreatic cancer. Raf is also an 
oncogene: V-raf murine sarcoma viral oncogene homolog B1 (BRaf) is frequently 
mutated in melanomas and CRCs (Davies, Bignell et al. 2002). However, no 
mutations in Mek and Erk have been reported so far. 
2.3.1 The MAPKs 
There are several MAPKs controlling different cellular functions after activation 
of the conventional MAPK pathway. In this thesis I will concentrate on MEK1/2 
and ERK 1/2 as these are the best studied downstream effectors of Ras 
mutations. Other MAP kinases include the cJun NTerminal kinases (JNK) which is 
predominately activated by stress signals and regulates transcription factors 
such as cJun or p53 to modulate cell cycle control and apoptosis. P38 is also 
activated by stress signals and induces similar cell responses to JNK. Erk5 is a 
kinase similar to Erk 1/2 but is only phosphorylated by Mek5. Erk5 is activated by 
stress signals and specific growth factors such as nerve growth factor (NGF) and 
induces angiogenesis and neural differentiation (Regan, Li et al. 2002; 
Nishimoto, Kusakabe et al. 2005).  
2.3.2 ERK 1/2 
Erk 1/2 are the two predominant Erk isoforms (Erk1 is 44KDa and Erk2 is 42KDa) 
and are ubiquitously expressed. They are encoded by the genes Erk1 and Erk2 
located on chromosome 16 in mice and chromosome 22 in human. They 
stimulate various and sometimes antagonistic cellular functions and the level of 
Erk 1/2 activation constitutes a balance which can control which cellular 
response is activated (Cagnol and Chambard 2010). 
Erk 1/2 induces apoptosis following DNA-damage or by regulation of Tumour 
Necrosis Factor (TNF) related apoptosis-inducing ligand (TRAIL) (Tang, Wu et al. 
2002; Drosopoulos, Roberts et al. 2005). Furthermore, Erk 1/2 can promote cell 
death by upregulation of p53 (Persons, Yazlovitskaya et al. 2000; She, Chen et 
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al. 2000; Tang, Wu et al. 2002). Overactivation of Erk 1/2 is also associated with 
senescence (Mooi and Peeper 2006). In this case, genes involved in senescence 
such as p53, p21 and p19/Arf are induced and there is an increased 
β-galactosidase activity (Bennecke, Kriegl et al. 2010). This senescence can be 
induced by oncogenic KRas (Tuveson, Shaw et al. 2004). Balancing with its cell 
growth arrest activity, Erk 1/2 induces cellular proliferation notably via 
activation of transcription factors cMyc, fos, jun and stimulates the transcription 
of cyclin-dependent kinase 4 (cdk4) and cyclin D. Furthermore, Erk 1/2 can also 
stimulate cell survival by phosphorylating Forkhead box O3 (FOXO3A) and by 
repressing Bim expression (Yang, Zong et al. 2008). It is important to note that 
most of these functions of Erk 1/2 can be inhibited by the use of Mek inhibitors 
such as PD184352 (CI1040) PD0325901 or AZD6244 (Sebolt-Leopold, Dudley et al. 
1999) (see result chapter). These drugs are currently in clinical trials (Rinehart, 
Adjei et al. 2004). However the antitumoural activity in human patients seems 
limited for the moment and an adjustment of the compound and/or the 
association with other drugs may be necessary. 
There is a dynamic shuttling of the Erk 1/2 between the cytoplasm and the 
nucleus. The subcellular localisation of this protein is very important and has a 
significant impact on the cellular response following Erk 1/2 activation. During 
growth arrest, Erk 1/2 is mainly located in the cytoplasm. The translocation to 
the nucleus will allow Erk 1/2 to activate certain transcription factors and 
induce the transcription of its target genes, however the retention to the 
cytoplasm is sufficient to prevent this phenomenon (Brunet, Roux et al. 1999; 
Kim, Nose et al. 2000). The translocation to the nucleus is transient. Indeed a 
study performed using NIH-3T3 cells showed that following serum activation, 
Erk 1/2 is translocated and accumulates in the nuclei. This accumulation is lost 
six hours after stimulation (Pouyssegur, Volmat et al. 2002). The control of Erk 
1/2 localisation is made by Mek activation (Lenormand, Brondello et al. 1998) 
and also anchoring proteins (Chuderland and Seger 2005) such as Dusp6 in the 
cytoplasm (Karlsson, Mathers et al. 2004) or Dusp5 in the nucleus (Mandl, Slack 
et al. 2005). Erk 1/2 also has a nuclear translocation signal (NTS) (Chuderland, 
Konson et al. 2008; Zehorai, Yao et al. 2010). 
Introduction 
 
42
2.4 Other Ras effector pathways 
In cells, signalling pathways are often overlapping. The MAPK pathway is no 
exception and whilst the direct pathway downstream of Ras activation is the 
Mek-Erk cascade, Ras also has impacts on many other signalling pathways (Figure 
10). Of these, one of the pathways importantly affected by Ras activation is the 
Phosphatidylinositol 3-kinase/Akt (PI3K/Akt) cascade. Other cascades such as 
T lymphoma invasion and metastasis/RAS-related C3 botulinum substrate 
(Tiam/Rac) and Ras Related (Ral) A/B are also affected. These multiple effects 
of Ras activation have consequences when a particular signalling cascade is 
modified. Therefore, we can hypothesize that the blockade of one cascade can 
result in a compensatory over-activation of another cascade. Other pathways 
that have been shown to be activated by KRas in cell type specific manners 
include Wnt signalling, nuclear factor κ-light-chain-enhancer of activated B cells 
(NFκB) and Signal Transducer and Activator of Transcription (STAT). In most 
cases the precise mechanism of this activation is unclear.  
2.4.1 The PI3K/Akt pathway 
The PI3K/Akt cascade starts with the activation of RTKs such as erythroblastic 
leukemia viral oncogene homolog 2 (Erbb2) or insulin growth factor receptor 
(IGFR). The activation of the RTK allows the activation of PI3K which then 
phosphorylates phosphatidylinositol biphosphate (PP2) to triphosphate (PP3). 
The Phosphatase and tensin homologue (PTEN) negatively regulates this pathway 
by removing a phosphate from PP3 reverting it back to its PP2 form. PP3 is an 
anchor protein for Akt (also called Protein Kinase B (PKB)) and phosphoinositide 
dependent protein kinase 1 (PDK1). This anchorage allows the phosphorylation of 
Akt by PDK1. Akt can then translocate to the membrane via PP3 or to the 
nucleus or remain in the cytosol where it can phosphorylate GSK3β. Akt 
negatively regulates NFκB by phosphorylating the inhibitor of kappa B (IκB) 
kinase (IKK) which will phosphorylate the IκB subunit to target it to the 
proteasome preventing NFκB activation. The PI3K/Akt pathway also indirectly 
activates mammalian target of Rapamycin (mTOR) (For review:(Steelman, 
Abrams et al. 2008; Castellano and Downward 2011). It is important to note that 
PI3K contains a Ras binding domain. Indeed, Ras can bind the p110α subunit of 
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PI3K and activate the downstream cascade. It has been shown that in mice 
expressing an oncogenic KRas (which results in lung tumourigenesis) (Johnson, 
Mercer et al. 2001), the inactivation of p110α by two point mutations was 
sufficient to drastically reduce the number of tumours formed (due to higher 
apoptosis) (Gupta, Ramjaun et al. 2007). 
2.4.2 The Tiam/Rac pathway 
Rac is a rho family small GTPase and Tiam1 is one of its GEFs. Rac can be 
activated by Ras and has several outcomes. It has been mainly described as an 
important effector of actin reorganisation; however, it can also be involved in 
other signalling cascades such as the JNK pathway leading to the activation of 
transcription factors such as cJun and Elk1. Tiam1 has a Ras binding domain and 
Ras has been showed to be essential to Tiam1 activation and consequently Rac1 
activation (Lambert, Lambert et al. 2002; Yamauchi, Miyamoto et al. 2005). Rac 
status has an impact on tumourigenesis. It has been shown to be upregulated in 
PDACs and its deletion in mouse models reduced tumourigenesis (Heid, 
Lubeseder-Martellato et al. 2011). Tiam1 is essential to tumour initiation in 
Tiam1 deleted (Tiam-/-) mice. Indeed Tiam1-/- mice treated with the skin tumour 
initiator 7,12-dimethylbenzanthracene / 12-O-tetradecanoylphorbol-13-acetate 
(DMBA/TPA) developed less tumours than wild type (wt) mice (Malliri, van der 
Kammen et al. 2002). Moreover the tumours from Tiam1-/- mice had an increased 
apoptosis and grew much slower than the corresponding tumours in wt mice. 
Interestingly, in this model tumours from Tiam1-/- mice were more advanced and 
a previous study suggested Tiam1 to be involved in invasion (Habets, Scholtes et 
al. 1994). 
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3 The dusp family  
In mammals, signal transduction is mostly controlled by phosphorylation and 
dephosphorylation. The MAPK signalling pathway is not an exception and 
phosphorylation represents a common mechanism to maintain the balance 
between kinase activation and negative regulatory controls. The Dual-Specificity 
Phosphatases (DUSPs) are a heterogeneous group of proteins which can 
dephosphorylate both threonine/serine and tyrosine residues in their substrates 
(hence their name “dual-specificity”).  
There are 61 DUSPs grouped together by their highly conserved catalytic domain 
which has the following consensus sequence containing a histidine, a cysteine 
and an arginine: HCXXXXXR (Patterson, Brummer et al. 2009; Huang and Tan 
2012). The consensus sequence (HCXXXXXR) creates a shallow catalytic site of 
5.5 Å. The active residues cysteine and arginine of the signature motif are 
located in a loop near another loop containing a highly conserved aspartic acid; 
together the 2 loops form the enzymatic active site (Farooq and Zhou 2004). 
The DUSPs are classified into seven subgroups (Figure 11). All these subgroups 
have very distinct targets. One of these DUSPs subgroup contains the preferred 
antagonist proteins of the MAPK pathway. These particular proteins are called 
the MAPK Phosphatases (MKPs). In this thesis we will only discuss this MKP 
subgroup due to their preferred targets the MAP Kinases. The proteins of the 
MKP subgroup of the DUSP family are defined based on the presence of the MAP 
kinase-binding (MKB) also named kinase-interaction motif (KIM) domain, an 
essential motif to MAP kinases interactions. The MKB/KIM domain interacts with 
the common domain of the MAPKs and is characterised by the conserved 
φφXRRφXXG motif where φ is a hydrophobic residue and X is any residue (Farooq 
and Zhou 2004). It is interesting to note that another DUSP subgroup, named 
atypical, presents some similarities with the MKP subgroup and has been 
sometimes been merged with this one. 
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Figure 11: Dual Specificity Phosphatases classification:  
The 61 Dusp proteins are classified into seven subgroups: Slingshots, MAP Kinase Phosphatases 
(MKPs), Myotubularins, Cdc14 phosphatases, Phosphatase of Regenerating Liver (PRLs) , 
Phosphatase and Tensin homologue deleted on chromosome 10-like (PTENs-like) and Atypicals.  
Adapted from Patterson et al, Biochem. J, 2009. 
 
3.1 MKP proteins 
The MAPK Phosphatases (MKPs), a subgroup of the DUSP family, are the 
preferred antagonist proteins of the MAPK pathway. There are ten catalytically 
active MKPs in mammals.  
3.1.1 Structure 
The MKPs can be subdivided into three groups according to their structure 
(Figure 12) (Farooq and Zhou 2004). The Type II MKPs have usually between 300 
and 400 amino acids and contain a MKB/KIM domain and the consensus catalytic 
sequence HCXXXXXR. The Type III contains only Mkp5 (also known as Dusp10). 
Finally the Type IV MKPs have between 600 and 700 amino acids and contain a 
C-Terminal (C-Ter) sequence rich in prolines, glutamates, serines and threonines 
(sequence PEST). However, all MKPs have a similar structure which includes an 
N-Terminal (N-Ter) non catalytic domain and a C-Ter catalytic domain (Camps, 
Nichols et al. 2000; Theodosiou and Ashworth 2002; Owens and Keyse 2007; 
Patterson, Brummer et al. 2009).  
Dual Specificity Phosphatases
Slingshots
PRLs
Cdc14 
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Figure 12: The MKPs classification and their human chromosome localisation  
The MKPs are grouped according to their structure in type II, III or IV. Their chromosome 
localisation in the human genome is indicated in the column Ch. 
Adapted from Keyse, Cancer Metastasis Rev., 2008. 
 
The C-Ter catalytic domain encompasses the conserved characteristic cysteine-
dependent protein tyrosine phosphatase active site sequence I/VHCXAGXXR, 
where X is any residue (Camps, Nichols et al. 2000; Keyse 2000; Dickinson and 
Keyse 2006). 
The N-Ter domain has a regulatory function. It contains a modular docking site 
determining the specificity to a given MAP kinase and a sequence determining 
the subcellular localisation of the MKP (Owens and Keyse 2007). 
3.1.2 Subcellular localisation 
There is a correlation between subcellular localisation and the specificity of the 
MKPs (Figure 13). Therefore they are subdivided in three categories: nuclear 
MKPs, cytoplasmic MKPs and shuttle MKPs (Camps, Nichols et al. 2000; 
Theodosiou and Ashworth 2002; Caunt and Keyse 2012).  
The Nuclear mitogen and stress inducible MKPs are Dusp1, Dusp2, Dusp4 and 
Dusp5. These phosphatases have a nuclear localisation signal (NLS) in their N-Ter 
non catalytic domain (Mandl, Slack et al. 2005; Wu, Zhang et al. 2005). All these 
proteins can target Erk but they can also target p38 and/or JNK.  
The MKPs
Gene Other names Ch. Type Cellular localisation
Dusp1 MKP1, CL100, hVH1 5q34 II Nuclear
Dusp2 PAC1 2q11 II Nuclear
Dusp4 MKP2, Sty8, hVH2, TYP1 8p12-p11 II Nuclear
Dusp5 hVH3, B23 10q25 II Nuclear
Dusp6 MKP3, PYST1, rVH6 12q22-q23 II Cytoplasmic
Dusp7 PYST2, MKPX, B59 3p21 II Cytoplasmic
Dusp8 HB5, hVH5, M3/6 11p15,5 IV Both
Dusp9 MKP4, PYST3 Xq28 II Cytoplasmic
Dusp10 MKP5 1q41 III Both
Dusp16 MKP7 12p12 IV Both
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The Erk specific cytoplasmic MKPs are Dusp6, Dusp7 and Dusp9. They all share a 
nuclear export signal (NES) within their N-Terminal non catalytic domain 
determining their preferential localisation in the cytoplasm (Karlsson, Mathers et 
al. 2004).  
Finally the JNK-p38 specific MKPs are Dusp8, Dusp10 and Dusp16. These 
phosphatases can be considered as shuttle proteins because of their dual 
subcellular localisation (Tanoue, Moriguchi et al. 1999; Masuda, Shima et al. 
2001). 
 
Figure 13: The MKPs specific targets and their cellular localisation 
Adapted from Keyse, Cancer Metastasis Rev., 2008. 
 
3.2 MKPs and cancer 
3.2.1 Dusp1 
Most of the MKPs have been reported as modified in cancer. I will briefly 
mention Dusp1 as this MKP has been studied most extensively in relationship to 
cancer.  
Dusp1 has been shown to be upregulated in various cancers such as colon, lung, 
prostate, ovarian, breast and bladder (Loda, Capodieci et al. 1996; Magi-
Galluzzi, Mishra et al. 1997; Zhang, Zhou et al. 1997; Denkert, Schmitt et al. 
Gene Specificity Cellular localisation
Dusp1 JNK, p38 > ERK Nuclear
Dusp2 ERK, p38 Nuclear
Dusp4 JNK, p38, ERK Nuclear
Dusp5 ERK Nuclear
Dusp6 ERK Cytoplasmic
Dusp7 ERK Cytoplasmic
Dusp9 ERK > p38 , JNK Cytoplasmic
Dusp8 JNK, p38 Both
Dusp10 JNK, p38 Both
Dusp16 JNK, p38 Both
Introduction 
 
48
2002; Wang, Cheng et al. 2003; Chattopadhyay, Machado-Pinilla et al. 2006; 
Moncho-Amor, Ibanez de Caceres et al. 2011). Also, it is interesting to note a 
loss of Dusp1 expression in more advanced stages of colon, prostate and bladder 
cancers (Loda, Capodieci et al. 1996; Zhang, Zhou et al. 1997). Due to these 
observations, Dusp1 is believed to be a tumour suppressor gene. However, in 
lung and breast cancer, Dusp1 overexpression has been reported to increase 
chemotherapy resistance (Wang, Xu et al. 2006; Small, Shi et al. 2007). This 
could be due to its high affinity to JNK-p38 (Camps, Nichols et al. 2000; Small, 
Shi et al. 2007).  
Interestingly the inhibition of Dusp1 has been showed to increase hypoxia 
(Laderoute, Mendonca et al. 1999; Liu, Shi et al. 2005; Jin, Calvert et al. 2010). 
Furthermore, a role in regulation of the immune function has been also reported 
in several studies using Dusp1 null mice (Chi, Barry et al. 2006; Salojin, Owusu et 
al. 2006; Frazier, Wang et al. 2009). Notably, Dusp1 plays a role in the 
regulation of the bacterial lipopolysaccharide (LPS) increasing the production of 
the inflammatory cytokines (Chi, Barry et al. 2006; Salojin, Owusu et al. 2006; 
Liu, Shepherd et al. 2007). Given the clear relationship between inflammation 
and cancer it is thus difficult to uncouple these functions of Dusp1. 
3.2.2 Other MKPs 
Several studies reported a significant impact on cancer by the nuclear MKPs 
subgroup. Dusp2 has been shown to be downregulated in acute leukemia (Kim, 
Hahn et al. 1999). However, the overexpression of Dusp2 in ovarian tumours was 
correlated with a poor prognosis in patients (Givant-Horwitz, Davidson et al. 
2004). Dusp4 overexpression is implicated in liver tumourigenesis (Yokoyama, 
Karasaki et al. 1997) and notably KRas activated cell lines exhibited high Dusp4 
expression (Yip-Schneider, Lin et al. 2001). Dusp5, the Erk specific phosphatase 
in the nucleus, has been suggested recently to be a p53 target as its 
transcription was activated by endogenous p53 after DNA damage in colon 
cancer cells (Ueda, Arakawa et al. 2003). Furthermore, we show in a microarray 
study that in a mouse model of intestinal tumourigenesis combining an Apc 
mutation and KRas activation resulted in Dusp5 upregulation (see result 
chapter). 
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Dusp7 is highly expressed in myeloid leukemia cells in correlation with MAPK 
pathway activation (Levy-Nissenbaum, Sagi-Assif et al. 2003; Levy-Nissenbaum, 
Sagi-Assif et al. 2003; Levy-Nissenbaum, Sagi-Assif et al. 2003). Dusp9 loss of 
expression is associated with advanced stages of epidermal carcinogenesis (Liu, 
Lagowski et al. 2007). The same study showed that the expression of Dusp9 
could induce tumour cell death, microtubule disruption and tumour regression in 
vivo. Furthermore, a low expression of Dusp9 has been associated with bad 
prognosis in patients with clear cell renal carcinoma (Wu, Wang et al. 2011). 
Dusp10 has been reported to have an anti-inflammatory activity (Zhang, 
Blattman et al. 2004) and it is thought to have a chemopreventive effect when 
activated by anti-cancer compounds such as resveratrol in prostate cancer cells 
(Nonn, Duong et al. 2007). An overexpression of Dusp16 downregulates JNK 
activation and results in reduced transforming capacity of BCR-ABL transformed 
fibroblasts (Hoornaert, Marynen et al. 2003). Furthermore, a methylation-
dependant silencing of Dusp16 resulting in a modification of JNK signalling has 
been shown in Burkitt’s lymphoma cells (Lee, Syed et al. 2010).  
One of the weaknesses of most of these studies is that they were predominantly 
correlating expression of a specific DUSP in different cancers and few functional 
definitive experiments have been performed. This is one of the major reasons 
we decided to take a genetic approach to delete Dusp6 and see if it modified 
tumourigenesis in vivo. 
3.3 Dusp6 
3.3.1 Structure of dusp6 
Dusp6 (also named Mkp3 or Pyst1) is located in human on chromosome 12 at 
band q22-q23 (Smith, Price et al. 1997). It has been cloned and characterised in 
1996 using the characteristic extended active-site sequence motif 
VXVHCXXGXSRSXTXXXAYLM (where X is any amino acid) found in Dusp1 (Groom, 
Sneddon et al. 1996; Muda, Boschert et al. 1996). Interestingly, Dusp6 shares 
73% sequence homology with Dusp7 however their expression in tissues remains 
very different. While Dusp6 shows a basal expression in most tissues, Dusp7 
seems to be limited to the liver and the muscle (Groom, Sneddon et al. 1996).  
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Mammalian Dusp6 has an N-Ter Cdc25 homology domain as well as an MKB/KIM 
domain (Figure 14). The MKB/KIM domain consists in open twisted five-stranded 
β sheets, each sheet being bordered by α helices (Farooq, Chaturvedi et al. 
2001). The catalytic site is located in the C-Terminal. The catalytic site is 2.5 Å 
and is located in a shallow phosphate-binding loop of 5.5Å between the β8 
strand and the α5 helix (Stewart, Dowd et al. 1999) (Figure 15). This rather small 
space allows the presence of both targeted residues (tyrosine and threonine) 
nearby the active site of Dusp6. The phosphatase possesses the three conserved 
residues of MKPs: Asp 262, Cys 293 and Arg 299. These amino acids have an 
important role in the modulation of the Dusp6 conformation during its 
activation. 
 
 
Figure 14: Structure of Dusp6/Mkp3 
Adapted from Caunt and Keyse, FEBS, 2012. 
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Figure 15: Representation of the MKB/KIM domain of Dusp6.  
The strands are symbolised by blue arrows and helices are represented by purple cylinders. 
Switch points are indicated by red arrows. 
Adapted from Farooq et al., Molecular Cell, 2001 
 
3.3.2 Subcellular localisation 
Dusp6 is only found in the cytosol, even following stimulation of the MAPK 
cascade (Groom, Sneddon et al. 1996), due to a NES sequence. This ensures a 
strong control of Erk 1/2 in the cytoplasm compartment. 
3.3.3 Dusp6 targets specifically Erk 
Several studies report the specificity of Dusp6 for Erk (Groom, Sneddon et al. 
1996; Muda, Theodosiou et al. 1998; Bermudez, Jouandin et al. 2011). Indeed, 
Dusp6 efficiency to dephosphorylate JNK or p38 in vitro is 90 to 100 fold less; 
consequently the phosphatase is unable to block the activation of these proteins 
in vivo. Moreover, Dusp6 specifically binds and co-precipitates with Erk (Groom, 
Sneddon et al. 1996; Muda, Theodosiou et al. 1998). Furthermore, whereas the 
treatment with the Mek inhibitor CI1040/PD184352 induced a decrease in Dusp6 
mRNA levels in cancer cell lines, no change was observed with treatment with 
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the compounds LY294002, SP600125 and SB203580 respectively inhibiting PI3K, 
JNK and p38 (Bermudez, Jouandin et al. 2011). 
3.3.4 Regulation of DUSP6 
Dusp6 plays a key role in the control of the activation of the MAPK cascade. In 
return, Dusp6 has been found to be regulated by MAP kinases (Figure 16). In 
response to the activation of the MAPK cascade, Dusp6 expression is activated in 
order to prevent an overactivation of Erk 1/2. Indeed, stimulation of the MAPK 
pathway by the fibroblast growth factor (FGF) or by platelet-derived growth 
factor (PDGF) results in Erk-dependant Dusp6 mRNA upregulation (Eblaghie, Lunn 
et al. 2003; Jurek, Amagasaki et al. 2009). Dusp6 is also regulated at the post-
transcriptional level. Whilst its normal mRNA half-life is between 20 to 40 
minutes depending on the cell line, a Mek inhibitor treatment can reduce this 
period to only 8 minutes (Bermudez, Jouandin et al. 2011). This stabilisation 
through Mek/Erk signalling seems to be via the 3’UTR region of Dusp6 mRNA 
since a construct enclosing the 3’UTR sequence of Dusp6 presented an increased 
activity following Mek/Erk pathway stimulation. Moreover, in lung cancer cell 
lines, Dusp6 expression seems regulated by the Erk-responsive transcription 
factor (ETS1) and is abrogated by Mek inhibition (Zhang, Kobayashi et al. 2010). 
Simultaneously, there is a negative control of the Dusp6 protein in order to allow 
Erk 1/2 to play its role in signal transduction. For example, stimulation of cells 
by PDGF results in Dusp6 degradation (Jurek, Amagasaki et al. 2009). This is due 
to a MAPK pathway dependant phosphorylation of Ser 174 and Ser 159 of Dusp6 
which induces the ubiquitinylation of the phosphatase and its degradation by the 
proteasome. Consequently, downregulation of Dusp6 enhanced Erk 
phosphorylation and therefore activation. Intriguingly, Dusp6 overexpression or 
stabilisation (by inhibition of the proteasome) enhanced Mek activation.  
Dusp6 regulation can also be MAPK pathway independent. A redox regulation of 
Dusp6 has been reported. Indeed, a correlation was found between the increase 
of reactive oxygen species (ROS) in senescent cells and Dusp6 inactivation (Kim, 
Song et al. 2003). Additionally, Dusp6 is reversibly inactivated by oxidation in 
vitro (Seth and Rudolph 2006). Interestingly, the same study shows a protection 
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system within the protein: the multiple cysteine residues are capable of trapping 
the oxidative species and reactivate Dusp6. 
 
Figure 16: Overview of MAPK pathway and Dusp6 interactions 
The activation of the MAPK pathway by growth factors (GF) induce Dusp6 transcription and 
stabilisation of Dusp6 mRNA via protection of its 3’UTR. The protein Dusp6 dephosphorylates 
Erk 1/2 to stop its activation. Simultaneously, the Erk phosphorylates Dusp6. Phospho-Dusp6 is 
then ubiquitinylated and degraded via the proteasome. 
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3.3.5 Reciprocal activation and inactivation relationship between ERK 
and DUSP6 
To understand the mutual regulation of Erk 1/2 and its negative regulator Dusp6, 
a number of studies have carefully analysed this precise interaction of Erk 
activation and Dusp6. 
Erk 1/2, after being activated by Mek 1/2, is then able to bind specifically the 
N-terminal non catalytic domain of Dusp6 to activate the protein (Camps, 
Nichols et al. 1998; Farooq, Chaturvedi et al. 2001). Interestingly neither 
JNK/SAPK nor P38 can bind Dusp6 (Camps, Nichols et al. 1998). In the presence 
of Erk 1/2, there is an allosteric activation of Dusp6 by a structural 
reorganisation of the protein which leads to the closure of the flexible linker 
near the active site by the placement of the aspartic acid (Asp 262) near the 
residues Cys 293 and Arg 299 (Camps, Nichols et al. 1998; Stewart, Dowd et al. 
1999; Fjeld, Rice et al. 2000; Farooq, Chaturvedi et al. 2001; Rigas, Hoff et al. 
2001; Mark, Smith et al. 2007) (Figure 17). Then, the active Dusp6 can 
dephosphorylate Erk 1/2. In the absence of Erk 1/2, the Dusp6 phosphatase 
enters a conformation where the N-terminal domains bind the C-Terminal ones 
resulting in an inhibition of their catalytic domains (Mark, Aubin et al. 2008) 
(Figure 18).  
 
Figure 17: Erk-induced activation of Dusp6 
Erk 1/2 binds to the N-terminal domain (green square) of Dusp6. Then the C-Terminal domain 
(pink square) of Dusp6 binds to Erk 1/2 leading to an allosteric activation of the C-Terminal 
domain of Dusp6 (pink square outlined in red). This activation leads to phosphorylation of the 
threonine and tyrosine of Erk 1/2 (red circles).  
Adapted from Mark et al, J Biol Chem, 2008. 
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Figure 18: Autoinhibition of Dusp6 
When Dusp6 is too abundant, oligomers are formed due to interdomain binding.  
Adapted from Mark et al, J Biol Chem, 2008. 
 
A regulation of Dusp6 by Erk 1/2 at a posttranslational level has also been 
reported (Marchetti, Gimond et al. 2005). Indeed, Erk 1/2 can phosphorylate the 
serines 159 and 197 of Dusp6 catalytic domain. This phosphorylation does not 
alter the catalytic activity of DUSP6 but leads to its instability since an inhibition 
of MAPK pathway by a Mek inhibitor protects Dusp6 from its degradation by the 
proteasome (Marchetti, Gimond et al. 2005). 
3.3.6 Dusp6 and cancer 
In human, Dusp6 is upregulated in pancreatic PanIN lesions (Furukawa, Fujisaki 
et al. 2005). Interestingly an abrogation of Dusp6 is reported in PDAC showing 
that the loss of Dusp6 is associated with the progression to aggressive pancreatic 
cancer. This abrogation could be due to hypermethylation (Xu, Furukawa et al. 
2005). Furthermore, in ovarian cancer cell lines and human ovarian cancer 
samples, Dusp6 level is downregulated (Chan, Liu et al. 2008). Moreover, the 
expression of Dusp6 in these ovarian cancer cell lines reduces tumourigenesis 
and cisplatin resistance. In primary lung tumours, the presence of Dusp6 is 
associated with a less growth (Okudela, Yazawa et al. 2009). Hypoxia is often 
associated with cancer and an effect of hypoxia on induction of Dusp6 mRNA has 
been reported (Bermudez, Jouandin et al. 2011). This effect seems to be 
indirect as the Dusp6 gene does not have a hypoxia responsive element (HRE). In 
cells expressing HIF1α, the level of Dusp6 mRNA was increased and this was 
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correlated with an activation of Mek/Erk pathway since treatment with 
CI1040/PD184352 reversed this upregulation. All of these studies are suggestive 
of the tumour suppressive potential of Dusp6. 
However, there are conflicting reports in the literature concerning the role of 
Dusp6 in tumourigenesis. In glioblastoma cell lines, Dusp6 is upregulated and 
surprisingly its upregulation is associated with an increased resistance to 
Cisplatin (Messina, Frati et al. 2011). There is other evidence of an association 
between Dusp6 overexpression and drug resistance. In Tamoxifen resistant 
primary breast tumours, there was a higher expression of Dusp6 than in the 
Tamoxifen sensitive ones (Cui, Parra et al. 2006). However, in the breast 
carcinoma cell line MCF7, Tamoxifen treatment reduced Dusp6 activity. 
4 Fra1, a Ras pathways target 
Fra1 (Fos related antigen 1), is a member of the Fos family proteins and is part 
of the transcription factor activator protein-1 (AP-1).  
4.1 The AP-1 transcription factor 
The Activator Protein 1 (AP-1) complex has been implicated as a driver of 
carcinogenesis because it regulates cellular processes such as proliferation, 
differentiation and apoptosis (Jochum, Passegue et al. 2001; Young and Colburn 
2006). Furthermore due to the nature of its components, it can be activated by 
the MAPK pathway via Erk, JNK and p38 (Jochum, Passegue et al. 2001; 
Hasselblatt, Gresh et al. 2008) and it has been shown that mutations of Apc and 
KRas lead to elevated AP-1 activity (Park, Jeon et al. 2006). 
AP-1 is composed of proteins of the Jun family (cJun, JunB and JunD) and of the 
Fos family (cFos, FosB, Fra1 and Fra2). It is classically a dimer consisting of Jun-
Jun homodimers or Jun-Fos heterodimers (Young and Colburn 2006). However, 
recent in vivo studies on mouse models have shown that AP-1 components can 
form other complexes (Nateri, Spencer-Dene et al. 2005; Toualbi, Guller et al. 
2007). After activation by JNK, cJun can interact with transcription factor 4 
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(TCF4) and β-Catenin (Nateri, Spencer-Dene et al. 2005). This complex increased 
tumourigenesis and therefore, the inhibition of JNK resulted in a reduction of 
colonic tumours. This finding illustrates the intricate overlap between pathways 
and suggests that the balance between the different complexes may be very 
important for homeostasis and tumourigenesis. 
4.2 Fra1 
Fra1 (also termed Fosl1) is a key component of the AP-1 complex and is essential 
during development of the placenta (Schreiber, Wang et al. 2000). The Fra1 
gene is located in man on chromosome 11 and encodes a 29KDa protein. The 
Fra1 structure is similar to Fos. The protein contains a basic leucine-zipper 
domain essential for its interaction with other AP-1 partners and for 
DNA-binding. 
Fra1 has been shown to be upregulated in a large variety of tumours including 
breast, lung, and colon carcinomas (Young and Colburn 2006). Its transcription is 
activated by the MAPK pathway but also by the Wnt pathway (Mann, Gelos et al. 
1999; Young and Colburn 2006; Adiseshaiah, Li et al. 2008). Furthermore, its 
expression is up regulated following Apc loss. Most studies suggest that Fra1 has 
a pro-tumourigenic role (Adiseshaiah, Li et al. 2008; Adiseshaiah, Vaz et al. 
2008; Hamdi, Popeijus et al. 2008; Baan, Pardali et al. 2010). However, the 
balance between AP-1 complexes mentioned previously may impact on the 
outcome of Fra1 deregulation (Mechta, Lallemand et al. 1997). 
5 Murine models of cancer 
To address the effects of the common mutations occurring in the main pathways 
involved in tumour initiation and progression, genetically modified mice are now 
routinely used.  
In order to address the importance of Dusp6 and Fra1 in intestinal and 
pancreatic tumourigenesis, I used the bacterial Cre-LoxP system in three 
different models. The Cre-LoxP system leads to the expression of a site specific 
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bacteriophage recombinase (Cre) which promotes the recombination between 
two 34bp DNA sequences called LoxP sites (Abremski and Hoess 1984; Hoess and 
Abremski 1984). The Cre DNA recombinase expression is under the control of a 
tissue specific promoter namely either the Cytochrome p450 subfamily A1 
(Cyp1A1) or the Villin gene (Vil) promoters in the intestine and Pancreatic and 
duodenal homeobox 1 (Pdx1) promoter in the pancreas.  
5.1 Cre Recombinase constructs:  
5.1.1 Intestinal model: Vil-cre-ER system (VilCreER+) 
In this system the Cre gene is fused to a mutated ligand binding domain of the 
human estrogen receptor (ER) and to a 9Kb regulatory region of the murine Villin 
gene promoter (el Marjou, Janssen et al. 2004). The injection of Tamoxifen, an 
estrogen receptor antagonist, will separate the Cre from the ER at the cell 
membrane and allow its translocation to the nucleus. This system yields up to 
80% recombination in the differentiated enterocytes and the undifferentiated 
cells of the crypt in the intestine following the gradient of expression observed 
by the endogenous Villin namely increasing from the crypt to the differentiated 
cells of the villus (Muda, Boschert et al. 1996; Camps, Nichols et al. 1998; De 
Palma and Hanahan 2012). However it is important to note this transgene is 
expressed within intestinal stem cells and thus a brief pulse of Cre induced by 
Tamoxifen injection will induce heritable modifications within the crypt (el 
Marjou, Janssen et al. 2004). 
5.1.2 Intestinal model: AH-Cre system (AhCre+) 
Here the Cre recombinase expression is under the control of the Cyp1A1 
promoter. This promoter is usually transcriptionally silent but β-Naphtoflavone, 
a lipophilic xenobiotic, injected into the mice, will bind to the cytoplasmic aryl 
hydrocarbon receptor (hence the name AHCre) allowing it to translocate to the 
nucleus and specifically bind to the Cyp1A1 promoter and initiate transcription. 
This system yields 80 to 100% recombination within the intestinal crypt (in both 
stem and transient amplifying populations) and the liver parenchyma (Ireland, 
Kemp et al. 2004). However this transgene also causes sporadic Cre expression, 
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even in the absence of the inducer, within the kidney, bladder, prostate, muscle 
and cerebellum.  
5.1.3 Pancreatic model: Pdx-Cre system (PdxCre+) 
This system allows the expression of the Cre recombinase under the control of 
the Pancreatic and duodenal homeobox 1 gene (Pdx1). Pdx1 is a gene coding for 
a protein involved in early embryonic development as well as in adult glucose-
dependent regulation of insulin gene expression. Here a segment of 4.5Kb of 
Pdx1 promoter has been inserted upstream the Cre recombinase gene and 
therefore drives a mosaic expression of the enzyme in both endocrine and 
exocrine pancreas as well as in the duodenal and gastric entero-endocrine cells 
(Gannon, Herrera et al. 2000). The recombination in this system is occurring 
during development between the embryonic stages E8.5 and E12.5 as well as in 
adult mice (Stanger, Tanaka et al. 2007). A mouse construct expressing GFP 
under the control of Pdx1 allows us to visualise the extension of recombination 
in the pancreas as well as in the duodenum (Figure 19). 
 
 
Figure 19: Recombination in the pancreatic model 
Paraffin sections of a PdxCre+-GFP+ mice were stained for reporter GFP. The staining shows the 
extent of recombination in pancreatic (A) and duodenal (B) tissues. 
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5.2 Modified alleles: 
5.2.1 Dusp6 
The Dusp6 constitutive knockout (Dusp6-/-) mouse has been engineered and 
kindly provided by Professor Stephen M. Keyse [MRI/ Division of Cancer 
Research, Cancer Research UK Stress Response Laboratory, Division of Cancer 
Research] (unpublished) (Figure 20). 
To construct the Dusp6 null mouse, a Neomycin cassette has been inserted in the 
gene locus as well as three LoxP sequences resulting in the gene inactivation. 
These mice are viable and have no overt phenotype in either the intestine or the 
pancreas (See result chapter). 
 
Figure 20: Dusp6 null allele 
A western blot was performed on three different protein extracts from epithelial extracts of 
VilCreER+ Apcfl/+ KRasLsL-G12D/+ (AK) and VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- (AKD) mice. The 
absence of band in the AKD extracts confirm the absence of Dusp6 protein in the Dusp6 null 
mice. 
 
5.2.2 Fra1 
Fra1 knockout is lethal during embryogenesis due to placental defects 
(Schreiber, Wang et al. 2000). Therefore, a conditional floxed allele of Fra1 
(Frafl) was generated in order to avoid lethality during embryogenesis (Eferl, 
Hoebertz et al. 2004). In this construct, the exons 3 and 4 containing the 
dimerisation and the DNA-binding domains of Fra1 are flanked by two LoxP sites 
and a Green Fluorescent Protein (gfp) reporter gene is integrated into the 
N-Terminal part upon the flanked DNA sequences. The expression of the Cre 
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recombinase inactivates the Fra1 gene and concomitantly allows the formation 
of a Fra1-GFP fusion protein (Eferl, Hoebertz et al. 2004). In order to highlight 
the recombination in the pancreas and the duodenum, we performed an 
immunohistochemistry for GFP on a Pdx+ P53fl/+ Fra1fl/fl mouse. The staining 
showed an almost complete recombination in the pancreas and a high 
recombination rate in the duodenum. 
The deletion of Fra1 alone in both gut and pancreas does not seem to be 
associated with any overt phenotype (See result chapter). 
5.2.3 Apc 
The complete inactivation of Apc is lethal before day 6.5 of mouse embryonic 
gestation (Moser, Shoemaker et al. 1995). This is why we choose to delete Apc in 
the adult intestine using a conditional allele. The LoxP sites here are located in 
the introns 13 and 14 of the Apc gene. The action of the Cre recombinase results 
in the removal of exon 14 which causes a frameshift mutation (Shibata, Toyama 
et al. 1997). This silent mutant allele originally named Apc580S is called in this 
work Apcfl because of its exon 14 deletion depending on the action of the Cre 
recombinase.  
The deletion of Apc in the gut of adult mice has a profound effect on the crypt 
homeostasis and results in an altered crypt–villus architecture, a defect in 
migration of the cells along the crypt-villus axis and a nuclear localisation of 
β-Catenin in the gut epithelial cells (Sansom, Reed et al. 2004). 
5.2.4 KRas 
In humans, the hot spots for mutations in the KRas gene are located in codons 
12, 13 and 61. At these codons, mutations result in decreased GTPase activity 
and constitutive signalling. 
Mutations in codon 12 are frequent in both pancreatic and colon cancer, we 
therefore choose to use two oncogenic KRas alleles targeting this codon.  
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KRasLsL-G12D: This construct has a LoxP-STOP-LoxP (LSL) cassette knocked into 
the endogenous KRas locus (KRasLsL-G12D). This construct leads to the inducible 
expression of a gain-of-function mutated KRas gene in the targeted organs 
whereby the KRas is constitutively active when the STOP codon is excised by the 
Cre recombinase (Jackson, Willis et al. 2001; Johnson, Mercer et al. 2001). 
KRasLSL-G12V: In some experiments, we also used another oncogenic 
K-RasLSLG12Vβgeo allele (referred in the thesis as KRasLSL-G12V) in order to confirm 
our findings. In this model an internal ribosomal entry site (IRES) along with a 
β-geo cassette was introduced within the 3’ UTR of the KRas allele. In this 
modified KRas allele, a STOP cassette flanked by two LoxP sites along with a 
sequence containing the codon 12 mutation was introduced in the first exon. In 
this system as well as in the KRasLSL-G12D, the oncoprotein expression is depending 
on the removal of a floxed STOP cassette (Guerra, Mijimolle et al. 2003; Guerra, 
Schuhmacher et al. 2007). In these mice, expression of the β-geo marker allows 
the recombination events to be followed.  
In the pancreas, the expression of both oncogenic KRas alleles induces the 
initiation of PanINs and, as the mice age, further stages of pancreatic lesions 
develop, up to the adenocarcinoma stage (Hingorani, Petricoin et al. 2003). 
These lesions present increased mucin production and can be senescent 
(Hingorani, Petricoin et al. 2003; Morton, Timpson et al. 2010). 
The outcome of activating KRas in the intestine has generated conflicting 
reports. While the expression of KRasLSL-G12V seems to have no phenotypical 
consequence on the gut epithelium (Sansom, Meniel et al. 2006), the expression 
of KRasLSL-G12D induces hyperproliferation and tumour progression (Haigis, Kendall 
et al. 2008). However, and surprisingly, both models fail to induce an increase of 
Erk activation (Sansom, Meniel et al. 2006; Haigis, Kendall et al. 2008). 
5.2.5 p53 
There are several mouse constructs to inactivate p53 which is an essential 
tumour suppressor gene. Here we choose to use the germline point mutant: 
p53LSL-R172H (Olive, Tuveson et al. 2004). The point mutation leads to a structural 
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change of the protein which then can promote tumourigenesis independently of 
wt p53 and allows metastasis formation. Moreover, in order to make the 
mutation inducible, the LoxP-STOP-LoxP cassette has been inserted into the 
intron 1 of the gene. The mutant protein accumulates in the cells and interferes 
with normal p53 functions. Interestingly, in order to have disease progression in 
a mouse model of pancreatic cancer, a LOH of the wt p53 allele is required 
(Hingorani, Wang et al. 2005).  
6 Thesis aim 
Despite the high frequency of oncogenic KRas mutations in cancer, the precise 
mechanistic consequences of these mutations are unclear. In pancreatic cancer 
KRas mutation is thought to initiate tumourigenesis. Understanding the precise 
outcome of KRas activation in cancer appears to be very important for the 
evolution of the therapeutic agents. In colorectal cancer KRas mutation causes 
tumour progression following an initiating Apc mutation. In this thesis, in these 
two distinct scenarios, I examined the functional importance of, two 
downstream transcription targets of KRas signalling: Dusp6 and Fra1. Dusp6 is 
predicted to be a tumour suppressor and on the other hand, Fra1 is part of the 
AP-1 complex and is predicted to drive invasion and metastasis. 
The aim of this work was first to determine the implication of the MAPK pathway 
in colorectal cancer. Then I intended to determine the functional significance of 
Dusp6 and Fra1 deletion in CRC and PC in vivo models as well as the mechanism 
of action of Dusp6 and Fra1 deletion. 
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MATERIALS AND METHODS 
7 In vivo experiments  
All experiments were performed following the UK Home Office guidelines. 
All standard mice were maintained under non-barrier conditions and given a 
standard diet [CRM (E) expanded diet from Special Diets Services; Cat nº 801730] 
and water ad libitum.  
Nude mice [Charles River Laboratories International, CD-1 nude mice] were 
housed in positively pressurised individually ventilated cages autoclaved prior to 
use. All animal handling was performed in a change station or category 2 hoods. 
The diet provided was irradiated and the drinking water was autoclaved. 
7.1 Drug treatments 
7.1.1 Induction reagents 
Only the intestinal mouse models needed an injection of an inducer to activate 
the Cre recombinase. 
• The recombinase of the VilCreER+ model is induced by an intra-peritoneal 
(IP) injection of Tamoxifen at 80mg/Kg.  
Preparation: 1g of Tamoxifen powder [Sigma; Cat nº T5648] was resuspended in 
10ml of 100% ethanol [Sigma; Cat nº 34870]. Subsequently 90ml corn oil [Sigma; 
Cat nº C8267] was added to make a 10mg/ml solution. The drug was stored at 
-20ºC. 
• The recombinase of the AhCre+ model is induced by an IP injection of 
β-Napthoflavone at 80mg/Kg. 
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Preparation: 1g of β-Napthoflavone powder [Sigma; Cat nº N3633] was 
resuspended in, 100ml corn oil [Sigma; Cat nº C8267] to make a 10mg/ml 
solution. The solution was heated with added stirring until the drug was 
completely dissolved. The aliquots were stored at -20ºC. 
7.1.2  MEK inhibitors 
For both drugs the treatment regime was twice a day at 9AM and 5PM. 
The inhibitor CI-1040/PD184352 [SYNthesis med chem; Cat nº SYN-1031] was 
resuspended in DMSO and diluted in dH2O/10% Cremophor [Sigma; Cat nº C5135] 
to obtain a solution at 10mg/mL. The solution was injected by IP route. 
The inhibitor AZD6244 [SYNthesis med chem; Cat nº SYN-1016] was resuspended 
in dH2O/0.5% hydroxymethylpropylcellulose [Sigma; Cat nº 09963]/0.1% Tween 
80 [Sigma; Cat nº P4780] to obtain a solution at 5mg/mL. The drug was 
administrated by oral gavage. 
7.2 Mouse experiments 
Two types of experiments were performed: survival or time point analysis. When 
the mice reached their end point, they were sacrificed using an approved 
schedule 1 procedure. 
7.2.1 Time point experiments 
The mice were sacrificed at a specific time point after induction of the Cre 
recombinase.  
• For the experiments investigating the CPL phenotype, the mice were 
sacrificed 3 days after induction.  
• For the intestinal Mek inhibitor treatment on established tumours 
experiment, the VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice were treated 
with CI1040 from day 10 and sacrificed at day 30 after Cre recombinase 
induction whereas the VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice were 
Materials and methods 
 
66
treated with CI1040 from day 50 and sacrificed at day 80 after Cre 
recombinase induction.  
• Finally, the β-Galactosidase staining on pancreatic mouse model were 
done on mice sacrificed at 40 days of age. 
7.2.2 Survival experiments: 
The mice were sacrificed when they displayed the following clinical signs: pale 
feet (only for the intestinal mouse model), hunched back and weight loss. Some 
mouse models developed skin papillomas. In this case if the papilloma reached 
1.5cm in diameter, the mouse was sacrificed even in the absence of signs of ill 
health. Finally mice reaching the age of 500 days without clinical signs were 
sacrificed. These rules were all clearly mentioned in the licence of O. Sansom 
and fully accepted by the Home Office. 
8 Mouse genotyping  
Most of the mice in our laboratory are genotyped externally using the Transnetyx 
services (http://www.transnetyx.com/). The company uses a proprietary method 
based on real time PCR and DNA hybridisation to determine which alleles are 
present in the mice.  
However, the assay for the Dusp6 allele was not suitable for this method of 
genotyping, therefore I genotyped the mice for this allele. 
8.1 DNA isolation: 
Step 1: The lysis buffer [Puregen system from Flowgen; Cat nº FD-50K2] was 
mixed with proteinase K [Roche; Cat nº 03115844001] in a ratio of 10µL of 
proteinase K for 500µL of buffer. 500µL of this solution was added to an 
eppendorf containing 3mm of mouse tail and left for incubation overnight at 
37ºC with shaking.  
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Step 2: 200µL of Protein Precipitation solution [Flowgen; Cat nº FD-50K3] was 
added to each tube. After shaking, the tubes were centrifuged at maximum 
speed for 10 minutes.  
Step 3: The resulting supernatants were placed in a new eppendorf and mixed 
with 500µL of isopropanol [Fisher; Cat nº P/7507/17] and then centrifuged at 
maximum speed for 15 minutes.  
Step 4: The resulting pellets containing the DNA were left to dry and then 
resuspended in 100µL of nuclease free water [Sigma; Cat nº W4502]. 
8.2 Genotyping via Polymerase Chain Reaction (PCR) 
8.2.1 Primers for the Dusp6 construct 
The primers sequences have been kindly given by Prof. Steve Keyse and have 
been synthesised by Integrated DNA Technologies. 
Sequences: Dusp6 Forward: 5’ TGC GAG TAT GAG CGC CCA TTT GGT GGA TGC 3’ 
 Dusp6 Reverse: 5’ TTC AGA CCT CAT CTG AAA GAC ATG AGT AGT 3’ 
8.2.2 PCR reactions 
The PCR reactions were performed using the GoTaq Flexi DNA Polymerase and its 
associated kit of polymerase buffer and 25mM MgCl2 [Promega; Cat nº M8305]. 
The final volume of the PCR reaction was 50µl including 2.5µl of the tail DNA 
preparation (Figure 21).  
 
Figure 21: PCR mix 
PCR mix for 1 well µL
5x Green GoTaq Flexi Buffer 10
MgCl2 (25nM) 5
dNTPs (10nM) 0.4
Primers (100µM) 0.2 (of each)
Go Taq 0.2
dH2O qsp 47.5
DNA sample 2.5
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PCR Program:  
Step 1: 95°C for 3 minutes 
Step 2: 95°C for 30 seconds 
Step 3: 55°C for 30 seconds 
Step 4: 72°C for 1 minute 
Step 5: Go to step 2, 30 times 
Step 6: 72°C for 5 minutes 
Step 7: 15°C forever 
Finally the product of the PCR were run on a 4% agarose [Melford; Cat nº 9012-
36-6] supplemented with ethidium bromide [Sigma; Cat nº E1510]. The products 
of this PCR gave the following bands: WT: 250bp and Null: 270bp. 
9 Primary cell culture 
9.1 Media for cell culture 
Pancreatic medium: DMEM [Gibco; Cat nº 21969] with 10% of Fetal Bovine Serum 
[PAA; Cat nº A15-101], 1% of Penicillin-Streptomycin [Gibco; Cat nº 15070], and 
2mM of L-Glutamine [Gibco; Cat nº 25030]. 
Gut medium: Advanced DMEM/F12 [Gibco; Cat nº 12634] with 10mM of Hepes 
[Gibco; Cat nº 15630], 1% of Penicillin-Streptomycin [Gibco; Cat nº 15070], 2mM 
of L-Glutamine [Gibco; Cat nº 15630], 0.1% BSA [Sigma; Cat nº A9647], 1% N2 
[Invitrogen #17502-048], and 2% B27 [Invitrogen #12587-010]. 
Gut washing medium: Advanced DMEM/F12 [Gibco; Cat nº 12634] with 1% of 
Penicillin-Streptomycin [Gibco; Cat nº 15070]. 
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9.2 Experiments on PDAC cell primary culture 
9.2.1 PDAC culture 
A piece of pancreatic tumour was harvested, mashed with a scalpel and then 
placed in 5mL of medium to shake for 30 seconds. The supernatant containing 
PDAC cells was harvested and placed in a 75cm flask [NUNC; Cat nº 153732] with 
an extra 10mL of medium. The cells were cultured at 37ºC in 5% CO2 humid 
atmosphere. 
9.2.2 Organotypic collagen I Invasion Assay 
Protocol adapted from: (Timpson, McGhee et al. 2011) 
The 3D matrix made of skin fibroblasts and collagen from rat tails was prepared 
by Paul Timpson. 
Step 1: Plating PDAC cells on top of the matrix 
The prepared 3D matrix was moved to a 24-well dish using blunt forceps. Then 
1mL of a 104 PDAC cells suspension in pancreatic medium was plated on top of 
the matrix. The cells were allowed to grow to confluence on top of the matrix 
for 3-5 days. 
Step 2: Transferring the matrix to a grid for invasion 
A stainless steel sterile grid (provided by Paul Timpson) was placed in a 6 cm 
dish and pancreatic medium was added to a level above the grid. Then the 
matrix coated with PDAC cells was placed on the grid and the medium was 
adjusted so the bottom of the matrix was in contact with the pancreatic medium 
but not submerged. This is referred to as the air/liquid interface, which creates 
a nutrient gradient that promotes invasion. The pancreatic medium 
supplemented or not with CI1040 (500nM) was replaced every two days. The 
cells were left to invade for 2 weeks. 
 
Materials and methods 
 
70
Step 3: Fixation 
The matrix was placed onto a flat surface and cut in half with a scalpel and 
transferred to 4% formalin [Leica; Cat nº 3800600E] for overnight fixation. The 
matrix was then embedded and cut for IHC by the histology services. 
9.3 Villi culture 
The gut was isolated, flushed with PBS and cut open. The villi were scraped off 
with a glass cover slip, put into PBS and gently shaked in order to separate 
them. The enriched villi solution was then diluted to prevent an excess of 
mucus. After centrifugation at 600rpm at room temperature for 3 minutes, the 
villi were plated with matrigel [Growth Factor Reduced Matrigel, BD Biosciences 
Cat nº 356231] in 24 well tissue culture plate [Falcon; Cat nº 353047], covered 
with 500µL of gut medium supplemented with 50ng/mL EGF [Peprotech Cat nº 
AF-100-15], 100ng/mL Noggin [Peprotech Cat nº 250-38] and 500ng/mL mR-
spondin1 [R & D Systems Cat nº 3474-RS] and placed at 37˚C in 5% CO2 
atmosphere. 
9.4 Crypt culture 
The gut was isolated, flushed with PBS and cut open. The villi were scraped off 
with a glass cover slip and the remaining intestine tissue was placed in cold PBS. 
The intestine was then cut into small pieces and washed by pipetting up and 
down in cold PBS until the solution became clear. The clean intestine pieces 
were placed in 25mL of PBS with 5nM EDTA for 30 minutes with gentle shaking at 
4˚C. After aspiration of the cleaning solution the pieces were rinsed once in cold 
PBS. Then the crypts were detached with strong pipetting up and down with cold 
PBS. The supernatant obtained was supplemented with gut washing medium 
until reaching a volume of 50mL. The solution enriched in crypts was passed 
through a 70µM cell strainer [BD Falcon; Cat nº 352350] and centrifuged at 
600rpm at room temperature for 5 minutes. The pellet was gently washed with 
gut washing medium and centrifuged 600rpm at room temperature for 3 minutes 
until the supernatant remained clear. The crypts were then plated with matrigel 
(Growth Factor Reduced Matrigel, BD Biosciences Cat nº 356231) in 24 wells 
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tissue culture plate [Falcon; Cat nº 353047], covered with gut medium 
supplemented with 50ng/mL EGF [Peprotech Cat nº AF-100-15] and 100ng/mL 
Noggin [Peprotech Cat nº 250-38] and placed at 37˚C in 5% CO2 atmosphere 
(Figure 22). 
 
 
Figure 22: Crypt culture 
 
 
10 Epithelial extraction 
To obtain an extract enriched in epithelial cell from both crypt and villus, the 
following method has been used on freshly dissected intestine. 
Step 1: A solution of HBSS [Gibco; Cat nº 14170-088] supplemented with EDTA to 
a final concentration of 10mM was prepared and 25mL of the solution were 
poured in 50mL Falcon tubes (2 tubes per mouse). The tubes were then placed in 
a water bath at 37ºC. 
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Step 2: After flushing the gut with PBS, the intestines were placed inside out on 
a glass spiral. 
Step 3: The intestines were incubated with shaking in the HBSS solution twice for 
15 minutes. Two extracts were obtained: 0-15min classically used for RNA 
extraction and 15-30min classically used for protein extraction. 
Step 4: The extracts were centrifuged at 4000 rpm at 4ºC for 15 minutes. 
Step 5: After supernatant removal, the pellets were resuspended in 1mL of cold 
PBS and centrifuged at maximum speed at 4ºC for 15 minutes.  
Step 6: The resulting clean pellets were snap frozen in liquid nitrogen and kept 
at -80ºC.  
11 Tissue isolation 
Mice were sacrificed and organs (classically spleen, lungs, pancreas and liver) 
were harvested. When needed, the intestines were removed and flushed with 
either water or PBS. The tissues were then fixed in 3 different ways:  
1- Quick Fixation 
The tissues were incubated in 4% formalin [Leica; Cat nº 3800600E], overnight at 
4oC for no more than 24 hours before processing and paraffin embedding.  
2- Long Fixation 
The tissues were incubated in 4% formalin [Leica; Cat nº 3800600E] for more 
than 24 hours before processing and paraffin embedding. 
3- Methacarn Fixation 
A solution of methanol (400mL) [Sigma; Cat nº 32213], chloroform (200mL) 
[Fisher Scientific; Cat nº C4960/PB17] and acetic acid (100mL) [Sigma; Cat nº 
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695092] was made fresh and used to incubate the intestines for no more than 24 
hours. Then the intestines were moved to a 4% formalin [Leica; Cat nº 3800600E] 
solution overnight before being processed and paraffin embedded.  
12 Immunohistochemistry on paraffin sections 
Mouse tissues were embedded and cut by the Beatson Institute histology 
services. 
Before antigen retrieval, all slides were dewaxed for a minimum of 5 minutes in 
xylene and rehydrated in decreasing concentrations of ethanol (100% - 95% - 
70%) to end with a wash in water. 
After counterstaining, all slides were dehydrated in increasing concentrations of 
ethanol (70%-95%-100%) and a final incubation in xylene for 5 minutes. The slides 
were then mounted. 
12.1 Histochemistry 
Most of the routine histochemistry and immunohystochemistry are performed by 
the Beatson Institute histology services. However, some IHCs were too complex 
to be done automatically. So I performed the IHCs for β-catenin, pSmad3, pErk, 
pMek and β-galactosidase. 
12.2 Immunohistochemistries (IHCs) 
12.2.1 β-Catenin IHC 
Step 1: Peroxidase block 
The slides were incubated 30 minutes in the following P-block supplemented 
with 2.5mL of 30% H2O2 [Fluka; Cat nº 95321] to a final concentration of 1.5% 
H2O2 
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Peroxidase block: 1L stock = 4.16g citric acid [Sigma; Cat nº 251275], 10.76g 
DiSodium Hydrogen Phosphate 2 hydrate [Sigma; Cat nº 71662]. 
Step 2: Antigen retrieval 
The slides were boiled in a water bath for 50 minutes in 1X Tris EDTA solution 
(pH: 8.0). Then the slides were allowed to cool for 1 hour. 
50X Tris EDTA solution: 1L stock = 242g Tris, 18.6g EDTA. 
Step 3: Primary antibody 
Endogenous staining was prevented by a prior incubation for 30 minutes in 
PBS/1% BSA. Then, the slides were incubated with β-catenin antibody 
(concentration 1:50) [BD Biosciences; Cat nº 610154] in 1%BSA/PBS for 2 hours at 
room temperature. Slides were then washed thoroughly in PBS. 
Step 4: Secondary antibody 
The slides were incubated with HRP-labelled polymer from Mouse Envision+ 
system [Dako; Kit: EnVision+ System- HRP Labelled Polymer; Cat nº K4000], for 1 
hour at room temperature. Slides were then washed thoroughly in PBS. 
Step 5: Visualisation of positivity and counterstaining using 
3,3'-Diaminobenzidine (DAB). 
The DAB solution [Kit: UltraVision Detection System; ThermoScientific; Cat nº 
TA-125-HDX] was prepared in a ratio 1mL: 1 drop and put on the sections until 
visualisation of positivity. Then the slides were rinsed in water and counterstain 
for 1 minute in Haematoxylin Z [CellPath; Cat nº RBA-4201-00A]. 
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12.2.2 pErk and pMek IHCs 
Step 1: Antigen retrieval 
The slides were incubated in 0.01M citrate buffer for 4 minutes in pressure 
cooker at pressure (100°C). Then, they were allowed to cool for 30 minutes at 
room temperature in the solution. 
Citrate Buffer: For 800mL: 14.4mL of Solution A and 65.6mL of Solution B. 
Solution A: 10.5g Citric Acid [Sigma; Cat nº 251275] in 500mL H20 and Solution B: 
29.4g NaCitrate [Sigma; Cat nº W302600] in 1L H20. 
Step 2: Prevention of endogenous staining 
Endogenous staining was prevented by a prior incubation for 20 minutes in 3% 
H2O2 followed by an incubation for 1 hour in TBS/0.1% Tween/10% Normal goat 
serum [Dako; Cat nº X0907] at room temperature. 
Step 3: Primary antibody 
The slides were incubated with the primary antibody diluted in TBS/0.1% 
Tween/10% Normal goat serum overnight at 4°C.  
pErk (1:100)[Cell Signalling; Cat nº 9101] ; pMek (1:125)[Cell Signalling; Cat nº 
2338] ; pSmad3 (1:50) [Abcam; Cat nº ab52903]. 
Step 4: Secondary antibody 
The slides were incubated with a biotinylated goat Anti-Rabbit secondary 
antibody (Vector labs; Kit: VECTASTAIN Elite ABC Kit (Rabbit IgG); Cat nº PK-
6101), 1/200 in 10% Normal goat serum in TBS/T for 30 minutes at room 
temperature. The second step reagent was prepared 30 minutes prior use and 
kept at room temperature reagents (5ml TBS/T + 2 drops A + 2 drops B). 
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After the 30 minutes incubation with the secondary antibody, the slides were 
incubated with the second step reagent of the ABC kit for 30 minutes at room 
temperature. 
Step 5: Visualisation of positivity and counterstaining using DAB 
The solution was prepared in a ratio 1mL: 1 drop and put on the sections until 
visualisation of positivity. Then the slides were rinse in water and counterstain 
for 1 minute in Haematoxylin Z [CellPath; Cat nº RBA-4201-00A]. 
12.2.3 β-galactosidase IHC 
Step 1: Solution preparation 
• Fix solution: 500µL Glutaraldehyde (0.25%) [Sigma; Cat nº G5882], 1g 
paraformaldehyde (2%) [Fluka ; Cat nº 76240] in 49.5mL PBS. 
• 20x Potassium cyanide stock solution (KC – solution) : 
Dissolve in 100ml PBS (total volume): 3.28g of Potassium ferricyanide(III) 
(K3Fe(CN)6), [Sigma ; Cat nº 702587-50g] and 4.2g of Potassium 
hexacyanoferrate(II) Trihydrate, (C6FeK4N6*3H2O), [Fluka; Cat nº 60279]. 
• X-Gal Staining solution: 9.3ml PBS 1mM MgCl2 (pH5.5), 0.5ml 20x KC-
solution and 0.25ml 40x X-Gal stock [Promega; Cat nº V394A]. 
Step 2: Thaw slides at RT and take care that the samples are not drying. Then fix 
the slides for 15 minutes in Fix solution at RT. Then wash samples with PBS 1mM 
MgCl2. 
Step 3: Cover samples with X-Gal staining solution and put into a “wet chamber” 
at 37ºC overnight. Then wash the slides. 
Step 4: Counterstain with nuclear fast red solution [Vector Laboratories; Cat nº 
H-3403]. 
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13 Protein analysis 
13.1 Protein extract preparation 
A lysis buffer was prepared as follows: 1mL T-PER [ThermoScientific; Cat nº 
78510] supplemented with 1µL of Aprotinin [Sigma; Cat nº A6279], 1µL of 1mM 
Sodium orthovanadate (Na3VO4) [Sigma; Cat nº S6508], 1µL Sodium Fluoride 
(NaF) [Sigma; Cat nº S7920] and 12.5µL Phenylmethanesulfonyl Fluoride Solution 
(PMSF) [Fluka; Cat nº 93482]. 
The adequate quantity of lysis buffer was added to the mouse tissue and left on 
ice for 10 minutes. Then the tissues were homogenized by pipetting up and down 
with decreasing size of needles and centrifuged at maximum speed for 10 
minutes at 4ºC. The supernatant containing the proteins was transferred into a 
new tube. This process was repeated until the extracts were clear. 
13.2 Protein concentration measurement 
The concentration of each protein extract were measured with the BCA Protein 
Assay kit [ThermoScientific; Cat nº 23225] and using the reader SPECTRAmaxPlus 
[Molecular Devices]. 
13.3 Western Blot 
For Western analysis, proteins were run on a NuPAGE 10% or 12% Bis-Tris gel 
[Invitrogen; Cat nº NP0301BOX or nº NP0341BOX] using the tank XCell II Blot 
module [Invitrogen; Cat nº EI9051] 
Protein samples were mixed with 2.5µL of NuPAGE LDS sample buffer 
[Invitrogen; Cat nº NP0007] supplemented with 2µL DTT and equalised with lysis 
buffer so that all samples were 40µg and of equal volume (20µl). They were then 
heated at 100ºC for 5 minutes and loaded onto the gel. 
Gels were run for 1 hour at 200V in NuPAGE MOPS SDS Running buffer 
[Invitrogen; Cat nº NP0001] or until the protein markers [Full Range Rainbow 
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recombinant, Invitrogen, Cat nº 2892534] had separated, on ice in order to 
preserve the phospho proteins.  
Gels were then placed on a Hybond PVDF Transfer membrane [GE Healthcare; 
Cat nº RPN303F] previously incubated in methanol and between two layers of 
Whatman paper [Schleider & Schuell; Cat nº 3003-917]. The “sandwich” was 
then placed in transfer buffer (200mL SDS Blotting buffer, 400mL Methanol, 
1400mL H2O) and transferred for 1 hour at 30V on ice. 
After transfer, the presence of proteins was checked by staining with a Ponceau 
red solution [Sigma; Cat nº P3504]. 
Blots were blocked in TBS/0.1% Tween/5% BSA for 30 minutes. Primary 
antibodies and conditions used to probe blots are listed below (Figure 23). 
Appropriate HRP-conjugated secondary anti-rabbit or anti-mouse antibodies 
were used [DAKO; Cat nº P0448 and P0447 respectively]. 
Blots were then washed in TBS/0.1% Tween and visualised using ECL plus 
(Amersham) on ECL film (Amersham).  
 
 
Figure 23: Immunoblot antibodies 
 
Primary antibody Cat. Number Concentration Secondary Antibody
MEK1/2 Cell Signalling; Cat nº 4694 1/1000 (αMouse) Dako Cat nº P0447 
pERK1/2 Cell Signalling; Cat nº 9101 1/1000 (αRabbit) Dako Cat nº P0448 
ERK1/2 Cell Signalling; Cat nº 9102 1/1000 (αRabbit) Dako Cat nº P0448 
pELK1 Abcam; Cat nº ab28818 1/1000 (αRabbit) Dako Cat nº P0448 
DUSP6 Abcam; Cat nº ab76310 1/500 (αRabbit) Dako Cat nº P0448 
TUBULIN Sigma; Cat nº T6199 1/40000 (αMouse) Dako Cat nº P0447 
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14 Statistics: 
In this work there are two major types of experiments: disease-free survival 
experiments and scoring experiments. 
Scoring experiments: 
I chose to use only three to five mice per group in order to comply with the rule 
of the three Rs: Refine – Reduce – Replace which promotes the ethical use of a 
minimum number of live animals for research. Due to this low number of mice 
per group it is not possible to test the distribution of the data. Therefore I 
assumed the data was not normally distributed and I used the non-parametric 
test Mann-Whitney which allowed the comparison of two groups of only three 
mice each. This test consist in comparing the medians of two sets of data 
assuming one set has larger values than the other one. 
Disease-free survival test: 
Disease-free survival experiments are routinely done in research and the data 
obtained are always considered not to have a normal distribution. Here I 
assumed that the data were not normally distributed and therefore I ran a 
non-parametric Log-rank test. 
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RESULTS 
15 Oncogenic KRas phenotype in the CRC mouse model 
Over 70% of colon cancers have a mutation in Apc and mouse models have shown 
that adenomas can be initiated by Apc mutation alone (Shibata, Toyama et al. 
1997). To drive tumour progression in the mouse, other mutations are necessary. 
Oncogenic mutations in KRas, a key member of the MAPK superfamily, occur in 
30% of cases of CRC. The association between Wnt pathway activation and KRas 
activation has been previously studied by Fodde’s group in a mouse model 
carrying the mutated Apc allele Apc+/1638N along with the oncogenic KRas allele 
KRasG12V. They found evidences of synergetic effect of the two mutations on 
tumourigenesis (Janssen, Alberici et al. 2006; Alberici, de Pater et al. 2007). As 
Dusp6 is thought to be upregulated following KRas activation, it was important 
to first analyse the phenotype associated with KRas mutation in the intestine.  
To test the effects of oncogenic KRas mutation in CRC, we used a transgenic 
mouse model where the VillinCre ER (VilCreER+) transgene is activated to drive 
an inducible Cre recombinase expression following an injection of Tamoxifen. 
These mice were crossed with models containing the conditional Apc mutant 
allele (Shibata, Toyama et al. 1997) and the knock-in Lox-STOP-Lox KRasG12D 
(KRasLSL-G12D/+) allele (Jackson, Willis et al. 2001; Johnson, Mercer et al. 2001).  
15.1 Oncogenic KRas mutation increases proliferation rates 
of intestinal cells following Apc deletion. 
15.1.1 Influence of KRas mutations on tumourigenesis 
To address the influence of KRas mutation on tumourigenesis, we compared the 
tumour free survival of VilCreER+ (WT), VilCreER+ Apcfl/+ (Afl/+) and VilCreER+ 
Apcfl/+ KRasLsL-G12D/+ (Afl/+K) mice. In this model, tumours initiate when the wild 
type Apc allele is lost. The tumourigenesis will then be delayed or accelerated 
depending on other mutations within the transgenic model used.  
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As expected, the VilCreER+ mice did not develop cancer. Furthermore, it has 
been shown that KRas activation alone leads to intestinal hyperproliferation but 
does not promote intestinal tumourigenesis (Haigis, Kendall et al. 2008). 
Consistent with previous studies, the VilCreER+ Apcfl/+ mice developed multiple 
adenomas and showed a median survival of 290 days. The VilCreER+ Apcfl/+ 
KRasLsL-G12D/+ mice exhibited a drastic acceleration of tumourigenesis leading to a 
median survival of 100 days (Figure 24). This finding is consistent with the idea 
of multiple sequential mutations leading to invasive carcinoma in CRC. 
 
 
Figure 24: Effect of KRas activation on the tumour free survival  
Kaplan-Meier curve showing the survival of VilCreER+ (WT) (light grey line ; n=10), 
VilCreER+Apcfl/+ (Afl/+ ) (grey dashed line ; n=7) and VilCreER+Apcfl/+ KRasLsL-G12D/+ (Afl/+K) (black 
dashed line ; n=13) mice.  
Mice with intestinal tumours were sacrificed at the same point of illness or when they reached 
500 days after induction of the Cre recombinase. The tumour free survival was significantly 
decreased between the VilCreER+ and the VilCreER+ Apcfl/+ groups (log rank p<0.001) as well as 
between the VilCreER+ Apcfl/+ and the VilCreER+Apcfl/+ KRasLsL-G12D/+ groups (log rank p<0.001). 
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15.1.2 Influence of KRas mutation on the phenotype after an 
acute Apc deletion 
To ascertain the mechanism by which KRas mutation cooperates with Apc loss 
we acutely deleted both copies of Apc (Apcfl/fl) in the presence or absence of the 
oncogenic KRas allele within the intestinal epithelium. To investigate the effects 
on proliferation we focused on the crypts of the intestinal epithelium. The 
crypts contain a population of intestinal progenitors called the transient 
amplifying cells and their constant proliferation allows, in mice, the renewal of 
the epithelium every 72 hours. After deletion of both Apc alleles, the structure 
of the crypt expands into the villus giving a crypt-progenitor-like (CPL) 
phenotype. The CPL phenotype consists of increased proliferation, loss of 
migration and differentiation and increase of apoptosis (Sansom, Reed et al. 
2004). Therefore the Apc deficient cells are blocked in a progenitor like state. 
Quantifying the CPL phenotype indicates the impact of different mutations on 
the epithelium. Proliferation was assessed using a 2 hours BrdU pulse-chase 
labelling which only marks cells in S-phase. In a normal epithelium, the 
proliferative cells are located in the crypt only whereas an acute deletion of Apc 
leads to an extension of the proliferative area. The quantification of the CPL 
phenotype is done by calculating the percentage as well as the total number of 
BrdU positive cells. Moreover an estimation of the size of the CPL area is given 
by the calculation of the position of the highest BrdU positive cell on the 
crypt-villus axis (Figure 25). The Wnt pathway activation is observed with the 
help of a β-catenin IHC: in a normal situation, β-catenin is located to the cell 
membranes and in some nuclei of cells at the bottom of the crypt. Nuclear 
staining is the sign of the activation of the pathway and all cells exhibit nuclear 
β-catenin following Apc loss in the intestinal epithelium.  
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Figure 25: Quantification of proliferation 
BrdU pulse-chase labelling experiment are performed on mice with an acute Apc deletion. At day 
3 to 6 after Cre recombinase induction, the mice are injected with BrdU. During 2 hours, the 
BrdU will be incorporated in cell in S-phase. Then mice are sacrificed and an IHC for BrdU is 
performed. 
Determining the position of the highest BrdU positive cell allows to estimate the CPL phenotype 
size. 
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At one day after induction of the Cre recombinase, no phenotypical differences 
were observed between VilCreER+ Apcfl/fl (A) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ 
(AK) mice (Figure 26). The proliferative cells were located in the crypt and the 
nuclear β-catenin positive cells were observed at the bottom of the crypt. From 
day 2, phenotypical differences began to appear. The CPL phenotype was 
increased in the presence of the oncogenic KRas allele as underlined by the 
number of BrdU and nuclear β-catenin positive cells. At day 3 after induction, 
the difference between the two genotypes was even more pronounced with a 
drastic increase in proliferation in the presence of the oncogenic KRas allele 
highlighted by areas of proliferation with nuclear β-catenin positive cells in the 
crypt villus structure. The BrdU positive cell number was also highly increased in 
AK compared to A mice. This is in good agreement with the enhanced tumour 
progression observed in the VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice of the survival 
experiment.  
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Figure 26: Effects of KRas activation on CPL phenotype following Apc deletion 
H&E, BrdU and β-Catenin IHC were performed on paraffin sections of intestine of 
VilCreER+Apcfl/fl (A) and VilCreER+Apcfl/fl KRasLsL-G12D/+ (AK) mice at days 1, 2 or 3 after induction 
of the Cre Recombinase.  
At day 1, no difference is observed between the two genotypes. From day 2, the AK mice have a 
larger CPL phenotype (CPL phenotype limit highlighted by a dashed line) with proliferative cells 
located higher on the crypt-villus axis and with an increased nuclear β-Catenin staining. 
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To determine the size of the CPL phenotype we then scored the position of the 
highest BrdU positive cells of 2 hours BrdU pulse labelling experiment 
(Figure 27). There were no differences noted at one day after induction, 
however, from day 2, the top BrdU positive cell was significantly higher on the 
crypt-villus axis in the AK compared to the A mice. 
 
Figure 27: Effects of KRas activation on CPL phenotype area 
The position of the last BrdU positive cell of 25 villi of VilCreER+Apcfl/fl (A) (white), 
VilCreER+Apcfl/fl KRasLsL-G12D/+ (AK) (grey) mice were scored and compared with a Mann-Whitney 
statistical test.  
At day 1, no significant difference was observed between the two groups. At day 2 and day 3 
there is a significant increase of the CPL phenotype area of VilCreER+Apcfl/fl KRasLsL-G12D/+ 
(p<0.001). 
 
15.2 Oncogenic KRas allows an expansion of the cell of 
origin of the tumour 
In our ageing mouse model described earlier, the VilCreER+ Apcfl/+ mice always 
presented adenomas which seemed to arise from the crypt compartment 
(Figure 28, top panel). However, the lesions in the VilCreER+ Apcfl/+ KRasLsL-G12D/+ 
mice seemed to arise separately from either the crypt or the villus compartment 
(Figure 28, bottom panel). This finding was consistent with the observation of 
proliferation areas in the villi of VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) mice 
(Figures 26). Interestingly, in colon, the tumours were similar between the two 
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genotypes (Figure 29). However, it is important to note that whilst all of the 
VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice developed colonic tumours only some 
VilCreER+ Apcfl/+ mice developed tumours in the colon resulting in an overall 
increased number of colonic tumours in VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice 
(despite a much shorter latency). 
 
 
Figure 28: KRas activation allows tumours to form in the villus 
H&E of VilCreER+Apcfl/+ (top panel), VilCreER+Apcfl/+ KRasLsL-G12D/+ (bottom panel) mice showing 
intestinal tumours.  
VilCreER+Apcfl/+ KRasLsL-G12D/+ mice developed several lesions (highlighted by black arrows) within 
the villi whereas the VilCreER+Apcfl/+ did not. 
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Figure 29: Tumour formation in the colon of KRas activated mice 
H&E staining on paraffin sections of colon of VilCreER+Apcfl/+ (top panel), VilCreER+Apcfl/+ 
KRasLsL-G12D/+ (bottom panel) mice showing colonic tumours. 
 
In order to investigate the possible expansion of cell of origin we decided to 
address the ability of the villus cells to form tumours. To do so, Patricia 
Cammareri performed an intestinal cell culture experiment where she 
specifically cultured villus cells from VilCreER+ (WT), VilCreER+ Apcfl/fl (A) and 
VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) mice. In this experiment, she quantified the 
percentage of adenoma structures (spheroids) formation in order to evaluate the 
ability of villus cells to initiate tumour formation. At both day 2 and day 3 after 
induction of the Cre recombinase, no spheroid formation was observed in WT 
mice (Figure 30). We observed an unexpected basal 0 to 2% rate of spheroid 
formation in A mice allowing us to conclude that the phenomenon can rarely 
occur without KRas activation. The dramatic increase of spheroid formation in 
VilCreER+Apcfl/+
VilCreER+Apcfl/+ KRasLsL-G12D/+
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the AK mice, which presented a minimum of 20% of spheroid formation, 
indicates that the combination of Apc deletion and KRas activation may allow a 
different cell population to act as a tumour initiator. However it would be 
important to validate the origin and the cell type in order to confirm the 
dedifferentiation of villus cells. 
 
 
Figure 30: Effect of KRas activation on spheroid formation from the villus epithelium 
The formation of spheroids in villi culture of VilCreER+ (WT), VilCreER+Apcfl/fl (A), and 
VilCreER+Apcfl/fl KRasLsL-G12D/+ (AK) mice were scored and compared with a Mann-Whitney 
statistical test.  
At both day 2 (grey) and day 3 (black) post-induction, there was a significant increase in the 
spheroid formation rate in AK mice compared to the two other mouse genotypes (p<0.001). 
Data provided by Patricia Cammareri 
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15.3 KRas activation signature 
In order to study further the outcomes of KRas mutations on general gene 
expression and therefore signalling pathways expressions as MAPK, I sent whole 
intestine RNA samples of various cohorts of VilCreER+ mice taken at day 3 after 
Cre recombinase induction to be analysed in a microarray. We then analysed the 
fold change of each gene expression with an Anova statistical test performed by 
Gabriela Kalna. From the fold change value, the Log2 expression value for each 
gene was calculated. It was this Log2 expression value that Ann Hedley has been 
used to cluster mice and draw the following heatmaps. It is important to note 
that these microarray studies are indications for further investigation as the RNA 
is extracted from whole gut extract which includes not only the epithelium but 
also the stroma and the muscle layers. A quantification of the epithelial cells 
ratio could be used to normalise more accurately the results. However these 
studies are good primary read out of the consequences of the mutations of 
interest. 
15.3.1 Wnt pathway signature 
We first analysed the Wnt pathway signature of VilCreER+ (WT), VilCreER+ Apcfl/fl 
(A) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) mice based on a list of upregulated 
genes in human colorectal lesions (Rigas, Hoff et al. 2001).To create this list of 
genes, H. Clevers’ group analysed RNA obtained from biopsied tissues of normal 
mucosa, adenomas and carcinomas of patients (Rigas, Hoff et al. 2001). They 
studied the transcriptome of both adenomas and carcinomas compared with the 
normal mucosa and identified 208 genes upregulated in either one or both type 
of lesions.  
We therefore compared the expression values of these genes in WT, A and AK 
mice taken at day 3 after induction of the Cre recombinase (Figures 31A and 
31B). The expression on the heatmap is determined by the Z-score which is 
calculated for each row of data (gene). Then the data are centred and scaled by 
subtracting the mean of the row from every value and then dividing the resulting 
values by the standard deviation of the row. From this analysis it is clear that 
most of the WNT signature genes are upregulated after Apc loss as well as 
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following both Apc loss and KRas activation. Interestingly, some genes such as 
cd44, ETS translocation variant 4 (Etv4) and Myc are gradually upregulated 
following Apc loss and both mutations. This confirms the Wnt pathway activation 
following the initiating Apc mutation and the importance of KRas activation in 
the upregulation of the Wnt pathway.  
We then asked the software to compute the expression values and cluster the 
different samples. These clusters were determined by the mathematical 
Euclidean distance between each sample. The software is grouping samples 
which behave similarly among all their genes. Here, the three samples of each 
were grouped together confirming homogeneity between the samples of each 
genotype (Supplementary figure 1 - All the supplementary figures can be found 
in the Appendix). 
Some of the results obtained were confirmed by qRT-PCR performed by Fatih 
Ceteci (Figure 32). He showed an upregulation following Apc loss of Axin2, Lgr5, 
Lef1, cMyc, cd44 and Sox9. After the activation of KRas, he showed an enhanced 
upregulation of cMyc, cd44 and Sox9 but a downregulation of Axin2, Lrg5 and 
Lef1. The surprising downregulation of Lrg5 and Axin2 could be linked to the 
downregulation of the transcription factor Lef1. 
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Figure 31A: WNT pathway signature 
The genes found to be up-regulated in human colorectal adenomas were tested in whole gut 
extracts of VilCreER+ (WT), VilCreER+Apcfl/fl (A), and VilCreER+Apcfl/fl KRasLsL-G12D/+ (AK) mice 
taken at day 3 after Cre recombinase induction. The Z-score is indicated by a range of colour 
from yellow (low expression) to red (high expression). 
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Figure 31B: WNT pathway signature 
The genes found to be up-regulated in both human colorectal adenomas and human colorectal 
adenocarcinomas were tested in whole gut extracts of VilCreER+ (WT), VilCreER+Apcfl/fl (A), and 
VilCreER+Apcfl/fl KRasLsL-G12D/+ (AK) mice taken at day 3 after Cre recombinase induction. The Z-
score is indicated by a range of colour from yellow (low expression) to red (high expression).  
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Figure 32: WNT pathway signature: confirmation of targets by qRT-PCR  
Some Wnt/β-Catenin target genes were tested in whole gut extracts of VilCreER+ (WT), 
VilCreER+Apcfl/fl (APC), and VilCreER+Apcfl/fl KRasLsL-G12D/+ (APCKRAS) mice taken at day 3 after Cre 
recombinase induction. * indicates a p value p<0.05 calculated with the eCt method. 
Data provided by Fatih Ceteci 
 
15.3.2 Stem cell signature 
We then analysed the expression of some intestinal stem cell markers in 
VilCreER+ (WT), VilCreER+ Apcfl/fl (A) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) mice. 
We observed an upregulation of stem cell markers after Apc loss (Figure 33). 
There were no clear enhanced upregulation following the addition of the 
oncogenic KRas allele. This shows the de-differentiation associated to 
tumourigenesis and the increased proliferation ability of the cells within the 
modified intestinal epithelium. Furthermore, the samples were clustered 
according to their genotype confirming their homogeneity (Supplementary figure 
2). We noted an unexpected pattern of the Olfm4 expression: the expression 
was similar in WT and A mice and was downregulated in AK mice. This is rather 
surprising as Olfm4 has been shown to be upregulated in several CRC cells (van 
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der Flier, Haegebarth et al. 2009). However this marker appears to be Wnt 
independent which could explain the result observed here. 
 
Figure 33: Stem cell signature  
The expression of intestinal stem cell markers was tested in whole gut extracts of VilCreER+ 
(WT), VilCreER+Apcfl/fl (A), and VilCreER+Apcfl/fl KRasLsL-G12D/+ (AK) mice taken at day 3 after Cre 
recombinase induction. The Z-score is indicated by a range of colour from yellow (low 
expression) to red (high expression).  
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15.3.3 MAPK pathway signature 
Finally we analysed the effect of Apc loss and KRas activation on the MAPK 
pathway gene signature. We used a list of MAPK pathway targets identified by 
microarray-based transcriptome profiling (Stewart, Dowd et al. 1999; Mark, 
Aubin et al. 2008).  
Once again, the software automatically clustered the samples according to their 
genotype confirming their homogeneity (Supplementary figure 3). However, the 
microarray shows that the expression of very few genes was changed following 
Apc deletion. These groups were then probably formed due to the presence of 
genes which are also part of the Wnt signature as cd44 and Myc. The genes cd44 
and Myc are gradually increasing with mutations of Apc and then KRas 
illustrating the increase of Wnt pathway activation following KRas activation. 
Interestingly, Ceacam1 (involved in angiogenesis) and mmp10 (involved in 
tumourigenesis) were respectively downregulated and upregulated following Apc 
deletion but were back to a normal expression after KRas activation (Figure 34). 
Finally some genes were only upregulated following KRas activation: Etv4, 
Dusp5, Fra1 (Fosl1) and in smaller extent Dusp6, all associated with 
tumourigenesis.  
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Figure 34: MAPK pathway signature  
The MAPK pathway target genes identified by microarray based transcriptome profiling were 
tested in whole gut extracts of VilCreER+ (WT), VilCreER+Apcfl/fl (A), and VilCreER+Apcfl/fl 
KRasLsL-G12D/+ (AK) mice taken at day 3 after Cre recombinase induction. The Z-score is indicated 
by a range of colour from yellow (low expression) to red (high expression).  
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Given this lack of dramatic pathway activation we next examined the expression 
of putative negative feedback proteins of the MAPK pathway namely the MKPs: 
Dusp5 and Dusp6. The microarray suggested Dusp5 to be upregulated. The 
redundancy between the MKPs, and particularily between Dusp6 and Dusp5 
which are both very specific for Erk 1/2, can explain why Dusp5 is also 
upregulated following KRas activation. Our collaborator Prof. Stephen Keyse is 
currently investigating the outcome of Dusp5 deletion in the context of Apc 
deletion in mouse model of colorectal cancer. Immunoblotting for Dusp6 
performed on epithelial extracts of VilCreER+ (WT), VilCreER+ Apcfl/fl (A) and 
VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) mice showed the upregulation of Dusp6 in 
KRas activated mice (Figure 35). The specificity of the western blot was showed 
by the absence of the protein band in AK mice homozygous for the Dusp6 null 
allele (AKD). Given, the very strong upregulation of Dusp6 following the MAPK 
pathway activation, we examined further its tumour suppressor capacity using a 
Dusp6 knockout mouse provided by Prof. Stephen Keyse. 
 
 
Figure 35: Levels of Dusp6 protein 
Western Blot performed on epithelial extracts of intestine from VilCreER+ (WT), VilCreER+Apcfl/fl 
(A), VilCreER+Apcfl/flKRasLsL-G12D/+ (AK) and VilCreER+ Apcfl/flKRasLsL-G12D/+Dusp6-/- (AKD) mice taken 
at day 3 after induction of the Cre recombinase. 
The protein Dusp6 was strongly upregulated following KRas activation while its expression was 
completely lost in Dusp6 null mice. 
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16 Dusp6 deletion effects in the context of Apc deletion 
driven tumourigenesis associated with KRas activation 
To address the tumour suppressor effects of Dusp6, we first intercrossed the 
VilCreER+ mouse model with the Dusp6 knockout mice (Dusp6-/-). We aged 
VilCreER+ and VilCreER+ Dusp6-/- mice and none of them developed tumours 
within 500 days (data not shown). This result showed that Dusp6 deletion alone 
is not sufficient to initiate tumourigenesis in the mouse intestine. As Dusp6 is 
deleted in the whole mice body, this also suggests that Dusp6 loss on its own is 
not sufficient to start tumourigenesis in any tissue. This is probably due to the 
numerous MKPs and their redundancy. However, the specificity of Dusp6 for Erk 
1/2 we predict the tumour suppressor function of Dusp6 may only be revealed if 
the gene was lost in the context of an oncogenic KRas mutation. Given the 
requirement of an Apc mutation to initiate intestinal tumourigenesis, we 
intercrossed Dusp6 deficiency to mice that carried both Apc and KRas mutations. 
16.1 Dusp6 deletion effects during oncogenic KRas driven 
tumourigenesis  
16.1.1 Dusp6 loss effects in VilCreER+Apcfl/+ KRasLsL-G12D/+ mice 
We intercrossed the VilCreER+ mouse model carrying the Apc mutant allele 
(Apcfl/fl) and the oncogenic KRas allele (KRasLsL-G12D) with the Dusp6 knockout 
mice. 
I aged VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice with or without Dusp6 deletion until 
sickness or until they reached the age of 500 days. I observed that VilCreER+ 
Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice develop tumours much faster than VilCreER+ 
Apcfl/+ KRasLsL-G12D/+ Dusp6+/- or VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice. The median 
survival was 30 days for Dusp6 null mice compared to 85 days for the VilCreER+ 
Apcfl/+ KRasLsL-G12D/+ mice (Figure 36). The VilCreER+ Apcfl/+ KRasLsL-G12D/+Dusp6+/- 
mice showed no difference in survival with the VilCreER+ Apcfl/+ KRasLsL-G12D/+ 
mice. Furthermore, consistent with my previous observations of the phenotype 
associated with KRas activation I found several adenomas growing within the villi 
of the VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice (Figure 37). Then, I performed 
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a β-Catenin IHC on tumours of the three mice genotypes. Nuclear β-Catenin 
accumulation was noted in intestinal and colonic tumours of the three mice 
cohorts indicating Wnt pathway activation in these lesions (Figure 38). 
 
 
Figure 36: Effects of Dusp6 deletion on tumour free survival 
Kaplan-Meier curve showing the cumulative survival of VilCreER+ Apcfl/+ KRasLsL-G12D/+ (black solid 
line ; n=13), VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6+/- (black dashed line ; n=22) and VilCreER+ Apcfl/+ 
KRasLsL-G12D/+ Dusp6-/- (red solid line ; n=15) mice. Mice with intestinal tumours were sacrificed at 
the same point of illness or when they reached 500 days after induction.  
The tumour free survival was significantly decreased between both VilCreER+ Apcfl/+ KRasLsL-G12D/+ 
and VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6+/- and VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice (log 
rank: p<0.001). No significant difference was found between VilCreER+ Apcfl/+ KRasLsL-G12D/+ and 
VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6+/- mice. 
VilCreER+ Apcfl/+ KRasLsL-G12D/+
VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6+/-
VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/-
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Figure 37: KRas activation allows tumours to form in the villus independently of Dusp6 status 
H&E staining was performed on paraffin intestinal sections of VilCreER+ Apcfl/+ KRasLsL-G12D/+ 
(Afl/+K) and VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- (Afl/+KD) mice at end point tumourigenesis. 
Both genotypes developed several lesions within the villi. 
Afl/+K Afl/+KD
Results 
 
Figure 38: Wnt pathway activation following 
IHC for β-Catenin was performed on paraffin sections of intestinal (left) and colonic (right) 
tumours of VilCreER+ Apc
B) and VilCreER+ Apcfl/+ 
In the three genotypes there is nuclear β
activation in these lesions.
Apc deletion and KRas 
fl/+ KRasLsL-G12D/+ (panel A), VilCreER+ Apcfl/+ KRas
KRasLsL-G12D/+ Dusp6-/- (panel C) mice. 
-Catenin staining in tumour tissue showing the 
 
104
 
activation 
LsL-G12D/+ Dusp6+/- (panel 
Wnt 
Results 
 
105
Given the very rapid tumourigenesis and high tumour burden, I thought that this 
short latency would not allow metastasis formation. Indeed lesions were limited 
to the epithelium area and were not crossing the muscle wall. Therefore, I 
wanted to assess if these tumours would progress further if they had a longer 
time to evolve. To attempt this, I aged a cohort of mice with the same 
genotypes but used a lower concentration of the inducer: only 8mg/Kg of 
Tamoxifen instead of the full 80mg/Kg dose (Figure 39). This induction regime 
reduced tumour initiation and therefore prolonged the median survival time to 
150 days instead of 30 days for VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice and to 
380 days instead of 85 days for VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice. In this model, 
as well as in the full induction one, the Dusp6 deletion drastically decreased the 
survival.  
 
Figure 39: Effects of Dusp6 deletion in the context of slower tumourigenesis 
Kaplan-Meier curve showing the cumulative survival of VilCreER+ Apcfl/+ KRasLsL-G12D/+ (black line ; 
n=16) and VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- (red line ; n=10) mice. These mice were induced 
with 8mg/Kg tamoxifen injection instead of the usual 80mg/kg concentration. Mice with 
intestinal tumours were sacrificed at the same point of illness or when they reached 500 days 
after induction.  
The tumour free survival was significantly decrease between both VilCreER+ Apcfl/+ KRasLsL-G12D/+ 
and VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- (log rank: p=0.02). 
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Surprisingly, very few lesions were found in the villi (Figure 40). This could be 
due to the induction regimen targeting and recombining less in the villi area. 
Furthermore, lesions invading through the intestinal muscle wall were observed 
(Figure 40A), indicating the ability of these genotypes to generate invasion. 
Indeed 75% of VilCreER+ Apcfl/+ KRasLsL-G12D/+ and 40% of VilCreER+ Apcfl/+ 
KRasLsL-G12D/+ Dusp6-/- mice had invasive tumours. However, these conditions 
remained insufficient to allow metastasis formation. This could mean that other 
events, as for example p53 mutation, are necessary to initiate the metastatic 
process more rapidly. 
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Figure 40: Effects of Dusp6 deletion in the context of slower tumourigenesis 
H&E staining was performed on paraffin sections of VilCreER+ Apcfl/+ KRasLsL-G12D/+ (A), VilCreER+ 
Apcfl/+ KRasLsL-G12D/+ Dusp6+/- (B) and VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- (C) mice. An arrow 
indicates invasion. 
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16.1.2 Dusp6 loss effects in VilCreER+Apcfl/+ KRasLsL-G12V/+ mice 
As previously noted, there are conflicting reports regarding the outcome of a 
constitutively active KRas mutation (Sansom, Meniel et al. 2006; Haigis, Kendall 
et al. 2008). I therefore assessed the effects of the KRasLSL-G12V allele in the same 
context as previously described. I aged a cohort of VilCreER+ Apcfl/+ KRasLSL-G12V/+ 
mice with or without Dusp6 deletion until sickness or until they reached the age 
of 500 days. Here I observed similar results to the KRasLSL-G12D allele when 
induced with 8mg/Kg of Tamoxifen: VilCreER+ Apcfl/+ KRasLSL-G12V/+ Dusp6-/- mice 
developed tumours much faster than VilCreER+ Apcfl/+ KRasLSL-G12V/+ mice with a 
median survival reduced from 150 to 100 days (Figure 41). It is interesting to 
note that KRasLSL-G12V allele had a slower tumourigenesis than the KRasLSL-G12D 
allele allowing tumours to undergo invasion and preventing lesion formation in 
villi (Figure 42). However, no metastases were observed in this model either. 
 
Figure 41: Dusp6 deletion decreases survival following KRas activation (KRasLsL-G12V allele). 
Kaplan-Meier curve showing the cumulative survival of VilCreER+ Apcfl/+ KRasLsL-G12V/+ (black solid 
line ; n=13), VilCreER+ Apcfl/+ KRasLsL-G12V/+ Dusp6+/- (black dashed line ; n=9) and VilCreER+ Apcfl/+ 
KRasLsL-G12V/+ Dusp6-/- (red solid line ; n=15) mice. Mice with intestinal tumours were sacrificed at 
the same point of illness or when they reached 500 days after induction.  
The tumour free survival was significantly decrease between both VilCreER+ Apcfl/+ KRasLsL-G12V/+ 
and VilCreER+ Apcfl/+ KRasLsL-G12V/+ Dusp6+/- and VilCreER+ Apcfl/+ KRasLsL-G12V/+ Dusp6-/- mice (log 
rank: p=0.004). No significant difference was found between VilCreER+ Apcfl/+ KRasLsL-G12V/+ and 
VilCreER+ Apcfl/+ KRasLsL-G12V/+ Dusp6+/- mice. 
VilCreER+ Apcfl/+ KRasLsL-G12V/+
VilCreER+ Apcfl/+ KRasLsL-G12V/+ Dusp6+/-
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Figure 42: Tumour formation following KRas activation (KRasLsL-G12V allele).  
H&E staining of intestinal (top) and colonic (bottom) tumours from VilCreER+ Apcfl/+ KRasLsL-G12V/+ 
(panel A), VilCreER+ Apcfl/+ KRasLsL-G12V/+ Dusp6+/- (panel B) and VilCreER+ Apcfl/+ KRasLsL-G12V/+ 
Dusp6-/- (panel C) mice. 
Invasion is indicated by arrows. 
 
These findings taken together showed that the association of Apc deletion and 
KRas activation was able to initiate tumourigenesis and invasion. Moreover, in all 
models Dusp6 deletion induced a drastic enhancement of the effects of the 
oncogenic KRas allele on tumourigenesis. 
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16.2 Dusp6 deletion effects on CPL phenotype  
16.2.1 Dusp6 loss effects on proliferation 
To investigate further the effects of Dusp6 deletion on proliferation I used the 
acute Apc deletion model previously described where both Apc alleles are 
deleted after induction of the Cre recombinase. Proliferation was assessed using 
a 2 hours BrdU pulse-chase labelling. The proliferative cells, as highlighted in 
Figure 43A, are illustrating a larger CPL phenotype area. I scored the total 
number of proliferative cells as well as the position of the highest BrdU positive 
cell in the CPL structure. This scoring has shown a trend of increased total 
number of proliferative cells (p value = 0.08) (Figure 43B). The percentage of 
proliferation in CPL area (Figure 43D) did not change between the groups of 
mice. However, there was an increase of CPL phenotype area in the AKD mice 
compared with the AK ones as highlighted by the highest BrdU positive cell at a 
median position of 119 on the crypt villus axis instead of 91 (Figure 43C) (p value 
0.02). These finding highlight an increase in proliferation zone but also 
demonstrate that the proliferation rate within the proliferation zone seems to 
remain unchanged between the different genotypes. 
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Figure 43: The effects of Dusp6 deletion on the CPL phenotype 
2 hours BrdU pulse-chase labelling experiment was performed on VilCreER+ Apcfl/fl KRasLsL-G12D/+ 
Dusp6+/+ (AK) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice. 
A: Immunohistochemistry for BrdU was performed on paraffin section of VilCreER+ Apcfl/fl KRasLsL-
G12D/+ Dusp6+/+ (AK) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice. The highest BrdU 
positive cells are highlighted by dashed lines showing an increase in CPL area following Dusp6 
deletion.  
B,C,D: Box plots showing respectively the total number of BrdU positive cells, the position of the 
highest BrdU positive cell on the crypt-villus axis and the percentage of proliferation in CPL 
phenotype of AK (dark grey) (n=5) and AKD (red) (n=3) mice. Mann Whitney test p values: B 
p=0.08 ; C p=0.02 ; D p=0.76. 
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16.2.2 Dusp6 loss effects on cell differentiation 
Given tumours can form from villi compartment we hypothesised that the 
capacity of the villi cells to dedifferentiate following KRas activation might be 
expanded by Dusp6 loss. In order to confirm the loss of differentiation and the 
strong proliferation, I performed several IHC (Figure 44). An H&E staining 
confirmed the CPL phenotype size difference between VilCreER+ Apcfl/fl 
KRasLsL-G12D/+ (AK) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice as 
highlighted by the red (AKD) and the dashed black (AK) lines. In these 
epitheliums, Goblets cells did not seem altered as shown by the Alcian blue 
staining. I observed an upregulation of p21 and p53 in a subset of cells within 
the CPL phenotype of both mice cohort. This increase of p21 and p53 in the CPL 
phenotype has been shown to be the result of a high proliferation (Fjeld, Rice et 
al. 2000). Finally, the presence of Sox9 positive cells in the CPL phenotype areas 
shown a Wnt pathway activation associated with this hyperproliferation.  
Apart from the clear proliferation increase in AKD mice compared to the AK 
ones, no other differences were observed suggesting Dusp6 deletion to be mainly 
resulting in upregulation of cell proliferation.  
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Figure 44: Comparison of the CPL phenotype of AK and AKD mice 
H&E staining, Alcian blue (marking goblet cells) staining, p21 IHC, p53 IHC and Sox9 IHC of CPL 
phenotypes of VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK, top panel) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ 
Dusp6-/- (AKD, bottom panel) mice. 
The length of the CPL phenotype is indicated by a dashed black line for AK mice and by a red 
line for AKD mice. 
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16.3 Dusp6 loss signature 
In order to study further the outcomes of Dusp6 deletion associated with KRas 
mutation on general gene expression and therefore signalling pathway output, I 
sent whole intestine RNA samples of VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) and 
VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice taken at day 3 after Cre 
recombinase induction to be analysed in a microarray. The samples were 
analysed as previously described. It is interesting to note that one sample in the 
AKD group behave rather differently than the other ones. An increase in the 
number of mice in each cohort could reveal if this mouse is a unique case. 
However for the following analysis I excluded this particular mouse. 
16.3.1 Wnt pathway signature 
I analysed the Wnt pathway signature of VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) and 
VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice based on the previously 
described H. Clevers’ group list of up-regulated genes in human colorectal 
adenomas (Rigas, Hoff et al. 2001) (Figures 45 A and B). There were no major 
changes brought by Dusp6 loss except a downregulation of few genes as Myb, 
Gemin5 and Rhobtb3 and an upregulation of Sox4. This strong similarity between 
the two groups shows that Dusp6 deletion does not affect much the WNT 
pathway signature in the context of oncogenic KRas driven tumourigenesis. 
However, these minor changes were enough to cluster the samples according to 
their genotype (Supplementary figure 4).  
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Figure 45A: WNT pathway signature 
The genes found to be up-regulated in human colorectal adenomas were tested in whole gut 
extracts of VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) 
mice taken at day 3 after Cre recombinase induction. The Z-score is indicated by a range of 
colour from yellow (low expression) to red (high expression).  
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Figure 45B: WNT pathway signature 
The genes found to be up-regulated in both human colorectal adenomas and human colorectal 
adenocarcinomas were tested in whole gut extracts of VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) and 
VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice taken at day 3 after Cre recombinase 
induction. The Z-score is indicated by a range of colour from yellow (low expression) to red (high 
expression).  
Results 
 
118
16.3.2 Stem cell signature 
I then analysed the expression of some intestinal stem cell markers in AK and 
AKD mice. I could not find any relevant difference between the two groups of 
mice (Figure 46). This is highlighting the absence of Dusp6 deletion effects on 
the stem cell signature genes in this context. Moreover, the samples were 
clustered in groups of genotype highlighting the absence of effects of Dusp6 loss 
on stem cell signature genes (Supplementary figure 5). 
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Figure 46: Stem cell signature  
The expression of intestinal stem cell markers was tested in whole gut extracts of VilCreER+ 
Apcfl/fl KRasLsL-G12D/+ (AK) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice taken at day 3 
after Cre recombinase induction. The Z-score is indicated by a range of colour from yellow (low 
expression) to red (high expression).  
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16.3.3 MAPK pathway signature 
Finally I analysed the effect of Apc loss and KRas activation on the MAPK 
pathway gene signature using the list of MAPK pathway targets identified by 
microarray-based transcriptome profiling (Stewart, Dowd et al. 1999; Mark, 
Aubin et al. 2008).  
Unexpectedly, the pattern of gene expression remained rather unchanged after 
Dusp6 loss (the remaining Dusp6 expression seen in the hitmap is due to the 
probe for Dusp6 which target the untruncated part of the RNA before the Neo 
cassette in the transgene construct) highlighting a minor effect of the gene 
deletion on MAPK pathway (Figure 47). However, this microarray analysis were 
done on whole gut samples and it would be interesting to analyse the outcome 
of the mutations in the cytoplasm and the nucleus separately as Erk is a shuttle 
protein between the two cell compartment and the balance in Erk concentration 
is strongly affecting cell signalling. Nevertheless, the samples were still grouped 
according to their genotype highlighting a constant gene expression pattern in 
samples of same genotypes (Supplementary figure 6). It is important to note the 
upregulation of Dusp5. Dusp5, as part of the MAPK phosphatases family, is the 
phosphatase specific for Erk 1/2 in the nucleus. This could be a compensatory 
upregulation limiting the impact of Dusp6 loss on Erk 1/2 phosphorylation and 
therefore on MAPK pathway. However, the microarray was performed on whole 
gut samples in order to obtain good quality RNA. Therefore, the RNA includes 
not only the gut epithelial cells but also the muscle layers which could buffer 
the variations of expressions. This difficulty could be bypassed by studying the 
impact of Dusp6 deletion on the Erk activation. Unfortunately, there is a lack of 
efficient antibodies detecting Dusp6 and Erk 1/2 in the tissues we decided to 
study. Therefore, we decided to analyse the functional significance of Dusp6 
deletion by association with a Mek inhibitor treatment. 
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Figure 47: MAPK pathway signature  
The MAPK pathway target genes identified by microarray based transcriptome profiling were 
tested in whole gut extracts of VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) and VilCreER+ Apcfl/fl KRasLsL-
G12D/+ Dusp6-/- (AKD) mice taken at day 3 after Cre recombinase induction. The Z-score is 
indicated by a range of colour from yellow (low expression) to red (high expression).  
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17 The functional outcome of Mek inhibition following 
Dusp6 loss 
17.1 The chemoprevention effects of Mek inhibition are 
Dusp6 loss dependent 
To investigate whether Dusp6 deletion was exacerbating the VilCreER+ Apcfl/+ 
KRasLsL-G12D/+ mice phenotype via MAPK pathway activation, I performed a 
chemoprevention experiment using the pharmacological MEK inhibitor CI1040 
(also named PD184352) (Sebolt-Leopold, Dudley et al. 1999) on the VilCreER+ 
Apcfl/+ KRasLsL-G12D/+ and VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice. In this case, 
inhibition of Mek1/2 should reduce the activation of Erk 1/2 and since Dusp6 is 
an Erk 1/2 phosphatase if this is the mechanism by which Dusp6 loss is 
accelerating tumourigenesis and/or tumour initiation then an inhibition of Mek 
should reverse Dusp6 deletion effects. 
The mice were treated with a 200mg/Kg daily dose of CI1040 or with vehicle 
from the first day after induction of the Cre recombinase and were sacrificed 
when showing signs of intestinal ill health (Figure 48). The VilCreER+ Apcfl/+ 
KRasLsL-G12D/+ mice treated with the drug vehicle had the same median survival 
(90 days) as the untreated mice. However, the VilCreER+ Apcfl/+ KRasLsL-G12D/+ 
Dusp6-/- mice treated with CI1040 doubled their median survival to 62 days after 
induction. Surprisingly, the same drug treatment on VilCreER+ Apcfl/+ KRasLsL-
G12D/+ mice did not result in tumourigenesis regression: the median survival 
remained at 85 days after induction of the Cre recombinase. So the inhibition of 
the MAPK pathway at Mek level is reducing tumour initiation only when Dusp6 is 
deleted. This finding is the first indication that Dusp6 loss has an effect on the 
MAPK cascade depending on KRas activation but also different than the KRas 
activation alone. 
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Figure 48: Effects of Mek inhibition on survival 
Kaplan-Meier curve showing the survival of VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice treated with 
CI1040 (black dashed line ; n=5) or untreated (black solid line ; n=13) and VilCreER+ Apcfl/+ 
KRasLsL-G12D/+ Dusp6-/- mice treated with CI1040 (red dashed line ; n=14) or untreated (red solid 
line ; n=15). Mice with intestinal tumours were sacrificed at the same point of illness. 
 The treatment increases significantly the survival in VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice 
(log rank p<0.001) but does not have an effect in VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice (log rank: 
p>0.5). 
 
I then investigated the effect of the drug on tumour progression. I treated 
VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice with CI1040 from day 10 after 
induction, namely when tumours had already raised in the intestine. I then 
compared their tumour number with the vehicle ones sacrificed at day 30 after 
induction. The treated mice had a drastic reduction in tumour number compared 
to the untreated ones and the tumours remaining in these mice appeared to be a 
lot smaller than in the vehicle treated mice (Figure 49). A similar experiment 
was performed on VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice. This time the mice were 
treated from day 50 after Cre recombinase induction namely when they had 
tumours developed. Here again the CI1040 treatment remained inefficient 
(Figure 50) bringing a second evidence of the particularity of the outcome of 
Dusp6 loss. 
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Figure 49: Effects of Mek inhibition on tumourigenesis in Dusp6 null mice 
H&E staining as performed on paraffin sections of VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice 
treated with vehicle (right) or CI1040 (left) and sacrificed at 30 days after Cre recombinase 
induction.  
Arrows are showing tumours in the intestine. CI1040 treated mice show a strong diminution in 
tumourigenesis. 
 
Figure 50: Effects of Mek inhibition on tumourigenesis 
H&E staining was performed on paraffin sections of VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice treated 
with vehicle (right) or CI1040 (left) and sacrificed at 80 days after Cre recombinase induction. No 
difference was observed between the two treatments. 
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17.2 Mek inhibition affects the CPL phenotype only when 
Dusp6 is deleted 
To investigate further the effect of Mek inhibition on Dusp6 deleted mice, I used 
the acute Apc deletion model. I quantified the CPL phenotype of VilCreER+ 
Apcfl/fl KRasLsL-G12D/+ (AK) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice 
treated with two different Mek inhibitors namely CI1040 and AZD6244. The drugs 
have an IC-50 of 300nM and 14nM respectively and were both shown to highly 
inhibit Mek 1/2 resulting in an inhibition of Erk 1/2 (Davies, Reddy et al. 2000; 
Yeh, Marsh et al. 2007). The drugs were given at a concentration of 100mg/Kg 
for CI1040 and 25mg/Kg for AZD6244 twice daily to ensure the presence of the 
drugs all day long. The results obtained with the two Mek inhibitors were similar 
despite their small specificity variations. Proliferation was assessed using a 2 
hours BrdU pulse-chase labelling. In good agreement with the previous findings 
both CI1040 and AZD6244 drug treatments reduced significantly the CPL 
phenotype area in AKD mice (p-values = 0.02 and 0.03 respectively) (Figure 51). 
As expected, no downregulation of CPL phenotype were observed in AK mice 
following the treatment with CI1040 (Figure 52). 
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Figure 51: Effects of Mek inhibition on proliferation in the CPL phenotype of Dusp6 null mice 
CPL phenotype quantification by two hours BrdU pulse-chase labelling experiment. 
VilCreER+Apcfl/fl KRasLsL-G12D/+Dusp6-/- mice (AKD) were sacrificed at day 3 after induction of Cre 
recombinase. The AKD mice were either untreated (red) (n=3), treated with CI1040 (n=4) or 
treated with AZD6244 (n=5) (both in yellow). 
Box plots showing the position of the highest BrdU positive cell of AKD mice (A), the total 
number of BrdU positive cells per half crypt (B) and the percentage of BrdU positive cells in the 
CPL area (C) were drawn. 
A Highest BrdU+ position - Mann Whitney test p-values 
AKD unt. Vs AKD CI1040  0.02 
AKD unt. Vs AKD AZD6244 0.03 
B Total of BrdU+ cells - Mann Whitney test p-values 
AKD unt. Vs AKD CI1040  0.18 
AKD unt. Vs AKD AZD6244 0.08 
C % of BrdU+ cells - Mann Whitney test p-values 
AKD unt. Vs AKD CI1040  0.29 
AKD unt. Vs AKD AZD6244 0.11 
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Figure 52: Effects of Mek inhibition on proliferation in the CPL phenotype of KRas activated 
mice 
CPL phenotype quantification by two hours BrdU pulse-chase labelling experiment. VilCreER+ 
Apcfl/fl KRasLsL-G12D/+ mice (AK) were sacrificed at day 3 after induction of Cre recombinase. The 
AK mice were either untreated (n=5) (dark grey) or treated with CI1040 (n=4) or AZD6244 (n=5) 
(light grey). 
A,B and C: Box plot showing respectively the position of the highest BrdU positive cell, the total 
number of BrdU positive cells per half crypt and the percentage of BrdU positive cells in the CPL 
area of AK mice treated or not with CI1040. 
A Highest BrdU+ position - Mann Whitney test p-values 
AK unt. Vs AK CI1040  0.27 
AK unt. Vs AK AZD6244 0.1 
B Total of BrdU+ cells - Mann Whitney test p-values 
AK unt. Vs AK CI1040  0.71 
AK unt. Vs AK AZD6244 1 
C % of BrdU+ cells - Mann Whitney test p-values 
AK unt. Vs AK CI1040  0.27 
AK unt. Vs AK AZD6244 0.03 
 
A B
C
Results 
 
129
Taken together this data suggests that when Apc is lost and KRas is activated, 
the MAPK pathway may not be the main signalling cascade involved. This is 
perhaps not surprising as both the Wnt and KRas pathways have many 
downstream effectors and thus dependence on any single pathway would be 
unlikely. Therefore the inhibition of other pathways such as Pi3K/Akt or Rac 
along with the inhibition of MAPK pathway is currently investigated in the lab 
and will help clarify which pathway is mainly involved in the response to Apc 
deletion and KRas activation. Moreover given potential feedback loops it is also 
likely that if any effector pathway is downregulated another may be stimulated 
(Tenbaum, Ordonez-Moran et al. 2012). Our data however suggest that the one 
reason the MAPK pathway is not the preferred cascade is that Dusp6 is already 
counteracting the activation of the MAPK pathway. When Dusp6 is removed 
there is an increase in proliferation which is now completely reliant of MAPK 
pathway as shown with the sensitivity to the Mek inhibitors. Indeed it seems that 
Dusp6 deletion channel the signal through the MAPK pathway by removing an 
important negative feedback loop. It is interesting to note Dusp5 activity is also 
high suggesting that again other feedback mechanisms are also limiting MAPK 
activation. We could speculate that combined deletion of Dusp5/6 might cause a 
dramatic activation of MAPK pathway. In this circumstance it may yield too high 
a level of pathway activity that may be deleterious for cancer cell proliferation. 
Indeed there are many reports that overexpression of KRas and/or high Erk 
pathway activation can lead to senescence. 
We next wished to test the specificity of Dusp6 deletion as our data would 
suggest Dusp6 was only activated in the context of a KRas mutation and 
therefore we might expect Dusp6 deletion to have some impact when KRas 
mutation is targeted to the intestine in the absence of an Apc mutation. 
Moreover we would expect, given the low expression of Dusp6 following Apc loss, 
very little impact in tumours that have just lost Apc (in the absence of KRas 
mutation). 
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18 Dusp6 deletion effects on tumourigenesis 
18.1 Dusp6 deletion effects in the context of Apc deletion 
alone  
In order to confirm the necessity of KRas activation to induce Dusp6 deletion 
effects on tumourigenesis, I aged VilCreER+ Apcfl/+ and VilCreER+ Apcfl/+ Dusp6-/- 
mice after induction of the Cre recombinase. As expected, in this context Dusp6 
loss did not have an effect on tumourigenesis confirming the dependence to 
MAPK pathway activation (Figure 53). 
 
 
Figure 53: Dusp6 deletion has no effect following Apc deletion alone 
Kaplan-Meier curve showing the survival of VilCreER+ Apcfl/+ (Afl/+) (black line ; n=19) and 
VilCreER+ Apcfl/+ Dusp6-/- mice (Afl/+D) (red line ; n=26). Mice with intestinal tumours were 
sacrificed at the same point of illness or until they reached 500 days after induction.  
The survival was not different between the two genotypes: log rank p=0.2.  
 
Afl/+
Afl/+D
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18.2 Dusp6 deletion effects in the context of KRas 
activation alone 
It has been shown that KRas activation alone could lead to intestinal 
hyperproliferation (Haigis, Kendall et al. 2008) but does not promote intestinal 
tumourigenesis. We therefore wanted to assess if Dusp6 deletion had an impact 
on intestinal tumourigenesis in the context of KRas activation only. 
To do so, I aged VilCreER+ KRasLsL-G12D/+ Dusp6+/+ along with VilCreER+ KRasLsL-G12D/+ 
Dusp6-/- mice until they show intestinal sickness or until they reached the age of 
500 days. In agreement with published data, VilCreER+ KRasLsL-G12D/+ mice did not 
develop intestinal tumours (Figures 54 and 56). The addition of Dusp6 deletion 
resulted in tumour formation and a median survival of 250 days (Figure 54). This 
is another evidence of the strong effect of Dusp6 loss lead by KRas activation on 
tumourigenesis. The tumours growing from these mice were not invasive but 
were highly proliferative as indicated by a 2 hours BrdU pulse-chase labelling 
(Figure 55). 
Interestingly, in the tumours of VilCreER+ KRasLsL-G12D/+ Dusp6-/- mice, a positive 
nuclear staining of β-Catenin as well as a positive Sox 9 staining showed Wnt 
pathway activation (Figure 56). However, the reason of this activation remains 
uncertain. On the other hand, the Sox 9 staining of VilCreER+ KRasLsL-G12D/+ mice 
remained restricted to the crypt and the pattern of β-Catenin staining remained 
normal, namely in the nucleus of cells of the bottom of the crypt and at the 
cells membrane. 
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Figure 54: Dusp6 deletion reduces the survival following KRas activation 
Kaplan-Meier curve showing the survival of VilCreER+ KRasLsL-G12D/+ (K) (black line ; n=9) and 
VilCreER+ KRasLsL-G12D/+ Dusp6-/- mice (KD) (red line ; n=20). Mice with intestinal tumours were 
sacrificed at the same point of illness or until they reached 500 days after induction.  
The survival was significantly different between the two genotypes: log rank p<0.001. Dusp6 
deletion decreases median survival from 500 days to 250 days. 
 
 
Figure 55: Dusp6 deletion allows tumour formation following KRas activation 
H&E staining and BrdU IHC were performed of paraffin sections of intestine of VilCreER+ KRasLsL-
G12D/+Dusp6-/- mice.  
A: H&E of an intestinal tumour of a VilCreER+ KRasLsL-G12D/+ Dusp6-/- mouse. 
B: BrdU staining in an intestinal tumour of a VilCreER+ KRasLsL-G12D/+ Dusp6-/- mouse showing the 
high level of proliferation of these tumours. 
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Figure 56: Activation of Wnt signalling in KRas activated mice 
Immunohistochemistries for BrdU, β-Catenin and Sox9 were performed on paraffin sections of 
intestine from VilCreER+ KRasLsL-G12D/+ (K) and VilCreER+ KRasLsL-G12D/+Dusp6-/- mice (KD). 
K: The BrdU staining shows proliferation is restricted to the crypt. The β-Catenin staining is 
located in the nuclei of cells at the bottom of the crypt and at the cell membrane and Sox 9 is 
also restricted to the bottom of the crypts. 
KD: Nuclear β-Catenin and Sox 9 staining is located in the nuclei of most of the cells of the 
intestinal tumour showing a Wnt pathway activation in these lesions. 
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19 Effects of Dusp6 deletion on MAPK pathway 
I have proven previously that Dusp6 deletion effects are dependent on KRas 
activation and are reversed by the inhibition of MAPK pathway at Mek level. It is 
now interesting to determine by which mechanism Dusp6 deletion affect the 
MAPK pathway and, at a more global level, cell proliferation and tumourigenesis. 
Dusp6 dephosphorylates Erk 1/2, so in order to assess the effects of Dusp6 
deletion on Erk activation I performed an IHC for pErk 1/2 and pMek 1/2 on 
VilCreER+ Apcfl/+ KRasLsL-G12D/+ and VilCreER+ Apcfl/+ KRasLsL-G12D/+ Dusp6-/- mice 
(Figure 57).  
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Figure 57: MAPK pathway activation following Apc deletion and KRas activation 
Immunohistochemistries for pErk and pMek were performed on paraffin sections of intestine from 
VilCreER+Apcfl/+KRasLsL-G12D/+ and VilCreER+ Apcfl/+KRasLsL-G12D/+Dusp6-/- mice. 
VilCreER+Apcfl/+KRasLsL-G12D/+ : The pErk staining is mainly restricted to the edge of the villi and 
the bottom of the crypts. The core of the tumour does not show an Erk activation. The pMek 
staining follow the pattern of pErk staining confirming the direct link between Erk and its 
specific kinase Mek. 
VilCreER+ Apcfl/+KRasLsL-G12D/+Dusp6-/- : The staining for both protein is similar to 
VilCreER+Apcfl/+KRasLsL-G12D/+ mice suggesting that Dusp6 deletion does not affect the MAPK 
pathway activation in this model. 
 
Erk activation (pErk) is restricted to the crypts forming a distinct line in the gut 
epithelium. There is also an Erk phosphorylation at the edge of the villi which 
could be caused by an activation of Erk by the bacteria found in the intestine 
(Sung Hee Lee 2010). The core of the tumours showed very little staining 
suggesting very little or no Erk activation in these intestinal tumours. The pMek 
pattern matched the pErk one in both normal and tumourigenic epithelium. 
VilCreER+Apcfl/+KRasLsL-G12D/+
pErk
VilCreER+ Apcfl/+KRasLsL-G12D/+Dusp6-/-
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Nonetheless the IHC for both phospho-protein stayed rather unclear and if Dusp6 
deletion did not seem to have an effect on Mek and Erk activation in this context 
we could not conclude this was a real effect. Indeed the staining here does not 
allow the visualisation of subtle changes that might appear between the 
genotypes.   
To study further the effect of Dusp6 deletion, I then performed a western blot 
analysis on epithelial extracts of VilCreER+ (WT), VilCreER+ Apcfl/fl (A), VilCreER+ 
Apcfl/fl KRasLsL-G12D/+ (AK) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice 
(Figure 58). Unexpectedly, I found a downregulation of active Erk following KRas 
activation while total Erk remained unchanged. This result were confirmed by 
the downregulation of pElk1 a direct target of Erk 1/2. This downregulation was 
not affected by the loss of Dusp6. However, a western blot analysis of protein 
samples from crypt culture of A and AK mice done by David Huels suggested that 
there were no difference in Erk activation between the samples. This result is 
not in agreement with the figure 58 and questions the conservation of the 
phospho-proteins in the protein samples from epithelial extracts. Further 
investigations are currently done on crypt culture samples with Dusp6 deletion in 
order to confirm the finding. However, the MAPK cascade is regulated by 
numerous kinases and phosphatases and a complex network of negative feedback 
loops and the surprising effect of KRas activation in our model may be the 
outcome of these complex regulation mechanisms. Interestingly, I found total 
Mek upregulated following KRas activation (Figure 58). I was unable to obtain a 
good immunoblot for pMek and therefore it was impossible to ascertain the 
impact of total Mek increase on Mek activation. I performed an IHC for pErk 1/2 
and pElk 1 on these mice gut epithelium (Figure 59). In these mice we found the 
pErk 1/2 staining restricted to the edge of the villi and to the crypt. The pElk 1 
staining was restricted to highly proliferative areas within the villi of VilCreER+ 
Apcfl/fl KRasLsL-G12D/+ (AK) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice. 
Here the activation of Elk 1 reveals the MAPK pathway activation in the CPL 
phenotype of these mice. However no differences were observed between AK 
and AKD mice.  
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Figure 58: MAPK pathway activation in the intestinal epithelium 
Western Blot performed on protein from epithelial extracts of intestine from VilCreER+ (WT), 
VilCreER+Apcfl/fl (A), VilCreER+Apcfl/flKRasLsL-G12D/+(AK) and VilCreER+ Apcfl/+KRasLsL-G12D/+Dusp6-/- 
(AKD) mice. 
 
Figure 59: MAPK pathway activation in CPL phenotype 
Immunohistochemistry for pErk 1/2 (left panel) and pElk 1 (right panel) were performed on 
paraffin sections of intestine from VilCreER+Apcfl/flKRasLsL-G12D/+ (AK) and VilCreER+ Apcfl/+KRasLsL-
G12D/+Dusp6-/- mice (AKD).  
AK and AKD: pElk 1 staining is increased in the proliferative zones of the CPL phenotype 
suggesting an upregulation of the MAPK pathway in the CPL phenotype however pErk staining is 
restricted to the edge of the villi. 
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These rather contradictory results taken together do not allowed having a clear 
answer regarding the outcome of Dusp6 deletion but also of KRas activation in 
this context. Here the lack of powerful tools to ascertain Erk activation is 
highlighted and the use of more advanced technics or better readout will be 
necessary to determine the impact of these two mutations on MAPK cascade 
activation. 
20 Impact of Mek inhibition on gene signature 
Given the conflicting results obtained by immunoblot and IHC, we decided to 
investigate alteration in genes expression signature using microarray analysis 
performed on whole gut RNA from VilCreER+ Apcfl/fl KRasLsL-G12D/+ (AK) and 
VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- (AKD) mice treated or not with the MEK 
inhibitor CI1040. 
20.1 Wnt pathway signature 
I analysed the Wnt pathway signature of AK and AKD mice treated or not with 
the Mek inhibitor CI1040 based on the previously described H. Clevers’ group list 
of upregulated genes in human CRCs (Rigas, Hoff et al. 2001) (Figures 60 A and 
B). Globally the CI1040 treatment has similar outcomes in both AK and AKD 
mice. There were however a small number of genes such as Rhobtb3 which were 
upregulated after CI1040 treatment only in AKD mice. This is confirmed by the 
clusters formed separating in two groups the untreated samples and the treated 
ones (if we exclude the already mentioned AKD sample with the very unique 
behaviour) (Supplementary figure 7). Interestingly, a number of genes were 
downregulated in both genotypes namely EphB2, Jag1, Etv4, Sox9, cd44 and 
Myc. Given the CI1040 was unable to stop the proliferation of the AK mice it 
suggests that reduction of these proteins is not sufficient to stop the efficient 
proliferation of AK cells. Interestingly Sox4 is upregulated after treatment in 
both AK and AKD mice. But overall, there were no major changes brought by the 
inhibition of Mek in the two genotypes.  
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Figure 60A: WNT pathway signature 
The genes found to be up-regulated in human colorectal adenomas were tested in whole gut 
extracts of VilCreER+ Apcfl/fl KRasLsL-G12D/+ untreated (AK) or treated with Mek inhibitor (AK CI1040) 
and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- untreated (AKD) or treated (AKD CI1040) mice taken at 
day 3 after Cre recombinase induction. The Z-score is indicated by a range of colour from yellow 
(low expression) to red (high expression).  
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Figure 60B: WNT pathway signature 
The genes found to be up-regulated in both human colorectal adenomas and human colorectal 
adenocarcinomas were tested in whole gut extracts of VilCreER+ Apcfl/fl KRasLsL-G12D/+ untreated 
(AK) or treated with Mek inhibitor (AK CI1040) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- 
untreated (AKD) or treated (AKD CI1040) mice taken at day 3 after Cre recombinase induction. 
The Z-score is indicated by a range of colour from yellow (low expression) to red (high 
expression).  
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20.2 Stem cell signature 
I then analysed the expression of intestinal stem cell markers in AK and AKD 
mice treated or not with the Mek inhibitor CI1040 (Figure 61). Here again, both 
genotypes reacted in the same way to the treatment and the samples were 
clustered in two distinct groups according to their treatment (Supplementary 
figure 8). No clear impact on the intestinal stem cells was observed with Mek 
inhibition: some genes such as Ascl2, Lgr5 and Olfm4 were upregulated following 
the treatment whereas genes such as Bmi1 and Lrig were downregulated. These 
rather conflicting effects did not allow us to establish a clear effect of Mek 
inhibition on stem cells. 
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Figure 61: Stem cell signature  
The expression of intestinal stem cell markers was tested in whole gut extracts of VilCreER+ 
Apcfl/fl KRasLsL-G12D/+ untreated (AK) or treated with Mek inhibitor (AK CI1040) and VilCreER+ Apcfl/fl 
KRasLsL-G12D/+ Dusp6-/- untreated (AKD) or treated (AKD CI1040) mice taken at day 3 after Cre 
recombinase induction. The Z-score is indicated by a range of colour from yellow (low 
expression) to red (high expression).  
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20.3 MAPK pathway signature 
Finally I analysed the effect of Mek inhibition on the MAPK pathway gene 
signature. As expected both genotypes behave in similar way and the samples 
were clustered according to their treatment (except the one AKD sample) 
(Supplementary figure 9). Among the changes observed we can note a 
downregulation of Fra1 and Dusp5 following CI1040 treatment (Figure 62). 
Interestingly Dusp6 was also downregulated in AK mice treated. This data 
highlights that the Mek inhibition was able to inhibit the MAPK pathway in AK 
intestines; however this was not sufficient to stop proliferation. 
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Figure 62: MAPK pathway signature  
The MAPK pathway target genes identified by microarray based transcriptome profiling were 
tested in whole gut extracts of VilCreER+ Apcfl/fl KRasLsL-G12D/+ untreated (AK) or treated with Mek 
inhibitor (AK CI1040) and VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- untreated (AKD) or treated (AKD 
CI1040) mice taken at day 3 after Cre recombinase induction. The Z-score is indicated by a range 
of colour from yellow (low expression) to red (high expression).  
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An analysis of 195 colon and rectum adenocarcinoma (TCGA, Nature 2012) on the 
website http://www.cbioportal.org/public-portal showed that 10% of tumours 
had a modification in Dusp6. Interestingly only 50% of these tumours were 
correlated with KRas activation suggesting that Dusp6 could have a wider 
spectrum of action. Given our failure to see an impact on Apc deletion, it is 
possible that Dusp6 loss could modify those tumours that carry BRaf mutation. I 
am currently testing this hypothesis in vivo by intercrossing mice that carry a 
BRafLSL-V600E allele to the Dusp6 KO mice. 
Despite difficulties in assessing the MAPK pathways in vivo, I have shown that 
Dusp6 deletion clearly increased cell proliferation and tumour initiation in CRC 
via a positive effect on the MAPK pathway. It would be interesting to investigate 
the effects of Dusp6 deletion followed by Mek inhibition on long term 
established tumours in order to see if a blockage of the MAPK pathway could 
induce tumour regression.  
Microarray analysis can be analysed in different ways. In this thesis I chose to 
use the fold change and the resulting Log 2 expression ratio. Given the limited 
impact of Mek inhibition on KRas activated mice, I investigated other ways to 
analyse microarray data in order to potentially highlight the unexpected effect 
of KRas mutation. Therefore I did another type of analysis called rank product 
analysis which ranks the genes according to their importance between two 
groups. I analysed the data of A and AK mice in order to investigate pathways 
importantly deregulated. The selection of the 1000 most deregulated genes 
between the two sets of samples established a link between KRas activation and 
metabolism. Indeed the gene selection entered into the IPA network analyser 
(https://analysis.ingenuity.com/) highlighted the importance of drug and amino 
acid metabolism pathways. The KRas activation impact on metabolism is 
currently investigated by Fatih Ceteci. 
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21 Dusp6 in Pancreatic tumourigenesis 
In the previous chapter I have shown that the effects of Dusp6 loss were 
dependent on KRas activation. Given that KRas activation alone does not initiate 
colorectal cancer, this suggests that in CRC, Dusp6 downregulation may occur at 
late stages in tumourigenesis. I therefore decided to test the role of Dusp6 in 
Pancreatic Cancer (PCs) as KRas mutations are the initiating event in nearly all 
PCs (Smit, Boot et al. 1988; Hingorani, Petricoin et al. 2003). Moreover Dusp6 
expression appears to be upregulated in dysplastic cells of the pancreatic ducts 
which are thought to be precursor lesions of the invasive pancreatic ductal 
adenocarcinoma (PDAC). Importantly, Dusp6 expression is reduced or abolished 
in the PDAC suggesting that its downregulation may drive tumour progression 
(Furukawa, Fujisaki et al. 2005). 
The mouse pancreatic model I used combines a pancreatic specific Cre 
recombinase (PdxCre) (Gannon, Herrera et al. 2000), with the previously 
described oncogenic KRas allele (KRasLsL-G12D). These mice were intercrossed with 
the Dusp6 knockout mice (Dusp6-/-) provided by Stephen Keyse. 
21.1 Dusp6 loss increases tumourigenesis following KRas 
activation 
I generated cohorts of PdxCre+ KRasLSL-G12D/+ mice with or without Dusp6 and aged 
them until they developed signs of ill health. The mice predominantly developed 
pancreatic cancer but also occasionally papillomas, due to the sporadic Cre 
recombinase expression in the skin. At the same time Cre expression in the 
caecum led to intussusceptions, particularly in PdxCre+ KRasLSL-G12D/+ Dusp6-/- 
mice, due to an increase in goblet cells in the colon as seen in the CRC mouse 
model.  
In this model, in good agreement with the results in the intestinal model, Dusp6 
loss dramatically shortened the disease free survival of the mice developing PC 
(Figure 63). With the deletion of Dusp6 the median survival was reduced from 
220 days (in PdxCre+ KRasLSL-G12D/+ mice) to 120 days. No significant difference 
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was observed between PdxCre+ KRasLSL-G12D/+ and PdxCre+ KRasLSL-G12D/+ Dusp6+/- 
mice.  
 
Figure 63: Effects of Dusp6 deletion on survival in the context of tumourigenesis driven by 
the KRasLsL-G12D/+ allele 
Kaplan-Meier curve showing the cumulative survival of PdxCre+ KRasLsL-G12D/+ (black solid line ; 
n=14), PdxCre+ KRasLsL-G12D/+ Dusp6+/- (black dashed line ; n=21) and PdxCre+ KRasLsL-G12D/+ Dusp6-/- 
(red solid line ; n=24) mice. Mice with pancreatic tumours were sacrificed at the same point of 
illness or when they reached 500 days.  
The tumour free survival was significantly decrease between both PdxCre+ KRasLsL-G12D/+ and 
PdxCre+ KRasLsL-G12D/+ Dusp6+/- and PdxCre+ KRasLsL-G12D/+ Dusp6-/- mice (log rank: respectively 
p=0.006 and p=0.001). No significant difference was found between PdxCre+ KRasLsL-G12D/+ and 
PdxCre+ KRasLsL-G12D/+ Dusp6+/- mice (log rank: p=0.7). 
 
Within the intestine I showed that Dusp6 deletion could expand the cell of origin 
in a MAPK dependent manner. Within PDAC there is discussion whether PDAC 
originates in the duct or occurs via acini to ductal metaplasia. Interestingly, in 
our pancreatic cancer model, lesions seemed to be initiated from 2 different cell 
populations: from the ducts but also from acini which here present a phenotype 
similar to the panINs, with an accumulation of mucine showed by alcian blue 
staining (Figure 64). This might indicate that PDACs could be derived from 
PdxCre+ KRasLsL-G12D/+
PdxCre+ KRasLsL-G12D/+ Dusp6+/-
PdxCre+ KRasLsL-G12D/+ Dusp6-/-
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multiple cells of origin in the background of Dusp6 deletion. A more careful 
characterisation of this would be of interest as several contracdictory reports 
have been written regarding the cell of origin of PDAC. 
 
 
Figure 64: Multiple cells of origin for pancreatic lesions 
Paraffin sections of PdxCre+ KRasLSL-G12D/+ Dusp6-/- mouse pancreas representative of all genotypes 
were stained for alcian blue.  
A: Normal pancreatic tissue. 1: Duct, 2: Acini and 3: Islet. B: panIN type I (ductal dysplastic 
pancreatic lesion). An accumulation of mucin in the cells of the duct can be observed. C: PanIN 
like acini lesions with an accumulation of mucin in the cytoplasm. 
 
It has been shown that early panIN lesions undergo senescence in the context of 
KRas activation (Morton, Timpson et al. 2010). Dusp6 deletion had no effect on 
the senescence response. IHC for β-galactosidase on pancreas from PdxCre+ 
KRasLSL-G12D/+ Dusp6+/+ and PdxCre+ KRasLSL-G12D/+ Dusp6-/- mice taken at 50 days of 
age shows that in both genotypes some panIN lesions were senescent (Figure 65). 
Therefore Dusp6 deletion is strongly accelerating tumourigenesis in PC and 
allows lesions to grow from not only the ducts but also the acini. However, it has 
no effect on the senescence of the PanIN lesions.  
1
2
3
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Figure 65: Senescence 
Frozen sections of pancreas of PdxCre+ KRasLSL-G12D/+ (K) and PdxCre+ KRasLSL-G12D/+ Dusp6-/- (KD) 
mouse were stained for β-Galactosidase. No difference was noticed between the two genotypes. 
Given the fact that the KRasLSL-G12V allele induced tumourigenesis with a longer 
latency in both the intestine and the pancreas, we wondered if Dusp6 loss would 
accelerate a slightly more rapid model of PDAC driven by the KRasLSL-G12V allele. 
The mutation of p53 occurs in 50% of human PCs. In order to renders the model 
more aggressive, I choose to add the p53 mutant allele (p53LSL-R172H) to the 
PdxCre+ KRasLSL-G12V/+ mice due to its faculty to mimic the p53 mutant 
accumulation in PCs and because of its high metastatic outcome (Olive, Tuveson 
et al. 2004; Morton, Timpson et al. 2010). In this case Dusp6 loss results in 
acceleration of tumourigenesis with PdxCre+ KRasLSL-G12D/+ p53LSL-R172H/+ Dusp6-/- 
mice having a median survival of 170 days compared to 240 days in PdxCre+ 
KRasLSL-G12V/+ p53LSL-R172H/+ mice (Figure 66). 
KDK
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Figure 66: Effects of Dusp6 loss on survival in the context of tumourigenesis driven by the 
KRasLsL-G12V/+ allele 
Kaplan-Meier curve showing the cumulative survival of PdxCre+ p53R172H/+ KRasLsL-G12V/+ (black solid 
line ; n=12), PdxCre+ p53R172H/+KRasLsL-G12V/+ Dusp6+/- (black dashed line ; n=17) and PdxCre+ 
p53R172H/+ KRasLsL-G12V/+ Dusp6-/- (red solid line ; n=8) mice. Mice with pancreatic tumours were 
sacrificed at the same point of illness or when they reached 500 days. The tumour free survival 
was significantly decrease between both PdxCre+ p53R172H/+ KRasLsL-G12V/+ and PdxCre+ p53R172H/+ 
KRasLsL-G12V/+ Dusp6+/- and PdxCre+ p53R172H/+ KRasLsL-G12V/+ Dusp6-/- mice (log rank: p=0.04). No 
significant difference was found between PdxCre+ p53R172H/+ KRasLsL-G12V/+ and PdxCre+ p53R172H/+ 
KRasLsL-G12V/+ Dusp6+/- mice (log rank: p=0.4). 
 
21.2 Dusp6 heterozygosity allows the formation of 
metastases 
Although I did not observe a difference in survival between PdxCre+ KRasLSL-G12D/+ 
and PdxCre+ KRasLSL-G12D/+ Dusp6+/- mice, there was a significant increase in liver 
metastasis in PdxCre+ KRasLSL-G12D/+ Dusp6+/- mice (Figure 68-Table). Indeed 
almost 35% of the Dusp6 heterozygote mice developed liver metastases while 
only 18% of the PdxCre+ KRasLSL-G12D/+ and 9.5% of PdxCre+ KRasLSL-G12D/+ Dusp6-/- 
mice did. Here the loss of one copy of Dusp6 clearly contributes to invasion. 
Intriguingly the mice which had lost both copies of Dusp6 developed very few 
metastatic tumours. This phenomenon could be explained by the rapid 
PdxCre+ p53R172H/+ KRasLsL-G12V/+
PdxCre+ p53R172H/+ KRasLsL-G12V/+ Dusp6+/-
PdxCre+ p53R172H/+ KRasLsL-G12V/+ Dusp6-/-
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tumourigenesis exhibited by the PdxCre+ KRasLSL-G12D/+ Dusp6-/- mice which result 
in large primary tumours often blocking the intestine and therefore showing 
quickly signs of ill health. This shorter latency may have not allowed enough 
time to develop invasive tumours. TGFβ signalling has been reported in several 
studies to be involved in tumour progression and invasion in late stages of 
tumourigenesis (for review : Millet and Zhang 2007; Tarasewicz and Jeruss 2012). 
Interestingly a positive staining for phospho-mothers against decapentaplegic 
homolog 3 (pSmad3) in lesions of the three genotypes suggested the activation of 
the TGFβ signalling pathway (Figure 67). However the TGFβ signalling status 
needs more investigation to determine if there was a pSmad3 increase in the 
PdxCre+ KRasLSL-G12D/+ Dusp6+/- mice and if it was linked to the increase seen in 
invasion. 
The liver metastases found in PdxCre+ KRasLSL-G12D/+ Dusp6+/- mice were confirmed 
to originate from the pancreatic tumour by a positive Pdx-1 staining. An IHC for 
Mcm2 (a protein essential to the replication process) showed that these lesions 
were highly proliferative (Figure 68-IHCs). Finally these metastases had an 
increase in MAPK pathway activation as showed by pErk positive staining (Figure 
68). This finding was the first evidence of MAPK cascade activation following 
Dusp6 deletion. 
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Figure 67: Activation of the TGFβ pathway 
Paraffin sections of pancreas were stained for pSmad3.  
In the three genotypes, a positive staining for pSmad3 were observed in pancreatic lesions. 
PdxCre+ KRasLsL-G12D/+
PdxCre+ KRasLsL-G12D/+ Dusp6+/-
PdxCre+ KRasLsL-G12D/+ Dusp6-/-
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Figure 68: Liver metastasis  
Table: H&E stained liver from mice sacrificed due to pancreatic cancer were analysed and the 
mice presenting liver metastasis was scored.  
There is an increase in formation of metastasis in the liver in PdxCre+ KRasLSL-G12D/+ Dusp6+/- mice 
compared to the two other genotypes. 
IHCs: Paraffin sections of liver from a PdxCre+ KRasLSL-G12D/+ Dusp6+/- mouse were stained for H&E 
(A), Pdx-1 (B), MCM2 (C) and pErk (D).  
The lesion seen on H&E is confirmed to come from a primary tumour in the pancreas with its 
positive staining for Pdx-1 (B). This lesion is positive for MCM2 (part of the DNA replication 
helicase complex) showing hyper proliferation (C) and has an activation of Erk (D). Taken 
together these data allow us to confirm the presence of metastases in the liver in PdxCre+ 
KRasLSL-G12D/+ Dusp6+/-  mice. 
 
Dusp6 +/+ Dusp6 +/- Dusp6 -/-
Mice with liver mets. / total mice 3/17 8/23 2/21
Percentage of mice developping mets. 17.60% 34.80% 9.50%
Age at death with mets. (days) 227 to 500 151 to 399 215 to 307
A B
DC
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In order to assess the capacity of 3D invasion of PDAC cells from PdxCre+ 
KRasLSL-G12D/+ and PdxCre+ KRasLSL-G12D/+ Dusp6+/- mice I performed with the help of 
Paul Timpson, an organotypic assay. To do so I first cultured cells from PDACs, 
then placed the cells on a 3D matrix of fibroblasts imbedded in rat collagen 
which was in turn placed on a stainless steel grid. This grid was then placed in a 
plate with enough medium to touch the bottom of the matrix but not 
submerging it creating a gradient of nutrients. The cells attracted by the 
nutrient gradient and in capability to invade are then starting to move towards 
the bottom of the 3D matrix. Invading cells were visualised with a pan-
cytokeratin AE1/AE3 staining specific for epithelial cells. Surprisingly both 
genotypes were able to invade through the matrix (Figure 69). However it is 
interesting to note the phenotypical difference between the invasion of cells 
derived from lesions from PdxCre+ KRasLSL-G12D/+ and PdxCre+ KRasLSL-G12D/+ Dusp6+/- 
mice. Indeed, the cells with wild-type Dusp6 showed a collective invasion 
forming cell clusters in a shape of a duct. In cells from Dusp6 heterozygote mice 
the invasion was similar to a mesenchymal migration with elongated cells 
invading further in the 3D matrix. This observation may indicate that the linear 
invasion exhibited by the Dusp6 haploinsufficient cells may be more efficient for 
metastasis formation than cluster invasion. Interestingly, treatment with a Mek 
inhibitor (CI1040 500nM) changed the invasion mechanism from linear to 
collective cluster in PdxCre+ KRasLSL-G12D/+ Dusp6+/- mice. 
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Figure 69: Organotypic assay 
A: The organotypic assay system 
B: Cultured PDAC cells from PdxCre+ KRasLSL-G12D/+ (top panel) and PdxCre+ KRasLSL-G12D/+ 
Dusp6+/- (bottom panel) were put on top of a fibroblast matrix placed on a grid. Only the bottom 
of the matrix touched the culture medium creating a nutrient gradient. The cells were culture 
with a CI1040 treatment or its vehicle. 
The fibroblast 3D matrix was embedded in paraffin and then sections were stained for pan-
cytokeratin AE1/AE3. 
Cells
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21.3 Effects of Dusp6 deletion on MAPK pathway 
21.3.1 Erk activation is independent of Dusp6 status 
Activation of Erk is a key event in tumourigenesis and the loss of Dusp6 could be 
one of the mediators of this activation. In order to prove this hypothesis, I have 
stained sections for pErk and pMek from mice with premalignant lesions at day 
35 and day 60 (Figure 70), as well as mice with pancreatic cancer (Figure 71). 
Interestingly, there seems to be an activation of Erk in both the early lesions and 
PDAC irrespective of Dusp6 status. However, this finding will need further 
investigation as, as previously mentioned, these IHC are not powerful enough to 
highlight possible subtle differences.  
 
Figure 70: Activation of Erk in early pancreatic lesions 
Paraffin sections of pancreas from PdxCre+ KRasLSL-G12D/+ (upper panel) and PdxCre+ KRasLSL-G12D/+ 
Dusp6-/- mice (bottom panel). Mice taken at 35 days of age were stained for pErk (left panel) and 
pMek (right panel).  
An activation of Erk but no activation of Mek can be observed in the lesions from the two 
genotypes.  
 
p-Erk p-Mek
PdxCre+ 
KRasLSL-G12D/+ 
Dusp6+/+
PdxCre+ 
KRasLSL-G12D/+
Dusp6+/-
Results 
 
165
 
Figure 71: PDAC characteristics 
Paraffin sections of a representative PDAC from PdxCre+ KRasLSL-G12D/+ Dusp6+/- mice were stained 
for H&E (A), pErk (B), pMek (C).  
 
21.3.2 Effect of Mek inhibition on tumourigenesis 
Finally I assessed the impact of Mek inhibition on tumourigenesis. To do so I 
performed an allograft experiment on CD1-nude mice where cultured PDAC cells 
from PdxCre+ KRasLSL-G12D/+, PdxCre+ KRasLSL-G12D/+ Dusp6+/- and PdxCre+ 
KRasLSL-G12D/+ Dusp6-/- mice were implanted subcutaneously. At day 3 after cell 
implantation, we started the treatment with 200mg/Kg CI1040 or vehicle daily. 
The PDAC cells from PdxCre+ KRasLSL-G12D/+ Dusp6-/- mice grow faster than cells 
from PdxCre+ KRasLSL-G12D/+ or PdxCre+ KRasLSL-G12D/+ Dusp6+/-. Treatment with the 
Mek inhibitor resulted in an important tumour growth reduction especially in the 
Dusp6 deleted mice (Figure 72). This confirmed the MAPK pathway activation 
within these pancreatic cancer models. However none of the nude mice 
presented liver or other organ metastasis.  
 
A B C
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Figure 72: Allograft experiment 
Nude mice were injected subcutaneously with cultured PDAC cells from PdxCre+ KRasLSL-G12D/+ , 
PdxCre+ KRasLSL-G12D/+ Dusp6+/- and PdxCre+ KRasLSL-G12D/+ Dusp6-/- mice . The tumours were 
measured every other day and the mice were sacrificed when the tumour reached 1.5cm or when 
they ulcerated. 
Statistics were calculated with the help of a method creatic by Russell Thompson and Gordon 
Smyth using the T-Test to determine the p-values between two curves: 
http://bioinf.wehi.edu.au/software/compareCurves/ .  
p-values obtained after 10000 random sampling steps 
PdxCre+ KRasLSL-G12D/+ unt. vs CI1040 0.003 
PdxCre+ KRasLSL-G12D/+ Dusp6-/+unt. vs CI1040 < 0.0001 
PdxCre+ KRasLSL-G12D/+ Dusp6-/-unt. vs CI1040 0.0001 
PdxCre+ KRasLSL-G12D/+ vs PdxCre+ KRasLSL-G12D/+ Dusp6-/+ < 0.0001 
PdxCre+ KRasLSL-G12D/+ vs PdxCre+ KRasLSL-G12D/+ Dusp6-/- 0.0004 
PdxCre+ KRasLSL-G12D/+ Dusp6-/+ vs PdxCre+ KRasLSL-G12D/+ Dusp6-/- < 0.0001 
 
These results taken together showed an activation of the MAPK cascade as well 
as a potential TGFβ pathway in the pancreatic cancer model independently of 
the Dusp6 status. However, Dusp6 deletion is strongly accelerating 
tumourigenesis. Furthermore, the loss of one copy of Dusp6 is contributing to 
invasion. This implies that Dusp6 loss exacerbate the effects of KRas deletion in 
the pancreas. Our finding that tumours are responsive to Mek inhibition could 
suggest that it is the activation of Wnt signalling in combination with KRas 
mutation that leads to a resistance of Mek inhibition. This is suggested by a 
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recent paper by the Barbacid group (Navas, Hernandez-Porras et al. 2012). They 
showed that loss of EGFR protected the pancreas form KRas driven 
carcinogenesis but not the intestine from Apc and KRas driven tumourigenesis. 
However as established PC only poorly responds to EGFR mediated therapy it 
suggests other mutations occur during pancreatic carcinogenesis that removes 
the dependency on the MAPK pathway. 
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22 The role of Fra1 in two in vivo cancer models – a 
paradox 
Fos related antigen 1 (Fra1) also named Fos-l 1, is a member of the Fos family of 
proteins and is part of the transcription factor activator protein-1 (AP-1). The 
AP-1 complex has been implicated as a driver of carcinogenesis given that it 
regulates cellular processes such as proliferation, differentiation and apoptosis 
(Jochum, Passegue et al. 2001; Young and Colburn 2006). It is a dimer consisting 
of Jun-Jun homodimers or Jun-Fos heterodimers (Young and Colburn 2006). AP-1 
can be activated by the MAPK pathway via ERK, Jun N-terminal Kinase (JNK) and 
p38 (Jochum, Passegue et al. 2001; Hasselblatt, Gresh et al. 2008). It has been 
shown that mutations of Apc and KRas lead to elevated AP-1 activity (Park, Jeon 
et al. 2006).  
Fra1 has been showed to be upregulated in a large variety of tumours including 
breast, lung, and colon carcinomas (Vial, Sahai et al. 2003; Pollock, Shirasawa et 
al. 2005; Zhang, Hart et al. 2005; Young and Colburn 2006) . Its transcription is 
activated by the MAPK pathway but also by the WNT pathway (Mann, Gelos et al. 
1999; Young and Colburn 2006; Adiseshaiah, Li et al. 2008). Fra1 has also been 
suggested to be essential for invasion (Adiseshaiah, Vaz et al. 2008) and to be a 
major transcriptional target following KRas activation (Mark, Aubin et al. 2008). 
Furthermore, we confirmed the upregulation of its expression following Apc loss 
and KRas activation (Figure 34). All of these studies suggested that Fra1 should 
provide an advantage in tumourigenesis following Apc loss. We therefore 
hypothesized that its deletion would decrease tumourigenesis in our in vivo 
models. 
22.1 Fra1 deletion impacts on intestinal homeostasis  
To address the effects of Fra1 deletion in the intestine the AhCre+ mouse model 
was intercrossed with the conditional floxed allele of Fra1 (Fra1fl). I then 
investigated the effects of Fra1 deletion on cell differentiation scoring the total 
number of entero-endocrine and Goblet cells and examining the position of 
Paneth cells (Figure 73). For the three cell types, no changes were observed 
following Fra1 loss.  
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Figure 73: Fra1 deletion does not affect differentiation 
AhCre+ (WT) and AhCre+ Fra1fl/fl (Fra1fl/fl) mice were taken at day 4 after Cre recombinase 
induction. Histochemistry specific for entero-endocrine cells, Paneth cells, and goblet cells were 
performed and total number of entero-endocrine (A) and Goblet cells (C) were scored. Pictures 
of Paneth cells were taken to assess cells position (B). No difference was observed between the 
two genotypes (p value > 0.05 calculated with a Mann Whitney test).  
 
To investigate the effects of Fra1 deletion on proliferation, I performed a 24 
hours and 48 hours BrdU labeling experiment on mice at day four after Cre 
recombinase induction. Whilst Fra1 deletion had no impact on differentiation, it 
significantly increased the number of BrdU positive cells observed at days 5 and 
6 post Cre recombinase induction following 24 and 48 hours BrdU labelling 
(Figure 74). Therefore this increase in proliferation following Fra1 deletion was 
in contradiction with the expected Fra1 role. In order to quantify mitosis in the 
gut epithelium, I performed a phospho histone H3 (phH3) IHC, a mitotic marker, 
on AhCre+ Fra1f/fl mice taken at day four after Cre recombinase induction. I 
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observed an upregulation of the mitosis following Fra1 loss (Figure 75). The 
upregulation of BrdU staining together with the upregulation of phH3 suggests an 
increase in cell proliferation following Fra1 loss alone. 
 
 
Figure 74: Fra1 deletion affects proliferation 
AhCre+ (WT) and AhCre+ Fra1fl/fl (Fra1fl/fl) mice were taken at day 5 and 6 after Cre recombinase 
induction and a BrdU labelling of 24 hours (A) or 48 hours (B and C).  
IHC for BrdU was performed in order to highlight cells in S phase of the cell cycle. There were 
significantly more cells in S phase after Fra1 deletion (p values = 0.03 (A) and 0.02 (B) calculated 
with a Mann Whitney test). This difference is illustrated by the IHC for BrdU of mice labelled for 
48 hours (C).  
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Figure 75: Fra1 deletion affects mitosis 
AhCre+ (WT) and AhCre+ Fra1fl/fl (Fra1fl/fl) mice were taken at day 4 after Cre recombinase 
induction. IHC for the mitotic marker phospho histone H3 (phH3) was performed in order to 
highlight cells in mitosis.  
A: I quantified the total number of phH3 positive cells. There were significantly more mitotic 
cells after Fra1 deletion (p values = 0.02) (calculated with a Mann Whitney test).  
B: The IHC for phH3 on WT (upper panel) and Fra1 deleted mice illustrated the increase in 
mitosis following Fra1 loss.  
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22.2 Fra1 deletion can accelerate tumourigenesis  
22.2.1 The effect of Fra1 deletion following Apc deletion 
In order to investigate the impact of Fra1 deletion on the mitotic index in the 
context of acute Apc deletion, I performed a phH3 IHC on AhCre+ Apcfl/fl Fra1f/fl 
mice taken at day four after Cre recombinase induction. I observed a similar 
increase in mitosis as previously described in the wildtype mice which had lost 
Fra1 (Figure 76).  
 
 
Figure 76: Fra1 deletion affects mitosis 
AhCre+ Apcfl/fl (Apcfl/fl) and AhCre+ Apcfl/fl Fra1fl/fl (Apcfl/fl Fra1fl/fl ) mice were sacrificed at day 4 
after Cre recombinase induction. An IHC for the mitotic marker phospho histone H3 (phH3) was 
performed in order to highlight cells in mitosis.  
The total number of phH3 positive cells was quantified. Following Apc deletion Fra1 loss 
increased the number of cells in mitosis (Mann Whitney: p value = 0.05).  
 
In order to confirm the surprising positive impact on proliferation and possibly 
on tumourigenesis, we decided to investigate the impact of Fra1 deletion on 
tumourigenesis. This work has been done by Rachel Ridgway. It is important to 
note that at this time, the Villin Cre system was not available in the laboratory 
hence the use of the alternative intestinal Cre system namely AhCre. AhCre+ 
Apcfl/+ and AhCre+ Apcfl/+ Fra1fl/fl mice were aged until they showed signs of 
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intestinal illness. This experiment confirmed the results previously found in the 
acute Apc deletion model: following the loss of one copy of Apc, Fra1 deletion 
decreased significantly the tumour free survival from a median of 180 in the 
presence of Fra1 to 150 days without Fra1 (Figure 77). 
 
Figure 77: Fra1 deletion decreases survival  
Kaplan-Meier curve showing the cumulative survival of AhCre+ Apcfl/+ (black line) (n=20) and 
AhCre+ Apcfl/+ Fra1fl/fl mice (green line) (n=23). Mice with intestinal tumours were sacrificed at 
the same point of illness.  
The loss of the two copies of Fra1 resulted in a reduction of the tumour free survival compared 
to AhCre+ Apcfl/+ mice (log rank: p<0.001).  
 
In good agreement with the results found on gut homeostasis after Fra1 deletion 
and the increased proliferation due to Fra1 in the acute Apc deletion model, 
Fra1 seems to act as a tumour suppressor gene as its deletion reduces the 
tumour free survival in the aging model. 
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22.2.2 Fra1 deletion in the context of KRas activation 
Given the finding of my previous chapter where the mutation of KRas revealed 
the strong phenotypes of Dusp6 deletion, I predicted that KRas mutation might 
alter the role plays into tumourigenesis switching it from a tumour suppressive 
role to the expected tumour promoter. Thus I decided to additionally examine 
the impact of KRas mutation on the phenotype of Fra1 deletion. 
Therefore in collaboration with Rachel Ridgway, we aged AhCre+ Apcfl/+ 
KRasLSL-G12V/+, AhCre+ Apcfl/+ KRasLSL-G12V/+ Fra1fl/+ and AhCre+ Apcfl/+ KRasLSL-G12V/+ 
Fra1fl/fl mice. The AhCre system induces recombination in the epithelium but 
also in kidney therefore, it is not compatible with the KRasLSL-G12D allele as this 
particular allele results in kidney failure leading to death soon after birth; this is 
why we crossed the KRasLSL-G12V allele to these mice. In this model, KRas 
activation did not alter the effect of Fra1 loss on tumourigenesis in the context 
of Apc loss. Indeed, the Fra1 deleted mice had a reduction in their median 
tumour free survival from 100 to 70 days compared with mice retaining Fra1 
(Figure 78). It is important to note that the loss of one copy of Fra1 was 
sufficient to induce this tumour free survival reduction.  
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Figure 78: Fra1 deletion decreases survival  
Kaplan-Meier curve showing the cumulative survival of AhCre+ Apcfl/+ KRasLSL-G12V/+ (black line) 
(n=15), AhCre+ Apcfl/+ KRasLSL-G12V/+ Fra1fl/+ (grey dashed line) (n=13), AhCre+ Apcfl/+ KRasLSL-G12V/+ 
Fra1fl/fl mice (green line) (n=24). Mice with intestinal tumours were sacrificed at the same point 
of illness.  
The loss of one and two copy of Fra1 resulted in a reduction of the tumour free survival 
compared to AhCre+ Apcfl/+ KRasLSL-G12V/+ mice (log rank: p=0.008 and p=0.05 respectively). There 
was no significant difference between the mice which have lost one or two copies of Fra1 (log 
rank: p=0.8).  
 
As explained in the introduction, the AhCre model delivers recombination not 
only in the intestine but also in the liver and constitutive cre expression to 
kidneys and other tissues. Therefore, as the Villin Cre system is specific to the 
gut and the KRasLSL-G12D allele is viable when intercrossed to the VillinCreER I 
next decided to intercross this mouse to the Fra1 deletion. Once again I 
obtained similar results to the AhCre system confirming the putative tumour 
suppressor role of Fra1 in the intestine (Figure 79). Indeed the loss of both 
copies of Fra1 reduced the median tumour free survival from 90 to 60 days. 
Interestingly, in this model the loss of only one copy of Fra1 was not sufficient to 
reduce the tumour free survival. This could be due to the choice of KRas allele. 
It should be noted the KRasLSL-G12D allele has a stronger impact on tumourigenesis 
AhCre+ Apcfl/+ KRasLSL-G12V/+ 
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than the KRasLSL-G12V allele and therefore could mask the potential effect of the 
loss of one copy of Fra1.  
 
Figure 79: Fra1 deletion decreases survival  
Kaplan-Meier curve showing the cumulative survival of VilCre+ Apcfl/+ KRasLSL-G12D/+ (black line) 
(n=16), VilCre+ Apcfl/+ KRasLSL-G12D/+ Fra1fl/+ (grey dashed line) (n=14), VilCre+ Apcfl/+ KRasLSL-G12D/+ 
Fra1fl/fl mice (green line) (n=10). Mice with intestinal tumours were sacrificed at the same point 
of illness.  
The loss of the two copy of Fra1 resulted in a reduction of the tumour free survival compared to 
both VilCre+ Apcfl/+ KRasLSL-G12D/+ Fra1fl/+and VilCre+ Apcfl/+ KRasLSL-G12D/+ Fra1fl/fl mice (log rank: 
p=0.05 and p=0.03 respectively). There was no significant difference with AK mice when only one 
copy of Fra1 was lost (log rank: p=0.7).  
 
22.3 Fra1 deletion can increase tumour free survival 
Given these very surprising findings in the intestine, namely that Fra1 loss 
accelerated tumourigenesis, I next wished to examine the role of Fra1 in another 
KRas driven cancer that had been shown to have upregulation of AP-1 complex. 
Within pancreatic cancer there was good evidence that the AP-1 complex is 
upregulated (Shin, Asano et al. 2009) and thus, we decided to investigate the 
impact of Fra1 deletion in the pancreatic cancer in vivo model. To do so we 
intercrossed mice with the pancreatic specific Cre recombinase PdxCre+ with the 
VilCre+ Apcfl/+ KRasLSL-G12D/+
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oncogenic KRas allele, the mutant p53 allele (p53LSL-R172H) and Fra1fl/fl mice. In 
the intestinal mouse model, we investigated the impact of Fra1 loss in the 
context of activated KRas testing both oncogenic alleles. Therefore we 
generated two mouse colonies one with with KRasLSL-G12V and another with the 
KRasLSL-G12D allele. The mice were aged until they showed signs of ill health.  
Whereas Fra1 deletion promoted tumourigenesis in the intestinal model, Fra1 
loss increased the tumour free survival in this model of PDAC (Figure 80). 
PdxCre+ KRasLSL-G12V/+ p53LSL-R172H/+ Fra1fl/fl mice showed signs of pancreatic illness 
at a latency of around roughly 100 days more than PdxCre+ KRasLSL-G12V/+ p53LSL-
R172H/+ mice. As in the CRC model, the loss of one or both copies of Fra1 had the 
same outcome (median survival of 300 days). A similar reduction in tumour onset 
was observed in PdxCre+ KRasLSL-G12D/+ p53LSL-R172H/+ when Fra1 was lost (median 
survival increased from 150 to 220 days). However in this model the loss of one 
copy of Fra1 were not sufficient to increase tumour free survival (Figure 81). 
Once again the use of the KRasLSL-G12D allele induced tumour onset a much faster 
latency that the KRasLSL-G12V allele. 
 
Figure 80: Fra1 deletion increases survival in a pancreatic cancer model 
Kaplan-Meier curve showing the cumulative survival of PdxCre+ KRasLSL-G12V/+ p53LSL-R172H/+ (black 
line) (n=49), PdxCre+ KRasLSL-G12V/+ p53LSL-R172H/+ Fra1fl/+ (dashed grey line) (n=13) and PdxCre+ 
KRasLSL-G12V/+ p53LSL-R172H/+ Fra1fl/fl mice (green line) (n=11). Mice with pancreatic tumours were 
sacrificed at the same point of illness or when they reached 500 days after induction.  
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The loss of one and two copy of Fra1 resulted in an extention of the tumour free survival 
compared to PdxCre+ KRasLSL-G12V/+ p53LSL-R172H/+ mice (log rank: p=0.009 and p=0.03 respectively). 
There was no significant difference between PdxCre+ KRasLSL-G12V/+ p53LSL-R172H/+ Fra1fl/+ and 
PdxCre+ KRasLSL-G12V/+ p53LSL-R172H/+ Fra1fl/fl mice (log rank: p=0.9).  
 
Figure 81: Fra1 deletion increases survival in a pancreatic cancer model 
Kaplan-Meier curve showing the cumulative survival of PdxCre+ KRasLSL-G12D/+ p53LSL-R172H/+ (black 
line) (n=10), PdxCre+ KRasLSL-G12D/+ p53LSL-R172H/+ Fra1fl/+ (dashed grey line) (n=6) and PdxCre+ 
KRasLSL-G12D/+ p53LSL-R172H/+ Fra1fl/fl mice (green line) (n=7). Mice with pancreatic tumours were 
sacrificed at the same point of illness.  
The loss of both copies of Fra1 resulted in a increase in the tumour free survival compared to 
PdxCre+ KRasLSL-G12D/+ p53LSL-R172H/+ and PdxCre+ KRasLSL-G12D/+ p53LSL-R172H/+ Fra1fl/+ mice (log rank: 
p=0.01 and p=0.08 respectively ). There was no significant difference between PdxCre+ 
KRasLSL-G12D/+ p53LSL-R172H/+ Fra1fl/+ and PdxCre+ KRasLSL-G12D/+ p53LSL-R172H/+ mice (log rank: p=0.5).  
 
The AP-1 complex and Fra1 has previously been suggested to be key in driver of 
invasion and metastasis. Given the PDAC model is an excellent model of invasion 
and metastasis I examined both gross and histological micrometastasis in the 
PdxCre+ KRasLSL-G12D/+ p53LSL-R172H/+ mice with and without Fra1 deletion. 
Surprisingly given Fra1 putative role in the metastatic process, Fra1 deficient 
tumours were still able to metastasise. Moreover, the Fra1 deleted mice had 
macrometastases. 
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Given this surprising result we went back to the intestinal model. We have 
previously shown that mice where p53 is additionally mutated in context of Apc 
and KRas mutation can develop invasive tumourigenesis. In a manner similar to 
our previous studies Fra1 deficient VilCre+ Apcfl/+ KRasLSL-G12D/+ p53LSL-R172H/+ mice 
still showed a trend toward accelerated tumourigenesis (but this was not quite 
statistically significant) (Figure 82). Analysis of intestines from these mice 
showed that 77% and 75% of mice which have lost respectively one or two copies 
of Fra1 developed invasive intestinal or colon tumours. Interestingly the tumours 
developed in either intestine or colon but never in both at the same time. 
 
 
Figure 82: The effects of Fra1 deletion are partially rescued by a p53 mutation  
Kaplan-Meier curve showing the cumulative survival of VilCre+ Apcfl/+ KRasLSL-G12D/+ p53LSL-R172H/+ 
(black line; n=15), VilCre+ Apcfl/+ KRasLSL-G12D/+ p53LSL-R172H/+ Fra1fl/+ (grey dashed line; n=10), 
VilCre+ Apcfl/+ KRasLSL-G12D/+ p53LSL-R172H/+ Fra1fl/fl mice (green line; n=10). Mice with intestinal 
tumours were sacrificed at the same point of illness.  
The loss of the two copy of Fra1 resulted in a reduction (but not quite significant) of the tumour 
free survival compared to the two other types of mice (in both cases log rank: p=0.07). There 
was no significant difference between  VilCre+ Apcfl/+ KRasLSL-G12D/+ p53LSL-R172H/+ (black line; n=15), 
VilCre+ Apcfl/+ KRasLSL-G12D/+ p53LSL-R172H/+ Fra1fl/+ mice (log rank: p=0.9).  
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22.4 Conclusion and discussion 
I investigated the impact of Fra1 deletion in two distinct in vivo cancer models. 
Surprisingly, the outcomes of this deletion were different in each model. In the 
CRC model, Fra1 loss resulted in an accelerated tumourigenesis whilst in the 
pancreatic cancer model it resulted in slower tumourigenesis. Further studies 
will allow us to investigate the potential mechanisms of how Fra1 loss could 
increase tumourigenesis in the intestine.  
I showed that the loss of Fra1 alone was able to modify gut homeostasis by 
increasing the cell proliferation. In the ageing CRC model, tumourigenesis is 
initiated when the remaining copy of Apc is lost. Therefore the increase of 
proliferation induced Fra1 deletion could aid tumour initiation or the formation 
of tumours outwith the stem cell zone.  
The main role of Fra1 is as part of the AP-1 complex. However, recent studies 
have showed that AP-1 members can also binds other proteins and participate in 
other cell functions. A study done on a breast cancer cell line showed that Fra1 
can interact with Smad2/3 in response to transforming growth factor β (TGFβ) 
(Sundqvist, Zieba et al. 2012). This complex promotes invasion by facilitating the 
interaction of Smad2/3 with the promoter of mmp10. More importantly, AP-1 
members have been shown to interact with members of the WNT pathway. TCF4, 
cJun and β-Catenin are significantly upregulated in human colorectal cancer 
(Takeda, Kinoshita et al. 2008). It has been shown recently that cJun interacts 
with TCF4 and β-Catenin to form a ternary complex. This complex activity seems 
dependent on β-Catenin since its siRNA-mediated knockdown reduces the 
activation of the complex target genes (Nateri, Spencer-Dene et al. 2005). 
Furthermore, in the ApcMIN model (a mouse model with a nonsense mutation in 
codon 850 in one allele of the Apc gene) the inactivation of cJun reduces tumour 
number and size (Nateri, Spencer-Dene et al. 2005; Toualbi, Guller et al. 2007). 
The precise activity and role of each AP-1 complexes as well as the complexes 
formed with other partners is still to be fully understood. Bryan Miller in our 
laboratory is currently investigating the role of some of these complexes. 
Concerning the unexpected outcome that I found in the CRC model, we can 
hypothesise that changes in the levels of Fra1 might liberate cJun from the AP-1 
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complex, allowing it to interact with β-Catenin. In this regard Bryan Miller has 
preliminary information to suggest that this may be occurring, with more 
β-catenin/Jun complex in the absence of Fra1. Thus investigating the nature of 
the AP-1 complexes in intestinal epithelium from AhCre+ Apcfl/+, AhCre+ Apcfl/+ 
Fra1fl/fl mice could define the mechanism of how Fra1 deletion accelerates 
tumourigenesis in the context of activated Wnt signalling. 
Within pancreatic cancer, as the activation of Wnt signalling is a much rarer 
event, then this might help explain why Fra1 deletion is having a much more 
predicted role namely slowing tumourigenesis. It is interesting to note that other 
differences between the two tissues might also aid our understanding of context 
specific impact on tumourigenesis. Recently a link between KRas-activation 
induced downregulation of reactive oxygen species (ROS) via upregulation of its 
regulator nuclear factor erythroid-derived 2-like 2 (Nfe2l2 or Nrf2) has been 
shown (DeNicola, Karreth et al. 2011). Importantly the loss of Nrf2 slows PanIN 
formation following KRas mutation in the pancreas. Importantly, in this study on 
KRas activated mouse embryonic fibroblasts (MEFs) it was observed that the 
effects of KRas activation on ROS production were partially rescued by the 
knockdown of Fra1 as well as other AP-1 members. Interestingly in the intestine, 
our laboratory has shown that the activation of ROS stimulates proliferation 
following Apc loss and thus if in this situation Fra1 deletion increases ROS we 
would again expect this might lead increased tumourigenesis. Future studies 
within the laboratory will specifically address this question. 
Finally in both the intestinal and the pancreatic model we showed that Fra1 loss 
does not protect against invasion and metastasis. From the literature this would 
have been the most expected phenotype. This might reflect in part that in vitro 
assays on migration do not fully recapitulate the invasion and metastasis process 
in vivo or that other family member might compensate to drive these functions. 
Moreover it should be noted particularly in pancreatic cancer studies as tumours 
are delayed those that grow have evolved to grow in the absence of Fra1 and 
thus the tumour may have already compensated for Fra1 absence.  
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DISCUSSION 
23 Colorectal cancer and the MAPK cascade 
Of all cancers, CRC is associated with activation of Wnt pathway as an early 
event. In this cancer, KRas activation occurs in more than 40% of cases during 
progression and confers a poor prognosis. Thus, it is crucial to work out the 
mechanism by which KRas activation increase tumourigenesis following Apc 
mutation and whether blocking the MAPK pathway at Mek level would be a good 
strategy to slow or reverse tumour progression. If so, several targets upregulated 
following Apc deletion and KRas activation, such as Dusp6 and Fra1, could be 
interesting potential diagnosis tools.  
Currently, there are several treatment options available to colon cancer patients 
once the cancer has been diagnosed and the cancer stage determined. 
Depending on the stage of the cancer, the patient can be treated by surgery, 
radiotherapy and/or chemotherapy. Research in these three fields is constantly 
improving the treatment options. Therefore detailed knowledge of the intrinsic 
molecular modifications leading to CRC is critical to improvement of 
chemotherapy treatments.  
23.1 Current CRC chemotherapy treatments 
Treating patients with CRC remains complicated despite the advance in diagnosis 
and treatment of the last years. Patients diagnosed with late stage CRC which 
has spread outside the colon are very difficult to treat and the various treatment 
regimens given are only giving small benefits in survival times. Patients with 
early stage carcinomas which have not spread beyond the wall of the colon have 
more treatment options (and are often cured by surgery) but a subset of these 
CRC’s at stage2 or Dukes B still have a poor prognosis with a low response to 
treatments. Therefore in these early stage malignancies as only a small subset 
recur (20%) treating all patients with chemotherapy would not be beneficial and 
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thus it’s a very important clinical question to know which patients to treat or 
find new therapies that have very few side effects. 
In the majority, tumour resection is the preferred therapy. However, a 
treatment following resection can be given to prevent relapse and sometimes or 
when the tumour is not operable. Two major categories of drugs are used: 
compounds directed against key proteins of signalling pathways involved in 
tumour progression and drugs targeting RNA and DNA metabolism. It is striking 
that none of the current treatments are specifically directed against the major 
pathways disturbed in CRC namely Wnt and MAPK pathway. 
(http://www.cancer.gov/cancertopics/pdq/treatment/colon/Patient/page4) 
Bevacizumab is an antibody directed against the vascular endothelial growth 
factor (VEGF) an important pro-angiogenic growth factor. The antibody binds to 
VEGF and prevents its ligation to the VEGF receptor. Cetuximab and 
Panitumumab are antibodies targeting the epidermal growth factor receptor 
(EGFR) preventing the activation of several pathways involved in tumour 
progression. Regorafenib is a small molecule which binds to and inhibits several 
targets such as VEGF receptor (VEGFR), platelet-derived growth factor receptor 
(PDGFR) and Raf kinases, which may result in the inhibition of tumor 
angiogenesis and tumor cell proliferation. Ziv-aflibercept is a protein made of 
segments of VEGF fused to the constant region of human immunoglobuline G1 
(IgG1). It binds to VEGF and prevents the binding to the VEGF receptors.  
Irinotecan hydrochloride is an alkaloid that converts into a metabolite inhibiting 
topoisomerase I activity. It stabilises the cleavable complex between 
topoisomerase I and DNA, resulting in DNA double stranded breaks during DNA 
replication. Oxaliplatin is an organoplatinum complex resulting in DNA 
crosslinks. Capecitabine metabolites inhibit DNA synthesis by reducing normal 
thymidine production and RNA and protein synthesis by competing with uridine 
triphosphate. Fluorouracil is an analogue of the nucleoside pyrimidine. When 
administrated to patients, fluorouracil is converted to different active 
metabolites and can be incorporated into RNA and /or DNA obstructing RNA and 
DNA processing. These drugs are given in advanced stage CRC, if the patient 
relapses or if no other chemotherapies are effective.  
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23.2 Finding new chemotherapy agents 
The identification of the signalling pathways involved in CRC is crucial to the 
development of novel therapies. Indeed, the characterisation of the genetic 
profile of individual tumours in each patient is essential to determine which 
treatment is best. However sequencing the tumour of each patient is currently 
not a realistic option as the cost of the tests could never be covered. 
Nevertheless it is reasonable to reduce the numbers of mutations screened to 
the frequently mutated genes in CRC such as Apc, KRas, BRaf and p53. Indeed 
the study of 195 human CRC tumours (http://www.cbioportal.org/public-portal) 
indicated that the sequencing of these four genes would cover 95.4% of CRCs. 
Interestingly the study shows that BRaf (mutated in 13% of CRCs) and the three 
other mutations are mutually exclusive highlighting two distinct pools of 
patients. As predicted from the microarray analysis of this thesis Dusp6 (mutated 
in 10% of CRCs analysed), Fra1 (mutated in 2% of CRCs analysed) and KRas have a 
co-occurence tendency. Furthermore, the study confirms a trend of co-
occurence between Apc and KRas mutations. It has been showed that patients 
with mutations in KRas are resistant to EGFR inhibitors (Lievre, Bachet et al. 
2006; Lievre, Bachet et al. 2008; Allegra, Jessup et al. 2009; Normanno, Tejpar 
et al. 2009; De Roock, Claes et al. 2010). Indeed, in a study on 1022 tumour DNA 
samples, amongst tumours resistant to Cetuximab, 97.1% were exhibiting KRas 
mutations (De Roock, Claes et al. 2010). Moreover, the treatment of KRas 
mutated tumours with cetuximab is suggested to drive disease progression 
(Bokemeyer, Bondarenko et al. 2009). In addition, amongst the tumours with 
wild-type KRas, up to 65% are resistant to Cetuximab. These tumours have other 
mutations in NRas, BRaf and PI3K genes (De Roock, Claes et al. 2010). The gene 
KRas is mutated in more than 40% of CRCs and patients are routinely tested for 
their KRas status to decide which treatment is adequate to treat their tumour. 
Therefore it is crucial to find other treatments aimed at different targets as an 
alternative to EGFR inhibitors. 
The one expected direct consequence of oncogenic mutation within Kras is that 
the MAPK cascade (Ras-Raf-Mek-Erk) should be upregulated in these CRCs. 
However, my experiments have shown that upregulation of pErk is hard to 
detect following KRas mutation in adenomas and critically, the treatment with 
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the Mek inhibitor CI1040 had no effect on either tumour free survival of 
VilCreER+ Apcfl/+ KRasLsL-G12D/+ mice or tumourigenesis of VilCreER+ Apcfl/fl 
KRasLsL-G12D/+ mice. These findings are in good agreement with the results 
obtained by J. Yeh and colleagues showing that elevated Erk activation depends 
on BRaf but not KRas mutation in human CRC samples (Yeh, Routh et al. 2009). 
Indeed, a phase 2 study on patients with CRC showed no significant antitumour 
activity of CI1040 (Rinehart, Adjei et al. 2004). It is of interest that this study 
did not indicate the KRas status of the patients. In our laboratory, Ee Hong Tan 
has shown in a murine model of invasive CRC, that an upregulation of pErk is 
seen at the invasive edge of the tumour, however not throughout the tumour 
bulk. In this case it will be of interest to see if the use of Mek inhibitor such as 
CI1040 seems might suppress invasion and metastasis within this model. 
These results suggest the signalling output and the functional importance of 
KRas mutations may be independent of the Mek-Erk cascade. KRas mutations 
could be therefore involved in the activation of other signalling cascades such as 
of PI3K pathway. Interestingly, a recent study on patient liver metastasis from 
KRas mutated primary CRC tumour transplanted in NOD/SCID mice reported a 
growth arrest effect of the Mek inhibitor AZD6244 as a monotherapy (Migliardi, 
Sassi et al. 2012). They observed a synergistic association of the Mek inhibitor 
AZD6244, the PI3K inhibitor BEZ235 and cetuximab. Yet the association of these 
chemotherapies did not lead to tumour regression as there was a reduction of 
the mitotic index but not an increase in apoptosis. This would be in favour of a 
cytostatic effect instead of a cytotoxic one explaining the rather weak effect on 
persisting tumours. They also noted similar results on samples from tumours 
presenting NRas, BRaf and/or PI3K mutations. These results suggest that such 
drug combination could have an effect on CRC patients with KRas mutations 
within their tumours. However preliminary data from our laboratory has shown 
little effects of combined Mek and mTOR inhibitor suggesting a more complex 
signalling in CRC. Nevertheless extra confidence would be gained if preclinical 
models showed a tumour regression as this is a much simpler model to treat than 
a human patient. Indeed when drugs have worked in the clinic, for example the 
BRaf inhibitor in tumours with BRaf mutation, preclinical models have shown 
tumour regression. 
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Another way to bypass the difficulty of targeting MAPK pathway in CRC would be 
to develop more drugs targeting the major deregulated pathway in CRC namely 
the WNT pathway. First the secretion of Wnt could be targeted. The Porcupine 
gene is required for the secretion of wingless and other Wnt protein in 
drosophila and mutation on its human ortholog is the cause of diseases. The 
conditional deletion of porcupine in mice impaired Wnt secretion and had drastic 
consequences in embryogenesis (Matozaki, Murata et al. 2009). The Frizzled (Fz) 
receptors are currently investigated as new drug targets. Notably, the use of 
secreted frizzled-related proteins (SFRPs) seems very promising. SFRPs are decoy 
receptors containing a cysteine-rich domain similar to the Fz Wnt binding 
domain. When the Wnt ligand binds these soluble receptors it does not reach its 
proper Fz/LRP5/6 receptor and therefore does not activate the Wnt pathway. 
Interestingly, Sfrp genes are often silenced by hypermethylation in CRC tumours 
inducing Wnt pathway activation (Suzuki, Watkins et al. 2004). The transfection 
of SFRPs in HCT116 (a CRC cell line with a β-Catenin mutation preventing its 
phosphorylation by the Apc/Axin/GSK3 complex) results in the decrease of 
β-Catenin level and then brought back Wnt signalling back to its basal level 
(Suzuki, Watkins et al. 2004). Furthermore collagen-derived SFRP-like 
polypeptide (such as V3NTer) reduces the expression of Cyclin D1 and c-Myc in 
CRC cell lines with a β-Catenin mutation (Quelard, Lavergne et al. 2008; 
Lavergne, Hendaoui et al. 2011). Moreover this polypeptide has been showed to 
reduce and delay the growth of tumours derived from HCT116 cells implanted in 
nude mice by binding Wnt3a (Lavergne, Hendaoui et al. 2011). Nevertheless, it is 
important to note that V3NTer had no effects on the SW480 cell line (containing 
an Apc mutation) limiting its effects to the β-Catenin mutant cell lines. Another 
soluble Wnt receptor has been generated by Polakis laboratory (Tenbaum, 
Ordonez-Moran et al. 2012). Their receptor coupling the frizzled8 cysteine-rich 
domain and the human Fc domain of immunoglobulin (F8CRDhFc) has been 
shown to inhibit the growth of mammary tumours allografts and of human 
teratoma xenografts in athymic nude mice. Furthermore an antibody targeted 
against LRP6 could be used to limit Wnt pathway activation. LRP6 antibodies 
targeting the LRP6 binding sites for Wnt1 and Wnt3a have been created 
(DeAlmeida, Miao et al. 2007). The treatment with these antibodies on xenograft 
of mammary tumours exhibiting high Wnt pathway activation implanted on nude 
Discussion 
 
187
mice resulted in tumour regression. Another way to suppress the effects of an 
overactive Wnt pathway is to render more available the components of the 
β-Catenin degradation complex. Axin is part of this degradation complex. As 
tankyrase targets Axin to program its degradation via the proteasome, tankyrase 
inhibitors (TNKi) are stabilising Axin by preventing its degradation (Huang, 
Mishina et al. 2009; Waaler, Machon et al. 2012). A TNKi has been already 
proven to reduce tumour initiation in vivo in a CRC model of Lgr5-CreERT2 mice 
with an induced Apc mutation (Waaler, Machon et al. 2012). Liam Faller in our 
laboratory has started to evaluate the effects of dual treatment in vivo 
combining TNKi and a PI3K inhibitor as well as TNKi and rapamycin. VilCreER+ 
Apcfl/fl KRasLsL-G12D/+ mice treated with both drug combinations have their CPL 
phenotype reduced. Moreover, a 5 day treatment with TNKi and rapamycin 
reduces proliferation in established tumours. Intriguingly, Resveratrol (3,40,5-
trihydroxystilbene), a natural compound found in several plants such as grapes, 
has been established to have anti-cancer effects. Recently, a link between 
Resveratrol effects and inhibition of WNT pathway has been found. Indeed, 
treatment with Resveratrol abolished the β-catenin/TCF-mediated 
transcriptional activity in cells stimulated with Wnt ligand (Chen, Hsu et al. 
2012). Resveratrol is believed to dissociate the complex β-catenin/TCF 
preventing the transcription of Wnt target genes. A summary of ways to target 
Wnt pathway can be found in Figure 83. As mentioned previously, KRas 
activation in CRC can dysregulated several signalling pathways. Interestingly 
aspirin has been reported to have a positive effect on survival of CRC patients 
(Janssen, Alberici et al. 2006; Alberici, de Pater et al. 2007; Kim, Song et al. 
2009). If the precise mechanism of action is still not fully understood, it seems 
that aspirin can act as an inhibitor of the phosphorylation, hence activation, of 
S6 kinase 1 (S6K1) and 4E binding protein 1 (4EBP1) two important effectors of 
the mTOR pathway as shown in CRC cell lines (Davies, Reddy et al. 2000). 
Furthermore aspirin activates adenosine monophosphate-activated protein 
kinase (AMPK), a key protein in cellular energy homeostasis, leading to tumour 
growth arrest and induces autophagy. These examples of possible treatments 
show the wide spectrum of targets that can be investigated to increase the 
range of chemotherapies and improve patient survival. 
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Figure 83: Targeting Wnt pathway  
A recent study on a mouse model of KRas dependent PDAC showed that KRas is 
involved in the regulation of glucose metabolism (Ying, Kimmelman et al. 2012). 
In good agreement with this study, we found that a KRas mutation results in a 
change in the transcription of metabolism genes in the intestine. A microarray 
performed on samples of VilCreER+ Apcfl/fl KRasLsL-G12D/+ mice showed 
perturbations in genes associated with metabolism. This could indicate that KRas 
mutations in CRC are mainly disturbing metabolism independently of the MAPK 
pathway activation. Interestingly, in the reported pancreatic cancer model used 
for these experiments, the expression of glycolytic genes such as Glut1, Hk1, 
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Eno1 and Ldha was reduced following Mek inhibition or oncogenic KRas 
inactivation. However, in the pancreatic cancer mouse model I have used Mek 
inhibition had an impact on tumour growth of PDAC cells from PdxCre+ 
KRasLSL-G12D/+ mice implanted subcutaneously into nude mice. In contrast, in the 
VilCreER+ mice model for CRC, there was no impact of Mek inhibition on 
tumourigenesis. The effects of Mek inhibition seem to be limited to the PCs 
models. We could argue that the Mek inhibition has no impact on CRC models as 
CRC seems to be driven mostly by WNT pathway activation whereas PC can be 
initiated by KRas mutations alone. Further studies are now ongoing within the 
laboratory to carefully characterise the metabolic differences driven by 
additional KRas mutation and the functional significance of these alterations. 
24 Is Dusp6 a tumour suppressor gene? 
Several lines of evidence indicate that Dusp6 may be a potential tumour 
suppressor. First, Dusp6 specifically dephosphorylates Erk, a key effector of the 
MAPK pathway involved in tumour progression. Secondly, Dusp6 expression is 
regulated by Erk in a negative feedback loop. However, there are conflicting 
reports in the literature leading to the question of its tumour suppressor role in 
vivo. 
24.1 Dusp6 can act as a tumour suppressor 
The results described in the in vivo models of PC and CRC of this thesis are 
arguing for a tumour suppressor effect of Dusp6. Indeed, in the CRC model 
following the acute Apc deletion, Dusp6 loss increased strongly the CPL 
phenotype. In addition, in both PC and CRC aging models, the deletion of Dusp6 
drastically reduced the tumour free survival of the animals. Moreover, the loss 
of one copy of Dusp6 in PC rendered the tumour more aggressive and allowed 
rapid formation of liver metastasis.  
The results reported for the PC mouse model are in good agreement with the 
observations made on human pancreatic tumours that Dusp6 is upregulated in 
PanIN lesions and lost in PDACs (Furukawa, Fujisaki et al. 2005). This suggests 
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that Dusp6 is upregulated in response to early KRas activation and then finally 
lost as part of the several mutations necessary for tumour progression. This 
observed silencing of Dusp6 in late PC stages is proposed to be mediated by 
hypermethylation of CpG sites in the promoter area (Xu, Furukawa et al. 2005). 
Consistent with observations made in pancreatic cancer, Dusp6 expression was 
described as low in immortalised lung cancer cell lines and more importantly in 
human lung tumours (Okudela, Yazawa et al. 2009). In fact Dusp6 expression was 
found inversely correlated with the tumour proliferation as indicated by Ki67 
staining. Finally, an experiment showed that Dusp6 expression could be 
recovered in cell lines by treatment with azacitidine which impairs DNA 
methylation and histone deacetylase suggesting, in good agreement with the 
observation made in human PC, that Dusp6 silencing is due to hypermethylation 
and/or histone acetylation (Okudela, Yazawa et al. 2009). Another study 
reported similar results on oesophageal squamous cell carcinoma (ESCC) and 
nasopharyngeal carcinoma (NPC) (Wong, Chen et al. 2012). Low expression of 
Dusp6 was observed in a large percentage of tumour tissues and cell lines and 
this downregulation was associated with hypermethylation of the Dusp6 
promoter. Interestingly, Dusp6 loss was suggested to be involved in the 
epithelial-mesenchymal transition. Surprisingly, a tissue microarray (TMA) of 
ESCC human tissues analysis revealed that Dusp6 expression was high in 
metastatic stages and was suggested to be a negative feedback loop response to 
oncogenic signalling of cancer cells. This upregulation is rather in contradiction 
with their previous observation and the results I found in the pancreatic cancer 
mouse model. One limitation of this study was that the matched primary tumour 
was not stained and thus it was unclear whether these tumours grew with high 
level of Dusp6 or whether there was reactivation of Dusp6 within the metastatic 
sample. As only 40% of ESCC analysed had low Dusp6 expression it is possible 
that changes in Dusp6 expression could be related to the mutation of different 
oncogenic and tumourigenic pathways during tumour progression ie KRas 
mutation. In ovarian cancer cell lines and primary cancer tissue, Dusp6 
expression was described as downregulated compared to normal tissue (Chan, 
Liu et al. 2008). Furthermore, the inhibition of Dusp6 in ovarian cancer cell lines 
accelerated cell proliferation whereas the transfection of Dusp6 in Dusp6-
depleted cells suppressed proliferation. More importantly, Dusp6 expression 
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restored cisplatin sensitivity in resistant cell lines suggesting that the loss of 
Dusp6 in ovarian cancer is a sign of aggressive and chemoresistant cancer 
evolution. The putative tumour suppressor role of Dusp6 in Ras activated 
tumours has also been suggested in a study on keratinocytes expressing activated 
HRas (Warmka, Mauro et al. 2004). In this study, the authors have used the 
tumour promoter drug Palytoxin to investigate signalling mechanisms which can 
be modulated during carcinogenesis. The Palytoxin treatment was inducing Erk 
activation by drastically reducing Dusp6 protein levels. In addition, despite the 
presence of Palytoxin, the sustained exogenous Dusp6 expression was able to 
reverse the Erk activating effects of the drug. All these experiments are 
confirming the hypothesis of a tumour suppressor role of Dusp6. However, there 
are some conflicting reports in the literature. 
24.2 Dusp6 can promote tumourigenesis 
Intriguingly, and in contradiction with its role as an Erk activation regulator, 
Dusp6 has been suggested to promote tumourigenesis in several models. 
Importantly, breast cancer models argue strongly in favour of a tumour 
promoting role of Dusp6. In cancer cell lines with induced growth arrest by 
phorbol 12-myristate 13-acetate (PMA) the silencing of Dusp6 was promoting 
filopodia formation and accelerated the growth arrest process (Nunes-Xavier, 
Tarrega et al. 2010). Moreover, ectopic expression of Dusp6 was able to stop the 
effects of PMA on cell lines and could also promote cell proliferation. Another 
study demonstrated a correlation between Dusp6 expression and Tamoxifen 
resistance in breast cancer cell lines (Cui, Parra et al. 2006), Dusp6 expression 
has also been associated with tumour promotion in glioblastoma cell lines 
(Messina, Frati et al. 2011). Indeed, Dusp6 overexpression in cell lines was 
stimulating cell proliferation. Moreover, the Dusp6 overexpressing cell lines 
implanted in nude mice produced tumours with rapid growth and cisplatin 
resistance.  
One study on melanocytes is a good example of the difficulties intrinsic to 
assessing a tumour role for Dusp6. In this study, the authors showed an opposite 
effect of Dusp6 expression in human melanocyte and mouse melanocyte cell 
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lines (Li, Song et al. 2012). Indeed Dusp6 was acting as a tumour suppressor in 
human melanocytes but had pro-tumourigenic effects in their mouse 
counterparts. Furthermore, a human primary melanoma TMA analysis showed a 
correlation between high Dusp6 and poor prognosis. This study illustrates the 
context dependant effects of Dusp6 expression and the importance to connect 
Dusp6 status to other mutations and tissue specificity in order to understand the 
role of Dusp6 in different cancer types. 
Therefore I believe my data has provided very important novel insights about the 
capacity of Dusp6 to act as a tumour suppressor. My functional studies have 
shown that Dusp6 loss can drive tumourigenesis in the presence of KRas 
mutation. One of the key questions is that although its loss can drive tumour 
progression, is this an important pathway in human carcinogenesis? As I 
mentioned in PDAC the data on human tumours does support this model: an 
early upregulation following KRas mutation and then a loss which could drive 
tumour progression. Functionally inhibition of Mek then affected tumour growth. 
Although mouse data in colon also gives a definitive answer that Dusp6 loss can 
accelerate tumourigenesis one key question that remains is whether there is 
selection for Dusp6 loss during tumourigenesis? The reason for this is that 
mutation of Apc and KRas together rapidly induces tumourigenesis and thus is 
there a strong selective pressure to lose Dusp6? It is important however to 
mention the lack of powerful tools to detect Dusp6 at the protein level. Indeed, 
the lack of Dusp6 antibodies is holding back the in situ analysis that could 
highlight the impact of Dusp6 level in tumours/normal tissues. Certainly in our 
mouse models Dusp6 expression is retained in tumours from VilCreER+ Apcfl/+ 
KRasLsL-G12D/+ mice and these tumours are resistant to Mek inhibition. Moreover 
investigation of RNA expression in human cancers suggests that Dusp6 may 
remain high in KRas mediated CRC (though extra data is required to support 
this).  
One other important implication from our work is that MAPK inhibition in CRC, 
will only affect proliferation once Dusp6 and perhaps other negative regulators 
of the MAPK pathway are lost. It is on interest to note that Dusp6 has previously 
been suggested to be a predictor on MAPK responsiveness in human CRC cell 
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lines (Yeh, Marsh et al. 2007). Moreover my studies have shown that Dusp5 is 
also upregulated following joint Apc loss and KRas mutation. Currently Dusp5 
knockout animals are being crossed in both the PDAC and CRC models. If Dusp5 
loss also has the same impact as Dusp6 deletion then it may be that before a 
prediction upon the efficicacy of Mek inhibition can be made a number of 
pathway components will need to be examined. 
This raises another very important finding of my thesis, the difficulty in assessing 
MAPK pathway activation in vivo. My work with Mek inhibition in the Dusp6 
deleted animal clearly showed that MAPK activation was functionally important 
however an upregulation was hard to observe either in levels of pMek and pErk 
or in target gene activation. This somewhat reflects the lack of robust target 
genes for the MAPK pathway and difficulty of phospho-antibody staining in vivo. 
In order to investigate further the signalling pathways implicated following Apc 
and KRas mutation, we could propose the use of optical proteomics technologies 
namely fluorescence lifetime imaging microscopy (FLIM) and Forster resonance 
energy transfer (FRET) (For review:(Tarasewicz and Jeruss 2012)). The use of the 
FLIM/FRET technique has highlighted a new level of regulation of MAPK pathway. 
Indeed it has been shown in cells that have a mutated FGF receptor remains 
longer at the cell membrane instead of undergoing endocytosis and therefore 
prolongs FGF binding and increases MAPK pathway activation (Millet and Zhang 
2007). This finding suggests a possible more complicated regulation of signalling 
pathways both upstream and downstream KRas activation in our models. This 
technique could help ascertain the major direct target of activated KRas in the 
complex CRC. Finally, this technique could be use to establish the different AP-1 
complexes formed following KRas and Fra1 mutations in order to determine a 
clearer role of Fra1: tumour promoter or suppressor. 
Overall my data have confirmed a tumour suppressor role for Dusp6 in both PC 
and CRC dependent on the MAPK pathway activation. However, the impact on 
Erk activation needs to be explored further. Importantly I showed that KRas 
activation oncogenic effects were not mainly driven by the direct downstream 
cascade namely the MAPK pathway and therefore, the investigation of the 
outcome of KRas activation is currently ongoing in the laboratory. Last but not 
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least, my data have highlighted a possible tissue-dependent outcome of Fra1 
expression which can act as tumour suppressor in CRC or as a tumour promoter 
in PC.  
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APPENDIX 
 
Supplementary Figures: Clusters of the microarray samples 
 
Microarray samples were analysed and their log2 expression values were 
calculated. Then, they were clustered based on the Euclidean distance between 
the rows of a data matrix. The samples clustered together have similar gene 
expression behaviour. The values on the height axis are an indication of how 
similar samples are. The shorter the line is, the more similar the samples are. 
Therefore long lines are indicating very different samples. 
 
Legend:  
WT: VilCreER+  
A: VilCreER+ Apcfl/fl  
AK: VilCreER+ Apcfl/fl KRasLsL-G12D/+  
AKD: VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/-  
AKCI1040: VilCreER+ Apcfl/fl KRasLsL-G12D/+ treated with CI1040 
AKDCI1040: VilCreER+ Apcfl/fl KRasLsL-G12D/+ Dusp6-/- treated with CI1040 
Appendix 
 
196
 
 
Supplementary figure 1: Wnt signature; Clustering WT, A and AK mice samples 
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Supplementary figure 2: Stem cells signature; Clustering WT, A and AK mice samples 
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Supplementary figure 3: MAPK signature; Clustering WT, A and AK mice samples 
Appendix 
 
199
 
 
Supplementary figure 4: Wnt signature; Clustering AK and AKD mice samples 
Appendix 
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Supplementary figure 5: Stem cells signature; Clustering AK and AKD mice samples 
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Supplementary figure 6: MAPK signature; Clustering AK and AKD mice samples 
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Supplementary figure 7: Wnt signature; Clustering AK and AKD mice samples treated with 
CI1040 
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Supplementary figure 8: Stem cells signature; Clustering AK and AKD mice samples treated 
with CI1040 
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Supplementary figure 9: MAPK signature; Clustering AK and AKD mice samples treated with 
CI1040 
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